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ABSTRACT OF THE DISSERTATION
CLINICAL TRANSLATION OF A HAND-HELD OPTICAL IMAGER
FOR BREAST CANCER DIAGNOSTICS: IN VITRO AND IN VIVO
TOMOGRAPHY STUDIES
by
Sarah J. Erickson
Florida International University, 2011
Miami, Florida
Professor Anuradha Godavarty, Major Professor
Optical imaging is an emerging technology towards non-invasive breast cancer diagnostics.
In recent years, portable and patient comfortable hand-held optical imagers are developed
towards two-dimensional (2D) tumor detections. However, these imagers are not capable of
three-dimensional (3D) tomography because they cannot register the positional information
of the hand-held probe onto the imaged tissue. A hand-held optical imager has been
developed in our Optical Imaging Laboratory with 3D tomography capabilities, as
demonstrated from tissue phantom studies. The overall goal of my dissertation is towards
the translation of our imager to the clinical setting for 3D tomographic imaging in human
breast tissues. A systematic experimental approach was designed and executed as follows: (i)
fast 2D imaging, (ii) coregistered imaging, and (iii) 3D tomographic imaging studies. (i) Fast
2D imaging was initially demonstrated in tissue phantoms (1% Liposyn solution) and in vitro
(minced chicken breast and 1% Liposyn). A 0.45 cm3 fluorescent target at 1:0 contrast ratio
was detectable up to 2.5 cm deep. Fast 2D imaging experiments performed in vivo with
healthy female subjects also detected a 0.45 cm3 fluorescent target superficially placed ~2.5

v

cm under the breast tissue.

(ii) Coregistered imaging was automated and validated in

phantoms with ~0.19 cm error in the probe’s positional information. Coregistration also
improved the target depth detection to 3.5 cm, from multi-location imaging approach.
Coregistered imaging was further validated in-vivo, although the error in probe’s positional
information increased to ~0.9 cm (subject to soft tissue deformation and movement). (iii)
Three-dimensional tomography studies were successfully demonstrated in vitro using 0.45
cm3 fluorescence targets. The feasibility of 3D tomography was demonstrated for the first
time in breast tissues using the hand-held optical imager, wherein a 0.45 cm3 fluorescent
target (superficially placed) was recovered along with artifacts. Diffuse optical imaging
studies were performed in two breast cancer patients with invasive ductal carcinoma. The
images showed greater absorption at the tumor cites (as observed from x-ray mammography,
ultrasound, and/or MRI). In summary, my dissertation demonstrated the potential of a
hand-held optical imager towards 2D breast tumor detection and 3D breast tomography,
holding a promise for extensive clinical translational efforts.
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CHAPTER 1
Introduction
Clinical imaging of breast tissue holds an essential role in cancer detection, staging1,
treatment monitoring, and surgical guidance. Early diagnosis of breast cancer by medical
imaging technology is integral for reducing the mortality2 and morbidity3 of the disease.
Breast cancer is the second leading cause of death in women in the U.S. and one out of every
eight women are diagnosed with the disease each year.[1] Figure 1.1 shows the mortality rate
by year per 100,000 women with breast cancer from different regions of the world. The
figure shows that the mortality rate due to breast cancer has declined since the early 1990s
(shaded yellow region), and this is largely due to early diagnosis with improved imaging
technology.
Current screening and diagnostic modalities used in the clinical setting include x-ray
mammography, breast ultrasound, nuclear imaging, and magnetic resonance imaging (MRI).
Combinations of these modalities are used complementarily to noninvasively detect the
presence of lesions and determine if they are benign or malignant. However, these methods
are neither comprehensive nor infallible leading to unnecessary biopsies and undetected
cancers. X-ray mammography has good resolution, however it requires painful compression
of the breast tissue, it uses harmful ionizing radiation, and the sensitivity decreases in women
with denser breast tissue. Breast ultrasound is nonionizing, portable, and inexpensive, but it
has poor imaging quality and contrast. MRI is nonionizing, has good resolution and good
1

Determination of the degree to which a cancer has spread

2

The rate of death due to a disease

3

The rate of incidence of a disease

1

sensitivity in dense breast tissue, however it requires expensive, bulky instrumentation and
strong magnetic fields.

Nuclear imaging methods, including positron emission

mammography (PEM) and breast specific gamma imaging (BSGI) provide functional
information and can detect small tumors, but they require harmful nuclear radiation.

Figure 1.1 Mortality rate by year per 100,000 women with breast cancer. (Adapted from American
Cancer Society, Breast Cancer Facts and Figures, 2009)

Currently, x-ray mammography is the gold standard for breast cancer detection.
There are two types of x-ray mammograms: (i) screening mammograms are performed annually
in women over age 40 or 50 in order to detect the presence of any suspicious mass; (ii)
diagnostic mammograms are performed once a mass is detected during the screening process in
order to try to gain more information of the size and location, and determine if the lesion is
benign or malignant. Diagnostic mammograms are typically followed by breast ultrasound
and then MRI and/or nuclear imaging methods. These clinical imaging methods are used to
noninvasively determine if a suspicious mass is benign or malignant prior to invasive surgical

2

biopsy.

However, 80% of biopsies performed turn out to be negative, resulting in

unnecessary physical and psychological trauma for the patient.[2] Hence, there is a clear
need for improved breast imaging technology to obviate the number of unnecessary invasive
biopsies.
Diffuse optical imaging using near-infrared (NIR) light is a promising technology
which has been developed over the past three decades towards applications such as
functional brain mapping and breast cancer diagnosis. The method is noninvasive, uses
nonionizing radiation, requires relatively inexpensive instrumentation, and provides
functional information from in vivo biological tissues. Diffuse optical imaging measures the
endogenous optical property difference between normal and diseased tissue (e.g. cancer).
External fluorescent contrast agents can be used towards imaging tumors at the molecular
stage (fluorescence-enhanced diffuse optical imaging).

Diffuse optical imaging has a

potential role in the clinical setting as a complementary diagnostic tool for breast cancer. Xray mammography has a 10% false negative rate [2] (and increases in women with denser
breast tissue) which means many cancers go undetected, especially in younger women with
denser breasts. Hence, additional imaging tools are required for improved diagnosis.
Several research groups are developing diffuse optical imaging as a complementary
imaging modality towards breast cancer diagnosis. Most of the optical imaging systems
require bulky instrumentation and/or compression of the breast tissue. To overcome these
limitations, hand-held based optical imaging devices are developed, which are portable and
patient-comfortable, towards clinical translation of the technology. However, the hand-held
devices developed to date have not demonstrated three dimensional (3D) tomography.4
4 A method of producing a three-dimensional image of the internal structures of an object by the observation and recording
of the differences in the effects on the passage of waves of energy impinging on those structures
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Currently, a hand-held based optical imaging device has been developed in our
Optical Imaging Laboratory, which is capable of 3D tomography, and has been tested in
homogeneous5 tissue phantoms6 [3]. The challenge now is to translate the device to the
clinical setting in order to perform 3D tomography on human breast tissue. The overall
objective of the dissertation is the clinical translation of our hand-held optical imager toward
bedside imaging and 3D tomography of breast cancer. The results will demonstrate for the
first time the feasibility of performing 3D tomography in complex human tissues using a
hand-held optical imager.
In order to facilitate clinical translation of the hand-held optical imager, a systematic
series of experimental studies was designed and executed to demonstrate and evaluate the
implementation of (i) two-dimensional (2D) imaging in near-real time (i.e. fast imaging), (ii)
coregistered imaging7, and (iii) 3D tomography in a clinical setting. To this end, experiments
were performed initially in homogeneous tissue phantoms to begin with a simplistic case.
Subsequent experiments were then performed in vitro8 to better mimic the heterogeneous9
nature of biological tissues. The bench-top10 imaging set-up was modified into a pseudobedside imaging set-up, and experiments were performed in vivo11 with healthy human
subjects to determine the performance on actual breast tissues. Finally, preliminary studies

5

Uniform distribution of scattering properties

6

A physical model designed to mimic the body or part of the body

7 The process of accurately positioning the acquired data at the probe location relative to the breast tissue geometry, which
is necessary to perform 3D tomography (details of our coregistered imaging approach are given in subsequent chapters)
8

Located outside the organism in a laboratory environment

9

Non-uniform distribution of scattering properties

10 Suitable
11

in size or configuration for use on a laboratory workbench

Located within the whole, living organism
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were performed with cancer patients to test the ability of the device to image breast cancer in
vivo. The experimental design is summarized in Figure 1.2.

Figure 1.2 Diagram summarizing the systematic experimental study design.

The dissertation is organized as follows: Chapter 2 provides background on nearinfrared optical imaging; Chapter 3 gives a review of the hand-held optical imaging devices
developed by different research groups; Chapters 4 and 5 summarize the recent work
performed in fluorescence tomography (in phantoms and small animals) and clinical breast
imaging studies (in human subjects), respectively; Chapter 6 provides the details of the
instrumentation of the hand-held optical imager and describes the procedures for data
acquisition, processing, and analysis; Chapter 7 describes the reconstruction method used to
perform 3D tomography; Chapters 8-14 detail the experimental studies described above and
summarized in Figure 1.2; Chapter 15 gives an overall discussion of the significant results of
the studies and Chapter 16 describes ongoing and future work. A flow diagram of the
dissertation structure is given in Figure 1.3.

5

The various studies are performed using both diffuse optical (i.e. using endogenous12
tissue contrast) and fluorescence-enhanced optical imaging (i.e. using an exogenous13
contrast agent) towards clinical translation of the hand-held optical imager. The work
presented herein will demonstrate the potential role of the hand-held optical imager as a safe
and patient-comfortable method to provide complementary physiological14, diagnostic and
prognostic15 information about human breast tissues.

12

Originating from inside an organism

13

Originating from outside an organism

14

Relating to the biological function of tissue

15

Predicting the likely outcome or progression of a disease

6

Figure 1.3: Flow diagram showing the organization of the dissertation.
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CHAPTER 2
Background: NIR Optical Imaging
2.1 INTRODUCTION
Optical imaging is an emerging technique for observing internal functionality of the human
body. Three major biomedical applications of optical imaging that have been investigated
are brain imaging for functional monitoring, breast imaging for cancer diagnosis and
monitoring response to neoadjuvant chemotherapy16, and muscle imaging for physiology
monitoring [4]. For these applications, diffusing light fields are used to measure blood
hemodynamics17 and to detect the presence of tissue inhomogeneities [5]. Biological tissues
have specific optical properties that become altered in diseased tissue.

These altered

properties can be discerned by NIR imaging for the application of cancer diagnosis. This
chapter will describe tissue characterization using NIR imaging, fluorescence enhanced
optical imaging, different measurement techniques and configurations used in optical
imaging, and different types of instrumentation used to perform optical imaging.
2.2 NIR IMAGING FOR TISSUE CHARACTERIZATION
When light travels through biological tissue, it becomes scattered and absorbed. Biological
tissues are characterized by their absorption coefficient, !a, and scattering coefficient, !s,
which represent the number of absorption or scattering events per unit length, respectively,
and are wavelength dependent properties intrinsic to the tissue. These properties govern
how the light will propagate within that tissue. The major biological chromophores (light
absorbers) are water (H2O), oxy-hemoglobin (HbO2), and deoxy-hemoglobin (Hb). The
16

Preliminary cancer therapy that precedes surgery or a second modality of treatment

17

The branch of physiology that studies the movement of blood
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major source of scattering is lipids (fatty tissue).

Light is minimally absorbed by the

chromophores and preferentially scattered at wavelengths in the near-infrared (NIR) region,
700-900 nanometers (nm) as shown in Figure 2.1. This region is termed the diagnostic or
therapeutic window because it is at these wavelengths that light can penetrate deep into the
tissue before being absorbed.

Figure 2.1 Absorption coefficient at various wavelengths for water, oxy-hemoglobin, and deoxyhemoglobin (adapted from R. Weissleder 2001 [6]).

NIR light can be used to detect the presence of inhomogeneities (such as a cyst or
tumor) within biological tissue because the optical properties (!a and !s) differ in normal and
diseased tissue. The functional information provided by NIR imaging enables differentiation
between benign and malignant lesions, whereas modalities such as x-ray mammography and
computed tomography (CT) only provide anatomical information requiring a needle biopsy
to identify the inhomogeneity. The endogenous contrast between normal and diseased tissue
can be measured by diffuse optical imaging systems to detect the presence of a tumor.
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2.3 FLUORESCENCE-ENHANCED OPTICAL IMAGING
An exogenous contrast agent can be introduced into the tissue to produce a stronger signal
towards detection of smaller lesions (<0.5 cm diameter). Indocyanine green (ICG) is a
fluorescing dye typically used for fluorescence-enhanced optical imaging and tomography
because it is nontoxic at low concentrations and is approved by the Food and Drug
Administration (FDA) for use in humans. Fluorescence occurs when incident light causes a
fluorescent molecule to excite. It remains excited for a period of time (the fluorescence
lifetime, �) and then relaxes to the ground state by emitting a photon of lower energy
(higher wavelength) than the energy of the incident light. The principle of fluorescence is
illustrated using a Jablonski diagram in Figure 2.2. The fraction of excited fluorescent
molecules that relax radiatively is known as the quantum efficiency.

Figure 2.2 Jablonski diagram showing the principle of fluorescence.

The principle of fluorescence enhanced optical imaging is illustrated in Figure 2.3 for
continuous-wave based imaging. When the fluorescent dye is injected into the tissue, it
tends to accumulate close to the tumor site depending on its specificity. NIR light excited at
the tissue surface propagates into the tissue and becomes attenuated due to absorption of

10

the light by the tissue chromophores.

Upon encountering a fluorescent molecule (or

fluorophore), the molecule becomes excited (Figure 2.2). As the molecule relaxes back to
the ground state, the energy is emitted at a higher wavelength (the fluorescent signal). The
fluorescent signal propagates through the tissue becoming further attenuated by absorption.
The emitted fluorescent light from the fluorophore combined with the original attenuated
excitation light from the incident source is collected at the tissue surface using NIR sensitive
detectors and appropriate filters to select the weak fluorescent signal.

Figure 2.3 Principle of fluorescence enhanced optical imaging using continuous-wave based
measurements.

2.4 MEASUREMENT TECHNIQUES IN OPTICAL IMAGING
Different measurements techniques are used in optical imaging which are timeindependent or time-dependent. The three types of measurement techniques used in optical
imaging are continuous wave (which is time-independent), frequency-domain photon
migration, and time-domain photon migration (which are time-dependent).

11

Figure 2.4

shows the basic principle of the three methods. The continuous wave (CW) technique uses
light intensity that is constant in time. The amplitude of the incident light attenuates as it
passes through tissue and the amount that it attenuates is related to the optical properties of
that tissue (Figure 2.4A). CW imaging is relatively simple, fast and inexpensive; however,
one major drawback is that the absorption (!a) and scattering (!s) properties cannot be
determined independently since information is collected as a single combined measurement.
Frequency-domain photon migration (FDPM) uses intensity-modulated light waves that
experience amplitude modulation decay and phase shift with respect to the incident wave
(Figure 2.4B). The amplitude decay measures the absorption properties and the phase shift
measures the scattering properties enabling each property to be measured independently.
Time-domain photon migration (TDPM) uses nano- or pico-second laser pulses of incident
light that broaden and attenuate according to the optical properties as they pass through the
tissue (Figure 2.4C).

The photon times-of-flight are recorded to acquire a photon

distribution as a function of time. TDPM has good temporal resolution and is capable of
measuring

absorption

and

scattering

properties

independently.

However,

the

instrumentation is more expensive and complex because it requires detectors with
picoseconds or better resolution, and the method requires longer imaging time due to low
signal-to-noise ratio (SNR) than CW or FDPM.
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Figure 2.4 Diagram of the three measurement techniques for optical imaging: (A) continuous wave,
(B) time domain photon migration, and (C) frequency domain photon migration (adapted from
http://www.medphys.ucl.ac.uk/)

2.5 MEASURMENT CONFIGURATIONS IN OPTICAL IMAGING
Imaging systems can be designed for reflection and/or transillumination measurements. For
reflection measurements, light that has passed through the tissue is diffusely reflected from
the same side upon which the incident light was launched.

For transillumination

measurements, light that has passed though the tissue is diffusely transmitted from the side
of the tissue opposite from which it was launched.
Different measurement configurations are used to perform optical imaging which
determine the type of signal that will be collected from the tissue (reflectance and/or
transillumination).

The measurement geometries used in breast imaging are typically

governed by the instrumentation, i.e. bulky instrumentation or hand-held device based
instrumentation. Additionally, different combinations of point and area illumination are
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used.

These different imaging geometries are described in detail in the following

subsections.
Most three-dimensional (3D) optical imaging studies towards breast cancer diagnosis
employ either compressed tissue based imaging configuration [7-12] (Fig 2.5A) or circularbased imaging configuration [13-28] (Fig 2.5B). The compressed tissue based configuration
is analogous to x-ray mammography, and is disadvantageous due to patient discomfort from
tissue compression and limited information obtained around the complete breast tissue. The
circular-based configuration has minimal patient discomfort, but is limited by the bulky and
non-portable instrumentation. The sub-surface based imaging configuration (Fig 2.5C) is a
relatively new method that requires no tissue compression, and can be designed to mimic a
portable and flexible imaging probe [27, 29-71]. In recent years, hand-held based optical
imaging devices employing the sub-surface imaging configuration are developed in an
attempt to translate the technology to the clinic, with maximum patient comfort and
portability (compared to the available bulky optical imagers). A literature review of handheld based optical imaging devices developed to date is given in Chapter 3.

Figure 2.5 Different imaging configurations: (A) compressed tissue, (B) circular, and (C) subsurface Adapted from B. Jayachandran, 2007.[27]
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2.7 IMAGING GEOMETRIES
2.7.1 Point source vs. area illumination and collection
Different imaging geometries include the use of point source versus area illumination and
collection. In area illumination and collection, the incident laser light from a single source is
expanded to cover the entire tissue region being imaged at one time. The light is collected
from the tissue over the same region by typically using a CCD camera based detector. This
method has the advantages of rapid data acquisition and large volume interrogation, but
requires bulky instrumentation and cannot be made to conform to the geometry of the tissue
surface. Point source and detection based imaging uses optical fibers to illuminate and
collect the light from the tissue surface. This method has the advantage of placing the fibers
in direct contact with the tissue surface and can be made into a portable hand-held device
based imaging system.
2.7.2 Simultaneous illumination using point sources to approximate area
illumination
Point source and detector based imaging systems typically illuminate the source points
sequentially, via optical fibers. An alternative approach involves simultaneous illumination
of multiple source points. Simultaneous illumination enables rapid data acquisition and
better approximates a more ideal case of area illumination since a large volume of tissue is
interrogated in a single measurement. The hand-held device described herein employs
simultaneous illumination of six source points in order to facilitate rapid data acquisition and
larger volume interrogation as in area illumination. More details will be given in Chapter 6.
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2.8 INSTRUMENTATION
Instrumentation for optical imaging is chosen based on the application.

The basic

components of any optical imaging system are a light source and a detector. A single source
and detector pair are used for measuring single-point locations in the tissue which is termed
optical spectroscopy. Multiple sources and detectors are required to collect measurements
over an area of tissue which is termed optical imaging.

The process of collecting

measurements over an area and reconstructing the spatial optical property maps in 2D or 3D
is termed optical tomography.

2.8.1 Bulky instrumentation vs. hand-held devices
Different research groups typically develop or use optical imaging instrumentation either in
the form of an optical bed using the circular or compressed-tissue imaging configuration, or
a hand-held probe using the subsurface based imaging configuration. Several research
groups have developed optical imaging methods for breast imaging which use a bed upon
which the subject lies prone while the breast is either suspended in a ring or cup, or
compressed between two plates. An example of this type of instrumentation is shown in
Figure 2.6A. This type of instrumentation allows for transillumination based imaging and
control of the tissue geometry for ease in 3D image reconstruction.

However, the

instrumentation is bulky and non-portable and can be uncomfortable for the subject.
Additionally, many systems use a matching fluid to compensate for lack of direct contact
with the tissue.

In order to overcome these limitations, several research groups have

developed hand-held based optical imaging devices. Examples of these hand-held devices
are shown in Figure 2.6B and a complete literature review of the hand-held devices
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developed to date is given in Chapter 3. Hand-held devices have the advantages of being
portable and patient-comfortable, and achieve full contact with various-shaped tissues. The
devices developed to date are typically used to collect spectroscopic measurements of tissue
optical properties and/or to estimate the 2D location of a tumor. The devices use point
illumination/detection and reflectance based imaging geometry. None of the hand-held
optical devices developed to date have attempted 3D tomography (without the addition of a
second imaging modality) since they are unable to coregister the image to the tissue
geometry. The device described herein is unique in its ability to perform 3D tomographic
imaging using a hand-held NIR imaging device.

Figure 2.6 Different types of instrumentation used for breast include: (A) bulky optical bed based
imaging, and (B) hand-held device based imaging. Adapted from S. Erickson, 2009.[29]
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2.8.1 Sources
The most common types of sources used in diffuse optical imaging are laser diodes, light
emitting diodes, halogen lamps, Ti:sapphire lasers, and helium-neon (He-Ne) long coherence
lasers. An example of each type of source is shown in Figure 2.7. Laser diodes (Figure
2.7A) and light emitting diodes (Figure 2.7B) are semiconductors usually formed by a p-n
junction powered by an electrical current. Laser diodes of different NIR wavelengths are
used

according

to

the

measured

parameter

of

interest

(e.g.

oxyhemoglobin,

deoxyhemoglobin, water, lipids, etc.). A halogen lamp (Figure 2.7C) uses a tungsten filament
combined with halogen gas to produce white light of all wavelengths. Different filters can
be used to select particular wavelengths appropriate to the imaging application. Ti:sapphire
lasers (Figure 2.7D) are tunable lasers which can emit light in the NIR range between 6501100 nm. A He-Ne laser contains a mixture of helium and neon gas in a small bore capillary
tube and is usually excited by a direct-current (DC) electrical discharge.

Figure 2.7

Types of sources commonly used in diffuse optical imaging: (A) laser diode
http://fr.digikey.com/1/3/indexb31.html; (B) light emitting diode http://energyboomer.typepad.com; (C)
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halogen lamp http://shopzlot.biz/products/abco-halogen-lamp-50w-04423; (D) Ti:sapphire tunable laser
http://www.dmphotonics.com/DPSS/DPSS_CWlasers_TiSa_pumping.htm; (E) helium-neon He-Ne long
coherence laser http://www.newport.com

2.8.2 Detectors
The most common types of detectors used in diffuse optical imaging are charge-coupled
device (CCD) cameras, avalanche photodiodes (APD), and photomultiplier tubes (PMT).
An example of each type of detector is shown in Figure 2.8. A CCD camera (Figure 2.8A)
converts optical light signal into electrical amplitude signals using multiple charge-coupled
devices and reproduces the image of the subject. An avalanche photodiode (Figure 2.8B) is
a highly sensitive semiconductor electronic photodetector device that converts light into
electricity via the photoelectric effect. Photomultiplier tube detectors (Figure 2.8C) are
designed to amplify the current of incident light up to 100 million times using multiple
dynodes in order to detect very low intensity light signals.

Figure 2.8

Types of detectors commonly used in diffuse optical imaging: (A) CCD camera

http://www.aegis-elec.com/products/hitachi-KP-M3AN.html;
(B)
avalanche
photodiode
http://www.newport.com; (C) photomultiplier tube http://www.prizmatix.com/docs/OptiBlocks.cfm.

Diffuse optical imaging is an emerging modality which noninvasively measures the
optical properties (absorption and scattering) of near-infrared light in biological tissues.
External contrast agents can be used to perform fluorescence-enhanced optical imaging
toward detection of smaller tumors. Instrumentation is selected based on the different

19

measurement techniques and imaging configurations for different applications of optical
imaging in human tissues. The next three chapters give a review of past work performed by
different research groups using optical imaging technology for breast tissue imaging.

20

CHAPTER 3
Past Work: Hand-held Optical Imaging Devices
3.1 INTRODUCTION
Different hand-held based optical devices have been developed by several research groups
[27,29-71] with differences in the instrumentation, capabilities, and their specific
applications. The current review will focus on all the hand-held based devices (termed handheld imagers, probes, devices, and imaging systems by various researchers) developed to date
towards optical imaging of biological tissues using NIR light.

Table 3.1 provides a

condensed summary of the different NIR hand-held devices developed to date in terms of
the measurement technique, source and detector type, source wavelengths and input
intensity, number of sources and detectors, target depth, and the number and type of subject
studies (see Appendix I for extensive version of the table). Herein, the different hand-held
devices are primarily discussed in terms of: (i) the measurement technique employed; (ii)
imaging methods implemented; and (iii) their specific applications, along with the advantages
and disadvantages of the different systems available to date.
3.2 MEASUREMENT TECHNIQUES IN DIFFERENT HAND-HELD
DEVICES
Optical imaging is typically carried out using one of the three measurement
techniques, namely, continuous wave (CW), frequency domain photon migration (FDPM),
or time domain photon migration (TDPM). These measurement techniques are described in
detail in section 2.4. Different research groups developing hand-held based optical devices
employed different measurement techniques based on their specific application and focus of
research.
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Table 3.1 Summary of different hand-held devices developed towards optical imaging (extensive
table provided in Appendix I).
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3.2 MEASUREMENT TECHNIQUES IN DIFFERENT HAND-HELD
DEVICES
Optical imaging is typically carried out using one of the three measurement techniques,
namely, continuous wave (CW), frequency domain photon migration (FDPM), or time
domain photon migration (TDPM). These measurement techniques are described in detail
in section 2.4.

Different research groups developing hand-held based optical devices

employed different measurement techniques based on their specific application and focus of
research.

3.2.1 Continuous Wave (CW) Based Devices
The CW measurement technique (which measures the attenuated light intensity that remains
constant with time) has been employed by several of the devices developed for breast
imaging, although using different sources and detectors. A CW-based device developed at
the University of Pennsylvania (Device #3, Table 3.1) employed light emitting diode sources
(at three wavelengths) and silicon diode detectors [50-51]. Parallely, a different CW-based
device (Device #7, Table 3.1) was developed by another research group at the University of
Pennsylvania [60,71], employing a long coherence laser source (4 sources) and fast photoncounting avalanche photodiodes as detectors (four of them) coupled via detector fibers. In
contrast, a hand-held device (termed as a tissue oximeter) developed at the Ohio State
University (Device #6, Table 3.1) contained embedded laser diode and photodiode modules
for CW-based NIR imaging [57-58,71].
Typically CW-based techniques are preferred over the time-dependent FDPM or
TDPM measurement techniques, since the instrumentation is simple, inexpensive, and can

23

be made portable towards developing hand-held based imaging devices. However, the CW
technique provides limited depth information in comparison to the FDPM and TDPM
techniques. This is because the technique only measures the changes in intensity, reflected
from the combined effect of absorption and scattering (and not individually) [72-75] . In
addition, if the CW-based hand-held devices were applied towards fluorescence-enhanced
optical imaging studies, it would limit the technique from differentiating the changes in
fluorescence intensity arising from the fluorophore concentration or its decay kinetics (i.e.
fluorescence lifetime and quantum efficiency).
3.2.2 Frequency-Domain Photon Migration (FDPM) Based Devices
Most of the hand-held devices developed towards breast imaging employ FDPM technique
due to the advantage of measuring amplitude and phase shift of the modulated signal
separately. The following hand-held devices employ the FDPM measurement technique and
are described in chronological order of device numbers in Table 3.1.
�

A multi-wavelength FDPM-based hand-held device (Device #1a, Table 3.1) was
developed at the University of California, Irvine [33-39]. The device is capable of
working between 300 kHz to 1 GHz frequencies.

Modulated light source is

generated using laser diodes and a network analyzer (generates radiofrequency
signals) and avalanche photodiodes (APD) are used as detectors, since they are
capable of detecting the collected signals at such high frequency.

A second

generation of the device (Device #1b, Table 3.1) was developed, which combines
CW and FDPM methods into a single CW/FD probe [40-46]. The CW component
was added for broad continuous wavelength coverage resulting in better
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chromophore identification and improved concentration quantification than that
achieved using FD alone.
� More recently, researchers from the University of California, Irvine miniaturized an
entire FD imaging instrumentation into a single hand-held device (Device #2, Table
3.1) [47-49] . Modulated light source is generated using a signal generator (10 MHz
to 1GHz) and a laser diode. A homodyne and heterodyne based imaging version of
the device were developed and tested on homogeneous phantoms. The homodyne
device was simpler, but the accuracy was compromised by noise, while the
heterodyne device was more complex but the filtering of noise enabled greater
accuracy [47] . The homodyne based device used a single frequency at the source
and detector end, thus contaminating the detected signal with noise from the
ambient light and harmonic frequency. Hence, a heterodyne based version of the
mini-imaging device was developed, wherein two different frequencies were
employed at the source and detector end (here +45 MHz difference between
frequencies) in order to generate a new lower-frequency detected signal.

The

heterodyne approach (along with the use of a sharp crystal filter) filtered the noise
due to ambient light and harmonic frequency, thus improving the sensitivity of signal
detection.

This first heterodyne version of the device used one detector for

amplitude measurements of the 45 MHz heterodyne signal alone, and a second
detector for the regular phase measurements. Another version of the above device
was developed into a full-heterodyne laser breast scanner, which used heterodyne
technique for both amplitude and phase measurements [49].

The amplitude and

phase results from a breast phantom using full-heterodyne matched those predicted

25

by diffusion theory better than the results from the homodyne and the first
heterodyne version of the devices [47].
�

Two multi-modality based imaging devices (Devices #10a, #10b, #11, Table 3.1)
were developed at the University of Connecticut that combined FDPM-based optical
imaging and ultrasound into a single hand-held device [66-71]. The optical part of
each system used 12 pairs of dual wavelength laser diodes (780 nm and 830 nm) and
8 photomultiplier tube (PMT) detectors. The two devices differ in the sourcedetector configuration as described in Section 3.3.

� A device was developed at the University of Pennsylvania (Device #4, Table 3.1) that
used two simultaneous light sources, in contrast to the various frequency-domain
based imaging devices developed by all researchers to date using sequential point
source illumination.

The device was based on an ac circuit that acquired low

frequency (3 kHz) measurements at a single wavelength from a pair of anti-phased
(i.e. out of phase by 1800) light emitting diodes, using a silicon diode detector [53].
The device collected only amplitude changes, which are independent of frequencies,
unlike the phase measurements that are optimal at higher frequencies of 100-200
MHz. Hence, even a low frequency based device was sufficient to provide an
optimal signal to noise ratio (SNR) for this device [53], apart from reducing the
instrumentation costs in comparison to a high frequency based device.

The

simultaneous anti-phased source illumination caused destructive interference of the
photon density waves (PDW), which in turn was used to determine the 2-D spatial
target localization of an absorbing (or fluorescing) target in a 3-D phantom(s) [7680].
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� A hand-held device was developed at the Huazhong University of Science and
Technology (Device #5, Table 3.1), which also uses the same principle of
simultaneous anti-phased source illumination. The device used two pairs of light
emitting diodes (LEDs) that produced 3 kHz signals to form a low frequency phased
array 2D fluorescence system [54]. One pair of LEDs was in-phase and the other
was out-of-phase to produce two null planes, which in turn indicated the 2D location
of a fluorescent target. The device was designed to provide real time detection and
2D localization of small fluorescent objects within a highly scattering medium.

The advantages of time-dependent (FDPM and TDPM) over time-independent
(CW) measurement techniques were described in section 2.4. In addition, FDPM is often
preferable over TDPM due to improved signal-to-noise ratio (SNR). Steady-state FDPM
measurements in terms of amplitude and phase are minimally corrupted by the ambient light,
since the instrument detects only modulated signals.

Thus the FDPM instrument

automatically acts as a filter for ambient light rejection, which is not only an advantage for
FDPM over CW or TDPM techniques, but favored for clinical application in a non lightproof environment. Since hand-held optical devices are designed toward clinical translation,
they typically employ the FDPM technique due to this advantage.
3.2.3 Time-Domain Photon Migration (TDPM) Based Devices
Time domain photon migration (TDPM) is not a favorable measurement technique for
hand-held optical devices due to its expensive and complex instrumentation (as described in
section 2.4). To date, only one TDPM-based hand-held device (Device #8, Table 3.1) has
been developed at Physikalisch-Technische Bundesanstalt in Berlin, Germany [60] for
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bedside assessment of cerebral perfusion in stroke patients. The device measured diffuse
reflectance of 803 and 807 nm light from two picosecond diode lasers with pulse width of
~100 ps and 60 MHz repetition rate. Detecting fiber bundles were used to collect the light
and deliver it to photomultiplier tubes. The TDPM technique was chosen in this application
because the measurement of variance in distributions of time of flight of photons can be
used to monitor changes of absorption in the cortex as opposed to the skin or the skull.
3.3 IMAGING METHODS OF DIFFERENT HAND-HELD DEVICES
The hand-held imaging devices employing any one of the three measurement techniques use
appropriate source-detector configurations to allow spectroscopic, tomographic, or
interference-based imaging studies. The source-detector configuration governs the type and
quality of information obtained using the imaging device (as described in section 2.8).
Spectroscopic and tomographic imaging were described in section 2.8. In addition, the
principle of interference can be used toward tumor localization. This method requires at
least two sources that simultaneously illuminate in-phase (constructive interference) or outof phase (destructive interference), and typically detected using a single detector. The handheld optical devices developed can thus be categorized in terms of the method of imaging as:
(i) spectroscopic imaging-based, (ii) tomographic imaging-based, and (iii) interference
imaging-based. Schematics of the different source-detector configurations employed by the
hand-held devices using the different imaging methods are shown in Figures 3.1, 3.2, and 3.3
for spectroscopy-based, tomography-based, and interference-based devices, respectively.
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3.3.1 Spectroscopic Imaging-based Devices
Spectroscopic imaging-based devices utilize the simplest source-detector configuration of a
single source and single detector, in order to obtain spectroscopic information.

The

spectroscopic imaging-devices developed by a research group at the University of California,
Irvine used the single source-detector design for characterization of breast tissue [33-46].
The Device #1a in Figure 3.1 developed by this research group has a single source-detector
pair to measure photon density wave phase and amplitude from which physiological
properties of normal and tumor tissue are extracted [33]. The second generation of the same
device (Device #1b, Figure 3.1) used two source-detector pairs, of which one pair obtained
FD measurements and the second pair obtained CW measurements [40]. The mini-FDPM
device developed by researchers at the University of California, Irvine (Device #2, Figure
3.1) also employed a single source (laser diode) and single detector (APD) that were housed
within the device in order to make direct contact with the tissue surface [44-49].
The use of multiple sources and detectors enables measurements from several
locations and tissue depths and provides more information for the reconstruction of the
tissue optical
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Figure 3.1 Schematics of spectroscopic imaging-based devices. (a) Device #1a developed by
researchers at the University of California, Irvine, which contains a single FD source-detector pair,
(b) Device #1b developed by the same group, which contains a single FD source-detector pair and a
single CW source-detector pair, and (c) Device #2 developed by other researchers at the same
university, which contains a single source and detector embedded within the probe, (d) Device #3
developed by researchers at the University of Pennsylvania, which contains a single source
surrounded by 8 detectors, (e) Device #6a developed by researchers at Ohio State University and
ViOptix, Inc., which contains 8 sources and 8 detectors, (e) Device #7 developed at the University of
Pennsylvania, which contains 4 sources and 4 detectors, (f) Device #8 developed at PhysikalischTechnische Bundesanstalt, which contains 2 sources and 4 detectors, (g) Device #9a developed at
the University of Pennsylvania, which contains 2 sources and 4 detectors, and (h) Device #9b
developed by the same group, which contains 4 sources and 2 detectors.

properties. Most of the spectroscopic imaging-based devices developed to date employ
multiple sources and detectors in their probe design. The hand-held devices which used
multiple sources and detectors are described below.
�

One of the research groups at the University of Pennsylvania [50], developed a device
for breast imaging (Device #3, Figure 3.1) consisting of a single LED source centered on
the device that is surrounded by eight silicon diode detectors, each of which were located
4 cm from the source. This configuration enables the device to interrogate a larger tissue
area than the use of a single detector would allow. Another research group in the same
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university [58-59] developed a device containing 4 sources lined up parallel to 4 detectors
(Device #7, Figure 3.1). The line of sources and line of detectors were separated by 2.5
cm.
� A breast imaging device developed at Ohio State University and ViOptix, Inc. (Device
#6a, Figure 3.1) contained 8 sources and 8 detectors arranged in a 2.5 cm x 2.5 cm
matrix [55-59] in order to image even larger areas. A second generation of the device
was later developed (Device #6b, Table 3.1) that contained 16 sources and 8 detectors to
form a 3 ! 3 cm2 matrix [57]. In these devices the photodiode detectors collected the
light simultaneously at a sampling rate of 100 kHz while the 16 source fibers were
illuminated sequentially.
•

Several hand-held devices with multiple sources and detectors have also been developed
towards brain imaging studies.

The device developed at Physikalisch-Technische

Bundesanstalt in Berlin, Germany (Device #8, Figure 3.1) to measure cerebral perfusion
in stroke patients contains 2 sources and 4 detectors [60]. One source and two detectors
are positioned on each hemisphere of the head and four distributions of times of flight
of photons were measured simultaneously at the 4 detector positions.

Two other

devices were developed at the University of Pennsylvania to monitor radiation therapy in
patients with head and neck tumors [61]. One device contains 2 sources and 4 detectors
with layout as shown in Figure 3.1 (Device #9a) and the second device contains 4
sources and 2 detectors (Device #9b, Figure 3.1). Both devices use NIR spectroscopic
tools, but the former device is used to measure tumor blood flow before and during
radiation therapy (method termed as diffuse correlation spectroscopy), and the latter

31

device is used for quantification of the concentration of tissue chromophores in the head
and neck regions (method termed as diffuse reflectance spectroscopy).
3.3.2 Tomographic Imaging-based Devices
The tomography imaging-based devices employ multiple sources and detectors in order to
obtain 2D surface images as well as employ the measurements towards tomographic
reconstructions. One group from the University of Connecticut developed hand-held NIR
devices with multiple source-detector configurations combined with an ultrasound array [6271] as shown in Figure 3.2 (Devices #10a, #10b and #11). The use of multiple sources and
detectors enabled area imaging using the NIR component, and a priori information from the
ultrasound component enabled 3D tomography, thus determining the target location.

Figure 3.2 Schematics of tomographic imaging-based devices. (a) Device #10a developed by
researchers at the University of Pennsylvania and University of Connecticut, which contains a central
ultrasound component surrounded by 12 sources and 4 detectors, (b) Device #10b developed at the
University of Connecticut, which contains an additional 4 detectors, and (c) Device #11 developed
by the same group, which contains an ultrasound component with 12 sources and 8 detectors.
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3.3.3 Interference Imaging-based Devices
All of the devices containing multiple sources are sequentially illuminated during imaging
studies. In contrast, the interference imaging-based devices are designed and developed to
perform simultaneous illumination of multiple sources for tumor location studies. The
interference imaging-based device developed at the University of Pennsylvania [53] for
breast

Figure 3.3 Schematics of interference imaging-based devices. (a) Device #4 developed at the
University of Pennsylvania, which contains a detector centered between two anti-phase sources for
phase cancellation technique, (b) Device #5 developed by researchers at the Huazhong University of
Science and Technology, which contains a detector centered between a pair of in-phase sources and a
pair of anti-phase which also uses the phase cancellation technique.

imaging employed two 800 nm LED sources that are illuminated simultaneously, but antiphase (i.e. out-of-phase) with respect to each other (Device #4, Figure 3.3). A single silicon
diode detector was placed mid-way (and in the same plane) between two sources, in order to
detect and locate breast tumors based on the principles of destructive interference signals (as
described in Section 3.3). A different breast imaging device developed at the Huazhong
University of Science and Technology (Device #5, Figure 3.3) employed two pairs of
simultaneous light sources, wherein one pair was in-phase (to generate constructive
interference pattern of the PDW) and the second pair was anti-phase (to generate destructive
interference pattern of the PDW). The emitted optical signals were detected using a single
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fiber located at the center of the four sources in the probe that was connected to a
photomultiplier tube (PMT) [54]. The in-phase and anti-phase sources interfere to create a
null plane which was used to locate a target within the turbid medium. The target location
was determined by the constructive or destructive interference pattern of the photon density
waves (PDWs) in the presence of a tumor. This is a different approach towards real time
localization of absorbing fluorescent objects within a highly scattering medium (in turn
applicable for breast cancer localization).
3.4 CLINICAL APPLICATIONS OF DIFFERENT HAND-HELD DEVICES
The selection of measurement technique and source-detector layout is influenced by the
application to which the hand-held optical imaging device will be used. Hand-held devices
for NIR spectroscopy/imaging are used for several different applications related to the
breast tissue (primarily), including measurement of normal and abnormal tissue physiological
properties, tumor localization, and monitoring tumor changes during neoadjuvant
chemotherapy treatment.
3.4.1 Measurement of Normal and Abnormal Tissue Physiological Properties
NIR spectroscopy has been used to show that the optical properties of normal breast tissue
vary under different circumstances. Studies were conducted at the University of California,
Irvine using the single source-detector device to demonstrate the differences in tissue
physiological properties in pre- and post-menopausal subjects [35,40], as well as during
different time periods of the menstrual cycle [38]. The results showed the ability of the NIR
device to demonstrate wavelength-dependent differences in absorption and scattering
properties between pre- and post-menopausal normal breast tissues as well as differences in
the same breast tissue during different time periods in the menstrual cycle. It was also
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shown that the tissue properties vary both amongst different normal subjects, and also with
respect to the different locations within the same breast of a normal subject [39].
One of the primary objectives of NIR spectroscopic imaging is to detect the
presence of a tumor, based on the differences in the optical properties of normal versus
diseased (tumor-bearing) tissue. Several hand-held devices have been developed toward
detection of tumors within breast tissue:
� Device #1a in Table 3.1 was used to obtain measurements from normal and tumorcontaining human breast tissue [33]. Measurements were performed on two human
subjects using a FDPM-based device, wherein one subject had fibroadenoma with
ductal hyperplasia and the other had a benign fluid-filled cyst. The FDPM-based
device was able to measure changes in absorption and scattering due to the presence
of a small (1 cm diameter) lesion in the human breast. The data demonstrated
differences in the concentrations of oxy- and deoxy-hemoglobin, and water in the
normal versus tumor-bearing breast. A second detector was added to the above
probe for a clinical study involving four human subjects with palpable lesions [34].
The second detector enabled two different source-detector distances (1.3 and 2.5
cm) to be applied with each measurement, which provided information from
different tissue depths.

The results showed the differences in tissue optical

properties between tumor and normal tissue, as well as between different types of
lesions.
�

The combined continuous wave and frequency-domain (CW/FD) based device
(Device #1b, Table 3.1) developed at the University of California, Irvine was used to
measure tissue properties in human subjects.

35

The CW/FD based device was

compared to a system that used only FD (Device #1a, Table 3.1) in a study involving
a total of 31 normal and abnormal human subjects [41]. The FD component used
only a few discrete wavelengths within the range of 650-1000 nm, whereas the CW
component measured continuously across the entire range. The added bandwidth of
imaged frequencies due to the CW measurements resulted in better chromophore
identification and improved concentration quantification than using FD component
alone. Another study was performed using the CW/FD based device in order to
identify functional contrast in normal and abnormal breast tissue within a statistically
relevant population of human subjects [45]. The spectra from tumor and normal
tissue measured with the CW/FD based device were compared in 57 patients. The
results showed differences in the optical properties of the tissue based on subject
age, tumor size, and tumor pathology. Optical measurements obtained towards
differentiating normal from diseased tissues were from lesions as small as 1 cm,
whose locations were determined a priori from standard x-ray mammography.
�

The full-heterodyne hand-held broadband breast scanning device developed at the
University of California, Irvine (Device #2, Table 3.1) was tested on breast and
muscle phantoms [47] and an abnormal human subject [49]. The device was used to
extract the optical properties (absorption and scattering coefficients) from
phantom(s) and human tissue(s).

Based on the measured differences in the

absorption coefficients between the diseased (i.e. tumor) and normal breast tissue,
the device detected the presence of a 6.36 ! 4.09 cm2 lesion in-vivo, located at a tissue
depth of 0.5 cm. The lesion size detected was relatively large compared to those
detected by other hand-held devices, yet this device is relatively simple, compact, and
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an inexpensive design that is capable of extracting optical properties within a tissue
volume [49].
�

The multi-detector hand-held device developed at the University of Pennsylvania
(Device #3, Table 3.1) was used in an extensive study to show the differences in the
biochemical and physiological properties of breast tissue containing growing cancers,
compared to corresponding normal tissue in the contralateral breast [50]. The use of
multiple detectors increases the area and volume that can be interrogated with each
scan, apart from increasing the overall data acquisition rates. Also, a source-detector
separation of 4 cm has a significant probability of detecting a target at a depth of 4
cm or more [50]. In a study involving 116 subjects recruited over six years, CW
measurements were obtained on both the normal and tumor-bearing breast tissues of
human subjects. The smallest lesion detected was 0.8 cm and the greatest tissue
depth reached was 4 cm. The results demonstrated the ability of the device to detect
the presence of lesions based on measured values of angiogenesis and
hypermetabolism. The difference in these values between the normal and the tumor
bearing breast indicated the presence of cancer. All the subjects involved in the
above study were patients undergoing biopsy, and hence the lesion location was
known a priori using a different imaging modality.

� The hand-held device (termed as tissue oximeter by the researchers) designed by Xu,
et al (Device #6, Table 3.1) was used for real time imaging of tissue oxygen saturation
and hemoglobin concentrations [55-57].

Simulation experiments and sensitivity

analysis were performed with respect to tumor size, tumor depth, tumor lateral
location, and optical contrast [55]. The maximum measurement depth was 1.5 cm
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with absorption sensitivity of 0.1 cm. The device was used in a study in conjunction
with ultrasound to image an abnormal breast in a human subject [56]. The results
from combining NIR spectroscopy and ultrasound modalities demonstrated 3D
tomographic imaging (towards 3D target localization) of functional parameters of a
breast lesion and the surrounding normal tissue. 3D reconstruction was performed
after the added information of a second imaging modality (ultrasound). The actual
lesion size imaged for this study was 0.58 ! 0.41 ! 0.51 cm3. In another study, the
same device was used (without ultrasound) to test the effect of compression on
human calf muscle and human breast tissue in vivo [57]. The homogeneous optical
property in terms of absorption coefficients was determined for these tissues, using
analytical solution of the diffusion equation in semi-infinite/infinite medium along
with the 2D and 3D experimental images.
� A hand-held device (Device #7, Table 3.1) was designed to measure blood flow
heterogeneity [58-59] in order to show that blood flow in a breast containing a
palpable tumor is different than that in a normal breast. The device was used to
obtain measurements from a 2.0 cm diameter lesion located at a depth of 1.0 cm.
The results showed that blood flow was greater in the tumor region than in the
normal tissue.
3.4.2 Tumor Localization and Characterization
Several hand-held devices have been designed not only to detect the presence of a tumor,
but also to determine the 2D location of the lesion within a breast using NIR optical
imaging.
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� The ac circuit based device developed at the University of Pennsylvania (Device #4,
Table 3.1) was used in phantom(s) and in-vivo human studies as well [53]. As
described in Section 3.2, the device worked by phase cancellation from the two light
sources. The device was scanned across the breast or phantom and when the
presence of a target was detected, a change in sound or light on the device indicated
the 2D location of the lesion. The device was able to detect the presence and 2D
location of phantom targets as small as 1.0 cm3, which were located up to a depth of
5 cm.
� The only hand-held device that was used for fluorescence measurements has been
developed at the Huazhong University of Science and Technology (Device #5, Table
3.1). A study was performed with a phantom containing a 1.0 cm3 target with 0.8
!M ICG, located at a depth of 0.8 cm [54]. The device uses the phase cancellation
technique (as described in Section 3.2) with a combination of constructive and
destructive interference patterns in order to locate the fluorescent target.
These hand-held devices demonstrate the ability to indicate the 2D location of a target from
surface measurements based on phase cancellation of PDWs. They have the advantage of
being simple and compact and give 2D target locations even prior to any tomographic
imaging.
One major goal of optical imaging is to not only localize a lesion, but also to
differentiate if the lesion is benign or malignant. Conventional imaging techniques such as
x-ray mammography and breast ultrasound have limited ability to differentiate benign and
malignant lesions leading to large numbers of benign biopsies [67]. Optical imaging using a
single wavelength can measure optical absorption, which is related to tumor vasculature.

39

When multiple wavelengths are used, oxyhemoglobin and deoxyhemoglobin can be
measured and give information regarding tumor malignancy [69].
Several versions of a multi-modal hand-held device (Devices #10a, #10b, #11, Table
3.1) have been developed at the University of Connecticut [62-71] which combine NIR
optical imaging and ultrasound into a single hand-held device. The optical information using
multiple wavelengths can better determine the tumor malignancy [67,69] and the ultrasound
component provides a priori information which enables tumor localization by 3D
reconstruction [65]. The device was used to image and differentiate benign and malignant
lesions in human subjects. The lesions were successfully reconstructed using the a priori
information from the ultrasound component and it was found that malignant lesions had a
much higher maximum total hemoglobin concentration due to increased angiogenesis
[67,69].
3.4.3 Monitoring Tumor Changes during Neoadjuvant Chemotherapy
Another important application of optical hand-held devices is to monitor the progression of
a tumor over time as chemotherapy treatment is administered. Neoadjuvant chemotherapy
treatment is administered to a cancer patient prior to surgery in an attempt to decrease the
size of the tumor. Several studies have been conducted toward this application.
� The CW/FD based device developed at the University of California, Irvine (Device
#1b, Table 3.1) was used in several studies conducted in order to monitor tumor
response to neoadjuvant chemotherapy in patients [42-43,46]. The tumor locations
were known a priori from mammography, ultrasound, or palpation. The device was
used to measure the physiological characteristics of the tumor prior to
chemotherapy.

This was followed by monitoring the changes in tissue optical
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properties over several months, due to changes in the tumor with neoadjuvant
chemotherapy treatment.
� In a different study, NIR spectroscopic imaging using the same CW/FD device was
performed along with MRI in order to monitor the response to neoadjuvant
chemotherapy in a human subject [43]. The initial lesion size was 3.8 ! 4.3 ! 4.3 cm3
before treatment and 3.0 ! 2.4 ! 2.3 cm3 after treatment. The NIR spectroscopy
measurements provided functional information in terms of absolute hemoglobin
concentrations and tumor hemoglobin oxygen saturation, while the MRI provided
anatomical information.

The final images were a combination of the functional

information from NIR spectroscopy and the structural information from MRI.
�

Researchers from the University of Connecticut used their multi-modal hand-held
device (Device #11, Table 3.1) to image heterogeneous hemoglobin distributions in
large cancers, which are used to monitor tumor vascular responses to neoadjuvant
chemotherapy [70].

Tumors ranging from 2.5 to 4 cm were monitored in six

patients. The studies showed that after several cycles of neoadjuvant chemotherapy
the measured values of total hemoglobin concentration and spatial extension were
much smaller in comparison to those prior to chemotherapy.
Most of the applications using the different hand-held devices were involved with the breast
tissue and hence described in detail above. In addition, there has been applications of handheld based NIR devices towards cerebral perfusion in stroke patients (Device #8, Figure
3.1), and monitoring radiation therapy in patients with head and neck tumors (Devices #9a,
9b, Figure 3.1).
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3.5 DISCUSSION AND CONCLUSION
Many hand-held based NIR devices have been developed for optical spectroscopy and
imaging applications. Apart from being non-invasive and non-ionizing, the advantages of
hand-held optical imaging devices are that they are also portable, relatively inexpensive, and
patient-comfortable because they do not require tissue compression. However, optical
measurements can be easily contaminated by motion artifacts caused by patient or operator
as well as relative motion of the probe and soft tissue during contact imaging, similar to 1D
ultrasound probes scanned in 2D to perform 3D imaging. Careful operation procedure and
operator training are required to obtain good quality images using hand-held based optical
devices over using bulky optical systems employing compression plates or circular geometry.
The optimal design of a hand-held device is determined by the parameter(s) to be
measured and the specific applications it is implemented towards. The hand-held devices
developed to date primarily use CW and/or FDPM measurement techniques. FDPM has
the added advantage over CW of collecting both amplitude and phase information separately
and thus provides improved optical contrast and greater depth information [77]. The handheld devices also differ in the source-detector configuration, which is primarily governed by
the desired applications they are developed towards. A single source and detector design has
been used for spectroscopic measurements of physiological properties.

Dual sources

illuminated simultaneously and out-of-phase have been used for target location by detection
of phase cancellation. Multiple sources and detectors have been configured towards imaging
a given area of the tissue.
The overall goal of any hand-held based optical device is to accelerate the clinical
translation of the technology, with maximum patient comfort and portability (compared to
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the many bulky optical imagers available). However, all of the hand-held optical devices
available to date have only flat probe heads, which limit them from contouring to tissue
curvatures with good surface contact. The flat probe head design also limits the devices to
collecting only diffuse reflectance measurements, and not transilluminated measurements.
Independent of the measurement technique (CW, FDPM, or TDPM) employed, reflectancebased measurements provide limited depth information and depth recovery of tumors in
comparison to transillumination-based measurements [3] (wherein the light is allowed to
propagate through tissue depths and NIR signals are collected on opposite surfaces with
respect to the illuminating surface).
In addition, most of the applications of these hand-held based optical devices are
limited to spectroscopic measurements of physiological properties and 2D target localization
(without tomographic analysis). To date, these hand-held optical devices (or imagers) have
not been successful in demonstrating 3D tomographic imaging of tissue phantoms or real
tissues using NIR imaging alone (with or without fluorescence), since the source and
detector points are not co-registered onto the tissue contours. In order to successfully
reconstruct a lesion size and location in three dimensions, a priori information from another
imaging modality (e.g. ultrasound) was required [65-70].
The hand-held optical imager developed in our laboratory is unique from other
devices in that it is capable of performing 3D tomography (using NIR imaging alone) via
implementation of self-coregistration facilities. The features and instrumentation of the
device are described in detail in Chapter 6.
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CHAPTER 4
Past Work: Fluorescence Tomography Experimental Studies
4.1 INTRODUCTION
Fluorescence-enhanced diffuse optical tomography (FDOT) has been explored by many
research groups in the past three decades.[3,81-133] This chapter gives a review of the
recent literature from 2008 to the present. A literature review of image reconstruction using
experimental data from fluorescence tomography (FT) studies up to the year 2007 is
provided in Appendix B. Table 4.1 provides a summary of the experimental research
performed in fluorescence tomography from 2008 to the present. The work performed by
different research groups is summarized here in terms of (i) efforts to improve the
reconstruction algorithm for fluorescence tomography, (ii) efforts to develop and/or
improve instrumentation for fluorescence tomography, and (iii) efforts to improve
experimental methods of fluorescence tomography.
4.2 RECONSTRUCTION ALGORITHM FOR FLUORESCENCE
TOMOGRAPHY
Reconstruction of fluorescent optical data is mathematically challenging due to the illposed18 nature of the inversion problem. Several research groups are currently working to
improve the computational aspect of fluorescence tomography.

18

Having more than one solution.
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Table 4.1 Summary of the experimental research performed in fluorescence tomography
from 2008 to the present
Phantom / Animal
Reference

Backgroun
d

Target

(Davis, et
al, 2008)
[121]

DPBS, 1%
intralipid,
ICG,
&
India ink

(Kepshire,
et al, 2008)
[115]

Water, 2%
India ink,
5% Tween20,
1%
intralipid
1% Liposyn
(10x10x6.5
cm)

(Ge, et al,
2008)
[3]

Measure
ment
Method

Contrast

Instrumentation
Source

Detector

(geometry)

(geometry)

CW (w/
MRI)

690 nm laser
diode (point)

CCD (point)

3.5:1 10:1

CW

635 nm laser
diode (area)

ICG

1:0

FDPM

Agent

Ratio

Plastic
cylinder
R=1 cm

ICG

3.3:1

Cylinder
R=4 mm

Pp-IX

Plastic
sphere
R=0.475
cm

2D
or
3D

Forward
Method

Inverse
Method

3D

Diff.
Approx.

Laplacian
&
Jacobian

CCD (area)

2D

Diff.
Approx.

FluoroFAS
T
(software
package)

785 nm laser
diode (point)

ICCD
(point)

3D

FEM

AEKF

(Mohajerani
, et al,
2009)
[122]

Nu/Nu mice

4T-1
murine
breast
adenocarci
noma cells

ProSen
se

in-vivo

CW

--

--

3D

Diff.
Approx.

MSE
&
coincidenc
e mask

(Davis, et
al, 2009)
[123]

Liquid
(water, 1%
intralipid)
Solid
(gelatin,
TiO2, blood)
rectangular
cuvette
(25x25x6
cm3)
Nude mice

2
small
heterogenei
ties

LuTex

2.5:1,
3:1

CW

690 nm laser
diode (point)

CCD (point)

2D

FEM

diffusionbased
optimizatio
n

delrin twin
cones

Omocy
anine

5:1

TDPM

Ti:sapphire
laser (point)

GaAs-PMT
(point)

3D

Diff.
Approx.

Rytov
approx.

Lewis lung
carcinoma
cells

in-vivo

CW

593 nm, 750
nm
laser
diode (area)

CCD (area)

3D

none

ART

(Kepshire,
et al, 2009)
[126]

Phantom
from ART,
Inc.

Sphere
R=4 mm

mCherr
y
fluores
cent
protein
Pp-IX

1:0

CW
(noncont
act)

635 nm laser
diode (point)

4
PMTs
(point)

2D

none

NIRFAST

(Ge, et al,
2009)
[127]
(Lin, et al,
2010)
[128]

1% Liposyn
(10x10x6.5
cm)
Agarose
powder,
India ink,
intralipid
(25
mm
diameter)
Transgenic
mice

R=0.290.475 cm

ICG

5:1
1:0

FDPM

785 nm laser
diode (point)

ICCD
(point)

3D

FEM

AEKF

Glass tube
R=1.2 mm

ICG

1:125:1

CW (w/
DOT &
XCT)

785 nm, 830
nm
laser
(point)

CCD (area)

2D

Coupled
Diff. Eq.

Laplacian

Amyloidbeta
plaques

Oxazin
e
derivati
ve
probe

in-vivo

CW

650 nm laser
diode (area)

CCD (area)

3D

Diff.
Approx.

Tikhonov
w/
structural
priors

(Ziegler, et
al, 2009)
[124]
(Deliolanis,
et al, 2009)
[125]

(Hyde, et al,
2010)
[129]

-
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(Schultz, et
al, 2010)
[130]

Euthenized
nude mice

Artificial
brain lesion

Alexa
750
fluoroc
hrome

in-vivo

CW (w/
XCT)

670 nm, 750
nm
laser
diodes
(point)

CCD (area)

3D

Diff.
Approx.

(Liu, et al,
2010)
[131]

Cylinder
phantom
R=1.5 cm
(1%
intralipid)
Cylinder
R=12.5 mm
(India ink,
titanium
oxide)
Intralipid
solution &
SCID/Ncr
mice

2
glass
tubes
R=0.15 &
0.3 cm

ICG

1:0

CW

Halogen
lamp (area)

CCD (area)

3D

Coupled
Diff. Eq.

Cylinder
R=2 mm

Alexa
Fluor
680

1:0

CW

655 nm laser
diode (area)

CCD (area)

2D

Diff.
Approx.

Lp
regularizat
ion

Glass tube
R=0.5 cm;
MDA231luc
cells

Cy7

5:1 50:1

FDPM

690 nm laser
diode (point)

PMT (point)

3D

none

Born
approxima
tion

(Baritaux, et
al, 2010)
[132]
(Biswal, et
al, 2010)
[133]

Tikhonov,
Laplace
prior,
diagonal
weighting
prior
ART

A research group from the University of Berlin used an algebraic reconstruction
technique (ART) method to analyze DOT data and incorporated a noise-weighted back
projection method.[124] This method has the advantages of: (i) allowing high cutoff
frequencies to be chosen due to the algorithm’s avoidance of significant distortions of the
reconstructed image, and (ii) the ART algorithm uses a normalized image vector which
improves the separation of absorption and scattering by rescaling to a dimensionless image
vector with comparable size of the norm of both images. The algorithm was tested with
experimental data from a breast phantom using measured time-domain diffuse reflectance
and transmittance of excitation and fluorescence radiation. Images were collected with a
fluorescent target embedded in the phantom with compressed-tissue geometry using three
different source-detector geometries: (i) projection-shadow geometry; (ii) slab fan-beam
geometry; (iii) slab reflection and transmission geometry. The results showed that collecting
reflectance data at the excitation and fluorescent wavelength in addition to the transmitted
data greatly improved the depth resolution. They concluded that scanning time-domain
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fluorescence mammography will be improved by the use of both reflectance and
transmittance measurements from both sides of the compressed breast.
A group from Georgia Institute of Technology developed a reconstruction approach
that uses a mean-square error algorithm and accounts for what they term as “tunneled light”,
i.e. the portion of light that passes through parts of the tissue which have lower absorption
and hence has higher intensity than the portion of light that passes through the other parts
of the tissue.[122] The reconstruction approach uses the strong spatial correlation between
the excitation and emission images to estimate the tunneled components and gain a resulting
image containing mostly signal due to the fluorescence. The resulting image is further
refined using a coincidence mask (i.e. a map of the ‘hot spots’ that occur in both emission
and excitation images). The algorithm was tested on experimental data from in vivo studies
performed on a human colon adenocarcinoma xenograft tumor model. The results showed
much stronger fluorescent signal from deeper tissues using this method. They concluded
that identification, estimation, and correction of signal from tunneled light can improve
image reconstruction in fluorescence tomography.
The research group from Harvard Medical School presented a Tikhonov based
method for reconstruction of multimodal FMT-XCT or FMT-MRI images which uses
information from within the data to get data-driven priors rather than the typical userdefined priors.[129] The first step compensates for the resolution differences between XCT
(high resolution) and FMT (low resolution) by labeling each FMT voxel as a linear mixture
of the different tissue types identified in the high-resolution image. The segment labels were
used to construct a low dimensional inverse problem that gives a single intensity value for
each anatomic area, and the values were used as parameters to define a spatially varying
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regularization term for the full resolution FMT problem. The algorithm was tested on
experimental data collected from APP23 transgenic mice exhibiting amyloid-� plaques in
the cortical region.

The results showed that the method of using data driven priors

generated improved reconstruction of the fluorescence in the cortical region.
A research group from Tsinghua University developed a method that uses principal
component analysis (PCA) on a time-series of FDOT images in order to detect and visualize
organs with different kinetics.[131] PCA is a method used to extract relevant features of a
correlation matrix based on principal components, which express different kinetic behavior
with high inter-correlations. PCA was performed on 6 frames from tomographic images
(with zero mean) from dynamic FDOT images at the same slice. The principal component
elements were used as weight factors to generate images containing different colors to
represent regions with different kinetic behavior. The method was tested on simulated
mouse data and experimental data from phantom studies. The results using the PCA
method showed images that illustrated organs and functional structures that had different
kinetic patterns. They concluded that the PCA method (i) provides a non-invasive method
for measuring changes in organ function, (ii) enhances the resolution and specificity of
FDOT through emphasis of differences in kinetic behavior, (iii) provides additional
anatomical information without the use of multiple modalities, and (iv) is not subject to
model-based restrictions since it is independent of any kinetic model.
A research group from the Swiss Federal Institute of Technology developed a
reconstruction approach that uses what they term as Lp regularization (p ! 1) to reconstruct
fluorescence data using a matrix-free strategy in order to reduce computational costs.[132]
They tested the sparsifying effect of using L1 regularization and compared it to L2
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regularization (Tikhonov method). 2D reconstructions were performed using experimental
phantom data. The results showed that the method improved the computation time and
memory requirements since it does not require calculation of a system matrix, and the
reconstructions obtained using the L1-regularization displayed fewer artifacts and improved
localization than those using a linear algorithm.
A research group from the University of Connecticut developed a Born
approximation based reconstruction approach which separately estimates the structural
parameters of a target such as target center (depth and spatial x and y locations) and size, as
well as reconstructs the functional information using only optical based measurements.[133]
The method was tested on data from phantoms and mice injected with VEGF/Cy7 (an
angiogenesis tracer). The results showed the ability to reconstruct fluorescent targets with
less than 25 nM of contrast agent up to 2 cm deep in both homogeneous and heterogeneous
backgrounds.
4.3 INSTRUMENTATION FOR FLUORESCENCE TOMOGRAPHY
One major challenge of fluorescence tomography from an instrument perspective is poor
spatial resolution due to the highly scattering nature of biological tissue. Several research
groups are currently developing instrumentation designed to improve the imaging ability of
fluorescence tomography by combining the method with spatial prior information from
other methods such as x-ray CT.
The research group from Dartmouth College developed a multi-channel spectrally
resolved fluorescence optical tomography system within a clinical MRI for imaging of
molecular targets in small animals.[121] The fiber-optic based NIR system was composed of
16 fiber bundles which each contain six detection fibers and one source fiber used to obtain
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transmission and emission NIR spectra. The emission light was spectrally fitted to separate
the fluorescent signal from the background improving the accuracy and sensitivity of images
with small concentration of fluorophores. The tissue morphology acquired from MRI was
used as an imaging guide for the optical reconstruction. Results from phantom and small
animal studies demonstrated the capability to image low fluorescent contrast (3.3:1) in 70
mm diameter tissue volumes using the spatial prior information from the MR images.
Another group from Dartmouth College designed a small animal imaging system
which couples fluorescence tomography (FT) and x-ray microcomputed tomography
(microCT).[126] The information from microCT was used as spatial prior information and
overlays the FT image on the microCT image. The FT system uses a rotating gantry with a
single source and and a fan-beam of detectors which rotate around the surface of the object
for non-contact excitation and detection. Results from phantom studies demonstrated the
ability of the system: (i) to allow maximum sensitivity in optical tomography with single
photon counting, (ii) use a noncontact imaging configuration to accompany microCT, (iii)
obtain fluorescence and transmission data in parallel, (iv) require only several minutes total
for imaging time, and (v) perform imaging with multiple detectors in parallel.
A research group from the University of California, Irvine developed a unique, fully
integrated tri-modality gantry-based system that combines FT, DOT, and x-ray CT (XCT).
XCT was used to provide anatomical prior information and DOT was used to provide
functional prior information of the heterogeneous optical background for the FT
reconstructed images.[128] The optical system used point source (3 optical fibers) and area
detection configuration for transmission based imaging.

Results using the DOT prior

information only demonstrated accurate localization of a fluorescent target within a
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heterogeneous phantom background; however, the concentration of the fluorophore was
recovered with 70% error.

Results using both the DOT and XCT prior information

recovered the fluorophore with only 8% error.
A research group from the Technical University Munich designed a hybrid small
animal imaging system which combines fluorescence tomography and x-ray computed
tomography.[130] The 360º-projection free-space FT system uses point source (two optical
fibers) and area detection configuration for transmission based imaging. Structural priors
from the XCT images were incorporated into the optical reconstruction to allow improved
imaging performance. Results demonstrated the ability of the system to reconstruct an
artificial brain lesion within a euthanized nude mouse.
Most of the instrumentation for fluorescence tomography studies has been focused
toward small animal imaging (especially multimodality imaging). In our Optical Imaging
Laboratory we have developed a hand-held probe based optical imaging system and
demonstrated 3D fluorescence tomography in clinically relevant sized tissue phantoms.[3]
Extensive phantom studies demonstrated the ability of the device to reconstruct a
fluorescent target (0.45 cm3) up to a depth of 2.5 cm under perfect uptake conditions.[127]
A 1.0 cm deep fluorescent target was recovered under a target to background contrast as low
as 25:1. The sensitivity and specificity of the device was estimated at 43% and 95%,
respectively, based on phantom studies. In vivo fluorescence tomography performed in
human subjects using the hand-held optical imager is demonstrated in Chapter 13 below.
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4.4 EXPERIMENTAL METHODS OF FLUORESCENCE TOMOGRAPHY
Fluorescence tomography imaging methods face several challenges such as strong excitation
light leakage which masks the weak fluorescent signal, limited depth recovery when using
reflectance-based measurements, and limited spatial resolution. Several research groups have
performed studies designed to improve the results obtained from fluorescence tomography
by optimizing the experimental imaging methods.
A research group from Dartmouth College performed a study to optimize
fluorescence tomography for sub-surface imaging of protoporphirin IX.[115]

Phantom

experiments were performed using a noncontact based imaging system to compare
fluorescence remittance imaging (FRI) and sub-surface fluorescence diffuse optical
tomography (FDOT) with the contrast agent protoporphirin IX.

They found that

tomographic imaging was able to produce a better contrast ratio, while simple planar
fluorescence imaging produced better signal to noise ratio. They concluded that an optimal
system for localizing embedded fluorescent regions should combine fluorescence reflectance
imaging and sub-surface tomography in order to increase sensitivity and improve depth
detection.
The same group performed another study to investigate the influence of tissue
optical properties on the shape of near-infrared (NIR) fluorescence emission spectra
propagating through centimeters of tissue-mimicking material.[123] Experimental studies
were performed using liquid and gelatin-based phantoms and Lutetium Texaphyrin (LuTex)
contrast agent. The NIRFAST model platform was used to calculate spectrally resolved
emission spectra at discrete wavelengths and compared to experimentally measured spectra.
The phantom results showed spectral distortion resulting in emission peak shifts of up to 60
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nm in wavelength which is analogous to beam hardening and softening in x-ray tomography
which causes image artifacts. They concluded that spectrally resolved detection strategies
should be implemented in order to account for these effects and reduce error.
A group from Harvard University tested the ability of a small animal imaging system
to perform complete-angle projection (360º) fluorescence tomography in vivo in mouse lung
and brain tumors.[125] In both tumor models, the fluorescence was positively identified
close to the tumor location with noncontact FT in all imaging experiments. They also
applied fluorescence dataset normalization in order to correct for dynamic range variation in
the resulting illumination through the tissue and inhomogeneity.
4.5 CONCLUSION
Fluorescence tomography is a promising technique for noninvasive functional imaging.
However, there are several challenges that are currently being addressed by researchers. The
challenges include strong excitation light leakage which masks the weak fluorescent signal,
poor spatial resolution due to high scattering of the light in biological tissues, and
mathematical complexity of image reconstruction due to the ill-posed nature of the inversion
problem. This chapter reviewed the current (2008-present) efforts of different research
groups to improve the experimental methods, reconstruction algorithm, and instrumentation
used in performing fluorescence tomography.
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CHAPTER 5
Past Work: Clinical Diffuse Optical Imaging in Human Subjects
Testing of diffuse optical imaging technology in human tissues is integral for translation of
the technology into the clinical setting. In the past decade, several research groups have
evaluated the performance of diffuse optical imaging in human breast tissue using different
methods and instrumentation.[134-152] A systematic review of diffuse optical imaging of
the healthy and diseased breast was performed by Leff, et al in 2008.[134]

This chapter

summarizes the major findings by Leff et al and then describes significant clinical studies
performed in 2008-2010.
Leff et al systematically reviewed clinical studies involving close to 2,000 females
who underwent diffuse optical imaging of healthy and diseased breast tissue. The review
focused on summarizing the studies to determine the ability of diffuse optical imaging to (i)
provide information on the tissue composition of healthy breast tissue, (ii) detect breast
lesions/abnormalities, and (iii) differentiate benign from malignant disease.
Several articles reported the use of diffuse optical methods for measuring the optical
properties of healthy breast tissue, namely the absorption coefficient (!a) and reduced
scattering coefficient19 (!s’). A summary of the experimentally determined absorption and
scattering properties at near-infrared wavelengths is given in Table 5.1. The global averages
(highlighted in pink in Table 5.1) determined the absorption coefficient (!a) to be 0.04 ± 0.02
cm-1 at wavelengths between 600 and 800 nm and 0.05 ± 0.03 cm-1 at wavelengths between
800 and 900 nm. The global average reduced scattering coefficient (!s’) was determined to
be 10 ± 5 cm-1 at wavelengths between 600 and 700 nm and 8 ± 4 cm-1 at wavelengths
19

The effective scattering coefficient which accounts for the anisotropy factor (cosine of the angle of scattering).
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between 700 and 900 nm.

The remarkable consistency in absorption and scattering

properties between studies using various methods and instrumentation supports the ability
of diffuse optical methods in providing information on the composition of healthy breast
tissue.
Table 5.1: Summary of optical properties of healthy breast tissue from the
literature. Adapted from Leff, 2008 [134]

Several research studies were reported which involved optical imaging of breast
tissue containing a lesion or abnormality (either benign or malignant). In a total of 212
cases, 179 lesions were detectable by different diffuse optical methods. This data suggests a
lesion detection rate of 85% for optical mammography based approaches. In order to detect
the presence of abnormal tissue by diffuse optical methods, there must be a detectable
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difference in the tissue optical properties of healthy and abnormal tissue. Several studies
focused on comparing total hemoglobin concentration (HbT) and oxygen saturation (SO2) in
healthy and abnormal tissue. The results showed that healthy breast tissue had an average
HbT of 21 ± 6 !M/l and average SO2 of 68 ± 5%. The average HbT and SO2 of
fibroadenoma was 54 ± 13 !M/l and 69 ± 3% respectively. The average HbT and SO2 of
malignant disease was 65 ± 34 !M/l and 66 ± 24% respectively. The findings show that
there is significant difference in the HbT of healthy and abnormal breast tissue, while there
is no obvious difference in SO2 between healthy and abnormal breast tissue. The review
pointed out that only one study reported on the sensitivity and specificity for detecting
malignancy using spectroscopic information. Chance et al used a multiwavelength hand-held
device to acquire data over six years from 166 patients with 44 confirmed malignancies.
They reported the ability to distinguish cancerous from noncancerous breast tissue with a
sensitivity of 96% and specificity of 93%. Overall, the results reported from different
research groups demonstrate potential of using diffuse optical methods to differentiate
healthy and abnormal breast tissue.
Several research groups reported studies to distinguish benign and malignant breast
lesions based on diffuse optical measurements of blood volume, saturation, or both. Several
of the studies showed that the maximum and average HbT were significantly higher in
malignant lesions than benign lesions. However, the results were from a relatively small pool
of data and more extensive trials will be required to demonstrate conclusive results.
Overall, the reports summarized by Leff et al suggest that diffuse optical studies of
healthy breast tissue show the breast to be nonuniform, and the composition of healthy
breast tissue is modified due to physiological changes during the life of the female. Diffuse
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optical methods seem capable of distinguishing lesions from healthy tissue and demonstrated
detection of 85% of lesions in breast tissue. Results suggest that diffuse optical methods
have potential to distinguish benign and malignant lesions, but further studies and
improvements in the technology are needed.
A summary of reported studies in clinical imaging of breast tissue using diffuse
optical methods between the years 2008 and 2010 is given in Table 5.2.
Table 5.2: Summary of clinical diffuse optical imaging studies between 2008 and 2010.
Refere
nce

Instrum
entation

Met
hod

Measurement
Geometry
Point/Ar
Reflect/
ea
Trans

You,
et. al.,
2010
[146]

Handheld
imager
(NIR &
US)
Optical
bed w/
parallel
plates &
matchin
g fluid
Optical
bed w/
parallel
plates &
matchin
g fluid
Optical
bed w/
ring

DO
T&
US

Point -Subsurf
ace

DO
S

Solim
an, et.
al.,
2010
[147]
Choe,
et. al.,
2010
[148]
Jiang,
et. al.,
2009
[149]

Measurem
ent
Technique

Measurem
ent
Parameter

Source

Dete
ctor

Reflection

Laser
diode (785,
830 nm)

APD

FDPM

THC

Point -Compre
ssed

Transillumi
nation

Laser
diodes
(690, 730,
780, 830
nm)

PMT

TDPM

DO
T

Point -Compre
ssed

Transillumi
nation

CCD
came
ra

DO
S

Point -Circular

Reflection
&
transillumin
ation

Laser
diodes
(650, 690,
750, 786,
830, 905
nm)
Laser
diodes
(660-850
nm)
Laser
diodes
(660, 690,
780, 808,
830 nm) &
tungstenhalogen
lamp
Laser
diodes
(690, 730,
750, 808,
870, 920,
970 nm)

Kukret
i, et.
al.,
2010
[150]

Handheld
imager

DO
S

Point -Subsurf
ace

Reflection

Stahel
, et.
al.,
2009
[151]

Handheld
imager

DO
S

Point -Subsurf
ace

Reflection

Sens
.

Spec
.

198
patients
(benign &
malignant)

83.9
%

66.7
%

HbO2, Hb,
%water,
SP

10 breast
cancer
patients

--

--

FDPM &
CW

HbO2, Hb,
THC, SC

47 patients
(benign &
malignant)

98%

90%

FDPM

HbT, SO2,
%water,
SP

16 cancer
patients

--

--

APD

FDPM &
CW

specific
tumor
component
s (STC)

60 subjects
w/ 22
malignant,
18 benign,
21 control

91%

94%

APD

FDPM

HbO2, Hb,
%water,
SP

20 healthy
subjects

--

--

--
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Subject

van de
Ven,
et. al.,
2009
[152]

Optical
bed

FD
OT

Point -Circular

Transillumi
nation

lasers
(690, 730,
780, 830
nm)

CW

Omocyanin
e (external
contrast
agent)

12 cancer
patients

--

--

Stahel et al performed a study to compare the optical properties of breast tissue
between females who use oral contraceptives to regulate their menstrual cycles and those
who had spontaneous menstrual cycles.[151] The study was performed using a
multiwavelength frequency-domain hand-held optical imager containing a single source and
detector fiber pair. The results of blood volume and oxygenation measurements showed
that the breast perfusion, water content, and scattering power in females using oral
contraceptives was nearly constant during the menstrual cycle and tended to vary in females
with spontaneous menstrual cycles, while oxygen saturation tended to remain stable in both
groups. This study further confirms the ability of diffuse optical methods to be used to gain
information about healthy breast tissue.
Three groups reported studies using diffuse optical methods to distinguish benign
and malignant breast lesions. Choe et al used an optical bed with parallel-plate imaging
geometry to measure oxy-, deoxy-, and total hemoglobin concentration, along with blood
oxygen saturation and tissue scattering in 47 subjects with 51 lesions.[148] 95% of the
malignant lesions were invasive ductal carcinoma; of the non-malignant lesions, 40% were
fibroadenoma, 30% were cysts, 30% were lobular carcinoma in situ, and 10% were fibrocystic
disease. The results showed higher total hemoglobin concentration (THC) and scattering in
malignant lesions than in the surrounding tissue. Cysts showed lower scattering than the
background. Fibroadenomas showed weak contrast in THC and scattering. The tumor-tonormal ratios of all parameters were close to unity in the benign lesions, whereas they were
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significantly different from unity in the malignant cases. Kukreti et al used data collected
with a combined FD-CW hand-held optical imager with dual source and detector pairs.[150]
They used data from 22 malignant and 18 benign lesions to retrospectively determine if
benign and malignant lesions could be distinguished using near-infrared spectroscopy.
Results showed a sensitivity of 91% and specificity of 94%. You et al used a combined nearinfrared and ultrasound based hand-held imager to measure THC in 198 females with 214
lesions (96 benign and 118 malignant).[146] The average THC in benign lesions was 125.5 ±
83.4 !M/l while in malignant lesions it increased to 222.2 ± 87.2 !M/l. Using a cutoff of
140 !M/l they were able to detect malignant lesions with a sensitivity of 83% and specificity
of 66.7%. The results from these three studies show continued promise of the ability of
diffuse optical methods to distinguish benign and malignant lesions which has potential to
reduce the number of surgical biopsies in women with breast lesions.
An additional aspect where diffuse optical methods have been applied for breast
imaging is to monitor the response to neoadjuvant chemotherapy. Jiang et al performed a
study to evaluate two methods used to summarize diffuse optical data by region of interest
analysis to compare complete and incomplete response to neoadjuvant chemotherapy in
patients with locally advanced breast cancer.[149] In seven cases of subject data, diffuse
optical spectroscopy (DOS) measurements of total hemoglobin concentration, blood oxygen
saturation, water fraction, optical scattering amplitude, and scattering power were analyzed
using both fixed- and variable-size region of interest (ROI). Results showed that only the
measurements of total hemoglobin demonstrated significant difference in the complete and
incomplete response outcomes. Soliman et al used diffuse optical methods to measure tissue
concentration of deoxyhemoglobin (Hb), oxyhemoglobin (HBO2), percent water (%water),
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and scattering power (SP) in ten patients undergoing neoadjuvant chemotherapy for locally
advanced breast cancer.[147] The results showed significant difference in all four parameters
between responders and nonresponders to the the therapy. The studies performed by these
two groups demonstrate the potential role of diffuse optical imaging in monitoring response
to neoadjuvant chemotherapy in breast cancer patients.
External contrast agents can be used in order to improve the detection and
characterization of breast lesions by diffuse optical methods, especially for smaller-size
tumors. Van de Ven et al performed a study to evaluate a novel fluorescent imaging agent,
Omocianine, in 11 women suspected of breast cancer.[152] Four different dosage levels
were used, the smallest and medium doses were each used in three cases and the two highest
doses were used in five cases. The results showed the ability to detect two out of three
tumors using the lowest dose and three out of three tumors using the medium dose. None
of the five tumors were detected using the two highest doses. These results demonstrate the
potential of using Omocianine as a fluorescent contrast agent to detect lesions using low
doses of the agent.
Diffuse optical imaging of breast tissues has been explored by several research
groups in the clinical setting using various methods and instrumentation. Studies show the
potential of diffuse optical methods to gain information in healthy breast tissue, distinguish
abnormal tissue from healthy background tissue, distinguish benign and malignant tumors,
and monitor response to neoadjuvant chemotherapy. Additionally, use of external contrast
agents can improve imaging ability of diffuse optical methods by increasing the contrast.
Clinical trial in human subjects is an essential and defining stage in the development
of new imaging technology. Hand-held optical imagers provide a promising avenue toward
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rapid translation of the optical imaging technology to the clinical setting. The overall
objective of the dissertation is toward the clinical translation of our hand-held optical imager,
which is unique in its ability to perform 3D tomography. Various studies were performed in
tissue phantoms, in vitro, and in vivo toward this objective. The next chapter describes the
instrumentation and data analysis procedures for the studies performed toward clinical
translation of the hand-held optical imager developed in our Optical Imaging Laboratory.
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CHAPTER 6
Instrumentation and Data Analysis
6.1 INTRODUCTION
A hand-held optical imaging device has been designed and developed in our Optical Imaging
Laboratory with the following unique features: (i) flexibility to image different tissue
curvatures (0o - 45o) via a geometrically adaptive probe head; (ii) ability to simultaneously
illuminate (at 6 point locations) and collect NIR signals (at 165 point locations) towards
rapid data acquisition; (iii) portability and comfort from the hand-held design with maximal
patient comfort [3]; and (iv) coregistration facilities to enable 3D tomographic imaging in
complex tissue geometries [153].
Previously, experiments were performed to demonstrate 3D fluorescence
tomography using the hand-held based optical device in slab tissue phantoms [3]. In order
to perform 3D tomography, the image collected with the hand-held device must be
coregistered to the geometry of the phantom being imaged. For the past studies, the images
collected using the probe were manually coregistered to the simple slab phantom geometry
at the known location on the phantom surface.

In the current research, automated

coregistration capabilities are implemented to facilitate translation of the device towards
clinical studies in order to perform 3D tomography in curved (in vivo) tissue geometries.
Experimental studies are performed using the hand-held based optical imaging system on
tissue phantoms, in vitro, and in vivo with human subjects. This chapter describes the
instrumentation

used

to

collect

continuous-wave

and

frequency-domain

based

measurements (Section 6.2), the principle of continuous-wave and frequency-domain based
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optical imaging (Section 6.3), the experimental protocol for data acquisition in phantom and
in vitro studies (Section 6.4), and the automated coregistered imaging process (Section 6.5).
6.2 OPTICAL IMAGING SYSTEM
The three major components of the imaging system are the hand-held probe, the laser diode
source, and the intensified charge-coupled device (ICCD) detector. The instrumentation is
developed such that it can acquire both continuous wave (CW) based and frequency-domain
photon migration (FDPM) based optical measurements as required.
The hand-held probe head is designed with unique features in that it is flexible to
contour to different tissue curvatures, it has a large imaging area (4 x 9 cm2) for large volume
interrogation, and it uses simultaneous illumination and detection for rapid data acquisition.
The hand-held probe head is shown in Figure 6.1. The six red dots show the location of six
source fibers and the black dots are the 165 detector fibers. The probe is divided into three
sections and each of the side sections is capable of curving up to 45°.

Figure 6.1 The actual hand-held probe face showing the source-detector configuration. The large
red dots represent the six source fiber locations and all other small holes are the 165 detector fiber
locations.

At the source end, a single 785-nm laser diode source (530 mW, HPD1005-9MM,
Intense Ltd., North Brunswick, NJ) is split into six illuminating fibers using a custom-built
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collimator-diffuser package. The laser source is coupled to the handheld probe as shown in
Figure 6.2. For FDPM measurements, the source end is modulated using a frequency
synthesizer (HP 8656B, Hayward, CA) and RF amplifier (ENI500L, ENI Inc., Rochester,
NY) as shown in Figure 6.3.

Figure 6.2 Hand-held probe based optical imaging system showing the hand-held probe is fiberoptically coupled to the laser source and ICCD camera (left). The probe face is flexible to contour to
different tissue curvatures (right).

At the detector end, a gain modulated image intensifier (FS9910, ITT Night Vision,
VA) is optically coupled to the CCD camera (PI-SCX 7495-0002, Roper Scientific, Trenton,
NJ).

For FDPM measurements, the image intensifier is modulated using a frequency

synthesizer (PTS 310, Programmed Test Sources Inc., Littleton, MA) and RF amplifier
(ENI503L, ENI Inc., Rochester, NY) as shown in Figure 6.3.

The two frequency

synthesizers at the source and detector end are phase locked and operated at the same
frequency (100 MHz). The output intensity from the ICCD camera is sensitive to the phase
delay and upon introducing a phase shift from 0 to 2�, phase-sensitive images are collected
from which measurements can be extracted in terms of amplitude (AC) and phase (�) of the
modulated signal.
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Figure 6.3 Schematic of the instrumentation for the hand-held optical imager. The CW based
imaging system is shown in white and the additional components for FDPM based imaging are
highlighted in blue.

The CCD camera acquires steady-state phase sensitive images at 32 phase delays
between 0 and 2�. The exposure time for the CCD camera is 0.2 seconds (s) for a single
image (in all experiments) and each collected image represents the average signal from 5
repetitions. The exposure time was kept small enough to allow rapid image acquisition and
using more than 5 repetitions was previously determined not to improve the result.[154]
The image is acquired in 1024 " 1024 pixels and is hardware binned to 128 " 128 pixels for
improved signal to noise ratio and faster imaging time. The raw image is post-processed in
MATLAB software developed in house to get the DC values (for CW imaging) at each
detector location on the probe and displayed as a 2D contour plot. For FDPM imaging, the
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amplitude (AC) and phase (�) information is extracted using fast Fourier transforms (FFT),
and the final image is presented as a 2D surface contour plot of the AC or phase values at
each of the 165 detector points of the probe.
When operated in continuous wave mode (Figure 6.3, white portion), the laser light
is emitted at a constant intensity and travels to the tissue via optical fibers connected at the
probe face. The light passes from the probe into the phantom or tissue and becomes
attenuated due to the effect of the absorption and scattering properties of the medium. The
reflected light is collected at the tissue surface by the optical fibers in the probe and carried
to the detector. Different types of filters are used depending on the type of study. For
absorption based studies a neutral density filter is used to uniformly attenuate the collected
signal. For fluorescence based studies two band pass interference filters of blocking OD 4
and 6 (HRF-830.0, blocking OD 6 and F-830.0, blocking OD 4, CVILaser, Albuquerque,
NM) are used to select the weak 830nm fluorescent signal and reject the 785 nm excitation
signal. The filtered signal reaches the image intensifier at the photocathode and is converted
into electrons. The electrical signal is amplified at the micro-channel plate (MCP) according
to the manual gain setting on the power supply of the image intensifier. The amplified signal
then encounters the phosphor screen where it is converted back to a light signal and imaged
onto the CCD camera. The raw image is a 1024 " 1024 distribution of intensity signal from
each of the 165 detector fibers in the bundle. The 1024 " 1024 image is hardware-binned to
128 " 128 to reduce noise and processing time.

Post-processing MATLAB software

developed in house is then used to back calculate the location of each detection point on the
hand-held probe face and interpolated to generate a 2D surface contour plot. Frequencydomain based optical imaging involves the use of a modulated laser signal. In our hand-held
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based optical imaging system, the incident light is continuously produced and the intensity is
sinusoidally modulated via a frequency synthesizer at 100 MHz. As the intensity-modulated
light passes from the hand-held probe into the tissue, the intensity of the signal becomes
attenuated and the phase of the modulation altered according to the optical properties of the
tissue. The attenuated and phase-shifted signal is then collected from the tissue surface and
the detected signal is modulated at the same frequency. The fast Fourier transform is used
to extract the intensity and phase information to generate separate 2D contour plots which
in turn provide information about the optical properties within the tissue.
6.3. ACQUISITION OF OPTICAL DATA WITH THE HAND-HELD IMAGER
Two-dimensional (2D) diffuse optical and fluorescence-enhanced imaging was performed,
using the hand-held device operated in the CW-mode, on tissue phantoms, and in vitro.
Spherical acrylic targets (of different sizes) filled with 0.02-0.08% India ink as an absorbing
contrast agent (for diffuse optical studies) or 1 !M ICG fluorescent contrast agent (for
fluorescence-enhanced studies) were used to mimic a tumor in experiments with tissue
phantoms, in vitro, and healthy human subjects.

The probe was placed in full contact with

the phantom or tissue surface as shown in Figure 6.4 and CW images of the absorption or
fluorescent intensity were acquired in close to real-time (~2 sec delay). The raw intensity
images at the ICCD camera end were acquired in 1-sec (0.2 sec exposure time " 5
repetitions). These images were post-processed (~1 sec) using in-house developed Matlab
codes (Section 6.4) in order to acquire the final 2D surface contour plots of fluorescence
intensity distribution of the imaged surface. The entire data acquisition and post-processing
was automated such that close to real-time (~2 sec delay) imaging is possible.

For

frequency-domain imaging, phase-sensitive images were collected with a ~2-minute imaging
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time.

The 2D surface contour plots of fluorescence intensity signal may or may not

differentiate the target from the tissue phantom background, based on the target and
background optical properties.

Figure 6.4 Experimental set-up for tissue phantom, in vitro, and in vivo studies: (A) empty phantom
showing target inclusion and placement of probe, (B) tissue slab phantom with 1% Liposyn solution
for uniform scattering in the background, and (C) in vitro slab phantom with heterogeneous scattering
in the background.

6.4. ELIMINATION OF EXCITATION LIGHT LEAKAGE (SUBTRACTION
BASED POST-PROCESSING)
During fluorescence optical imaging, the output signal at the tissue surface is a mixture of
fluorescence signal and the attenuated incident NIR (i.e. excitation) signal. This fluorescence
signal is filtered from the strong excitation signal (3-4 orders of magnitude higher) using
appropriate optical (bandpass) filters and imaged by the detector. However, the filters are
not capable of 100% rejection of the excitation light, causing excitation leakage and
contamination of the fluorescent signal. Hence, a second-level of post-processing is carried
out to subtract a background non-fluorescing image from the final fluorescence image plots
for each experimental case, in order to account for the excitation leakage. Initially, optical
measurements were acquired prior to placing the fluorescent target in the phantom, in an
attempt to represent the excitation leakage (or background noise). These (background noise)
measurements were subtracted from the fluorescence optical measurements obtained from

68

experimental cases that included fluorescent targets, in order to effectively eliminate the
signal from the excitation source light. In the clinical setting involving actual diseased tissues
(unlike the simulated fluorescent targets in the current study), this could be accomplished by
acquiring image(s) of the tissue before and after the contrast agent (e.g. ICG) injection. The
non-fluorescent image(s) acquired prior to ICG injection will in turn be subtracted from the
fluorescent images acquired after ICG injection, in order to account for the background
noise. Another method is to collect an image from both breasts and subtract the image of
the ipsilateral (tumor-containing) breast from the image of the contralateral (non-tumorcontaining) breast. This was the method applied in the human subject studies with breast
cancer patients (Chapter 14).
A single image acquisition consists of collecting an image with target (~ 2 sec),
collecting a background image (~ 2 sec) and subtracting the two images (~ 1 sec). The
subtracted 2D optical images are generated rapidly (< 5 sec), making the entire process a fast
2D surface imaging technique.
6.5. AUTOMATED COREGISTERED IMAGING PROCESS
In order to perform 3D tomography using a hand-held optical imager, it is necessary to
coregister the 2D image at the appropriate location on the tissue geometry. For the past
tomography studies with cubical tissue phantoms, the images were manually coregistered at
the known locations on the simple cubicle geometries. In order to perform 3D tomography
in human tissue with varied complex geometries, it is necessary to track the probe location in
real time and automatically coregister the image at the tissue location.

To this end,

coregistered imaging facilities developed by a master’s student in our lab have been
implemented with our hand-held based optical imaging device.
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Coregistered imaging involves the alignment of two or more images (planar or
volumetric) in a single coordinate space. Herein, an intramodality20 coregistration method
(similar to 3D ultrasound imaging) is used to acquire 3D coregistered surface images from
2D surface data collected using the hand-held device. These 3D surface images will in turn
be used towards 3D tomographic analysis.

In coregistered imaging, the position and

orientation of the probe is tracked with respect to the tissue or phantom surface being
imaged. This tracked 3D positional information is then used to accurately position the
acquired optical images onto the tissue geometry.
Tracking of the probe position is achieved using an acoustic-based 3D tracker
(Logitech Inc., Fremont, CA) which consists of a transmitter (positioned ~2 feet above the
hand-held probe), receiver (implemented onto the probe head), and a processing unit. The
position and orientation of the receiver (probe head) is tracked in real-time in reference to
the transmitter. The probe’s position is acquired by the computer with six degrees of
freedom (x, y, z, pitch, yaw, and roll21) using MATLAB software developed in house and
interfaced to the processing unit tracking software.

The tracked probe’s position and

orientation are displayed on the computer screen as position coordinates angles of rotation.
Coregistered imaging of tissue/phantoms is implemented as a three-stage process
(see Figure 6.5).
Stage 1: The special 3D location of the probe is determined and the probe’s position and
orientation is tracked in real-time with respect to a discretized mesh of the phantom or tissue
geometry (steps 1-4 in Figure 6.5).
20 Two types of coregistration techniques that exist include intermodality and intramodality. Intermodality coregistration
combines images of different modalities (e.g. CT/MRI, SPECT/MRI, optical/MRI, etc.), whereas intramodality
coregistration combines images from the same modality (e.g. 3D ultrasound imaging).
21

Pitch, yaw, and roll refer to the tracked object’s rotational orientation in reference to the x-, y-, and z-axis respectively.
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Figure 6.5 Flowchart of the coregistered imaging process, implemented as automated coregistration
software during optical imaging studies.

Stage 2: The hand-held probe based imaging system is used to acquire raw data, i.e.
optical signals of intensity (step 5 of Figure 6.5). The raw data is post-processed (step 6 of
Figure 6.5) using MATLAB software developed in house as described in section 4.1 to
generate and display the image as a 2D surface contour plot (step 7 of Figure 6.5). The
average time to acquire the raw data and display the post-processed images (2D contour
plots) is ~2 sec (0.2 sec exposure time for each of the 5 repeated measurements, and ~1 sec
for data post-processing to obtain 2D surface contour plots).
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Stage 3: Image coregistration is performed using tracking/coregistration interfacing
software developed in house in MATLAB/LabVIEW. The optical data from the 2D surface
contour plot is coregistered onto the 3D discretized phantom at the probe location using the
positional information of the entire probe head (i.e. all source and detector point locations)
during each scan. The entire coregistered imaging process is described in detail in reference
[153].
The current version of the coregistration software is designed to work with
phantoms with known position/orientation, and does not take into account any motion of
the phantom or tissue being imaged. In the future, this can be remedied by adding tracking
abilities to the phantom (or subject) being imaged, thereby allowing location and orientation
of the phantom/tissue to be automatically known and updated in real-time. The use of
additional trackers is currently being implemented by a master’s student in our laboratory.
6.6. CONCLUSION
A CW and FDPM based hand-held optical imaging system has been developed in our
laboratory for coregistered imaging and 3D tomography of breast tissue. This chapter
detailed the instrumentation and data analysis procedure for the experimental studies to
perform fast 2D imaging. The next chapter will describe the AEKF based reconstruction
algorithm used to perform diffuse optical and fluorescence-enhanced diffuse optical
tomography using our hand-held based optical imaging device.
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CHAPTER 7
Fluorescence-enhanced Diffuse Optical Tomography
7.1 INTRODUCTION
Three dimensional (3D) optical tomography is used to reconstruct the 3D volume and
location of the tumor within the tissue. Measurements collected at the surface of the tissue
are used to mathematically reconstruct the optical property distribution at discrete points
within the tissue volume.

The optical properties of interest in biological tissue are

absorption and scattering. There are two types of mathematical problems addressed in
tomography: the forward problem and the inverse problem. The forward problem is used to
simulate light propagation in tissue of known optical property distribution. The inverse
problem is used to reconstruct the optical properties within the tissue given a set of
experimentally measured values (fluence) at the tissue surface.

In each mathematical

formulation, the tissue volume is discretized and the optical properties are calculated at each
discrete location. This chapter will describe the mathematical model of light propagation in
tissue, the forward and inverse problems, and the AEKF reconstruction algorithm used to
perform 3D tomography.
7.2 LIGHT PROPAGATION IN BIOLOGICAL TISSUES
The propagation of light through a highly scattering medium is often modeled using the
diffusion approximation of the radiative transport equation.

The coupled diffusion

equations for the case of fluorescence-enhanced imaging in the frequency domain are [104]

)
i" &
+ * • [Dx*# x ] + 'µ ax + $ # x = S! (r - rs )
cx %
(

73

(1)

'
i+ $
' 1 $
!x
( ) • [Dm)! m ] + %µam + "! m = qµax*m %
cm #
&1 ( i+, "#
&

(2)

where the subscripts x and m are used to represent the excitation and emission wavelengths
of light respectively. In these equations, � is used to represent the amplitude of the fluence
signal "a and "s represent the absorption and scattering coefficients, q and � are the
quantum efficiency and fluorescent lifetime of the fluorophore, c is the velocity of light, � is
the modulation frequency, and r is the positional vector. D is the diffusion coefficient given
by:

Dx,m =

1
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where g is the anisotropy factor. The partial current boundary condition is applied which
assumes that once a photon leaves the tissue it does not return. It is expressed by
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where � is the index-mismatch parameter, which is a function of the effective refractive
index, and n is the normal to the surface.
The diffusion approximation of the radiative transport equation is applied in the
forward and inverse problems to model light propagation in tissue and to reconstruct the
internal distribution of tissue optical properties using surface measurements.
7.3 FORWARD PROBLEM
The forward problem in optical imaging is used to predict light transport in biological tissue
during simulations. The problem is stated as follows: Given a distribution of light sources
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on the boundary of an object and a distribution of tissue parameters within the object, find
the resulting measurements that would occur at the surface. Figure 7.1 illustrates the
forward and inverse problems. In the forward problem (left), the parameters !a and !s’ are
known within the tissue and the propagation of light to the boundaries is predicted. In
biomedical optical imaging, the forward problem is typically solved using the diffusion
approximation to the radiative transport equation described in section 7.2. The diffusion
equation is solved numerically using a finite difference or finite element based approach.
For the studies described herein, a Galerkin based finite element approach was used to solve
the forward problem.

Figure 7.1 Illustration of the forward and inverse problem in optical tomography. In the forward
problem, the optical property distribution is known and used to predict the measurements that would
occur at the surface of the tissue. In the inverse problem, the measurements obtained experimentally
at the surface are used to reconstruct the unknown optical property distribution within the tissue.

7.4 INVERSE PROBLEM
The inverse problem in optical imaging is to reconstruct the unknown optical properties
within a tissue given a set of measurements at the boundary. The problem is stated as
follows: Given a distribution of light sources and a distribution of measurements on the
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surface, calculate the tissue parameter distribution within the tissue. The inverse problem is
illustrated in Figure 7.1 (right) where a set of measurements of fluence (�i) is collected at the
boundary, and the unknown internal properties of the given tissue are mathematically
reconstructed (in this case, !a and !s’). In the case of the inverse problem, the number of
unknowns is much greater than the total number of surface measurements acquired and the
problem is to solve an underdetermined system of linear equations. The solutions are nonunique and inconsistent making the problem ‘ill-posed’
7.5 APPROXIMATE EXTENDED KALMAN FILTER (AEKF) BASED
RECONSTRUCTION ALGORITHM
Optical tomography has been performed using different algorithms such as Algebraic
Reconstruction Techniques (ART) [125], NIRFAST [126], and Born approximation [133].
For the tomography studies performed herein, a Bayesian reconstruction technique was used
which is an approximate extended Kalman filter (AEKF).[104] The Kalman filter is a linear
state Bayesian estimator that is used in process control in order to estimate a state
recursively, using the previous observations. The filter yields estimates of true measurement
values and the corresponding calculated values by the following process: (i) predict a value,
(ii) estimate the uncertainty of the predicted value, (iii) compute a weighted average of the
predicted value and the measured value. The estimator determines the mean value of the
conditional probability function of the unknown parameters using given measurements,
assuming that the state variables and observations are normally distributed random variables.
This Bayesian estimator was chosen due to the following advantages: (i) the updates in each
iteration are weighted and the matrix inversion is regularized using measurement error
(between repeated measurements) and model error (which results from simplifications of the
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diffusion approximation), and (ii) the parameter error values are estimated separately from
the parameter value itself and used to damp and regularize the inversions. The method of
the AEKF algorithm is given by the following pseudocode[104]:
iterate
1: x = f(y)
for i = 1 to # source illuminations
2:
T

Ji =

!x i
!y

(

3: K i = P " J i " R i + Qi + J i " P " J i
4:
5:

)

T !1

#y i = K i " (z i ! x i )

P # P " Ki ! Ji ! P
end
6:

y # y + ! "y i
i

until convergence

where the definitions of each term is given in Table 7.1.
Table 7.1. Definitions of terms used in AEKF pseudocode.

x
z
y
J
K
Q
R
P
f

distribution of predicted measurements
corresponding experimental measurements
unknown parameter (updated recursively)
Jacobian matrix
gain matrix
model error covariance
measurement error covariance
parameter error covariance
forward solver

The parameter x represents the distributed predictions of the referenced measurements (the
logarithm of AC and the phase shift for the case of frequency-domain measurements), which
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are generated by the forward simulator f. The parameter y represents the vector of current
estimates of the unknown optical property, which is an inverse pseudo-� transform of the
optical absorption coefficient !axi (in the case of fluorescence imaging, it is the absorption
coefficient due to the fluorophore, !axf). The measurement error covariance was assumed
uncorrelated, and repeated observations (in this case, five) at each detector location were
used to experimentally determine the variance for each source-detector pair. The model
error covariance Q is difficult to estimate for unknown domains, and was empirically chosen
to be one-fourth the mean of the measurement error variance. The discrepancies between
measurements and predictions (z - x) are weighted by a gain matrix K in order to update the
uncertain parameters y and the parameter error covariance P. The gain matrix K is used to
update the unknown optical parameter y and the parameter error covariance P. An initial
variance estimate was set (typically 0.01, however 0.1 was used for some in vitro cases due to
inhomogeneous background) and the parameter error was assumed uncorrelated with the
initial estimate.
A flow diagram of the AEKF based reconstruction algorithm used herein is
illustrated in Figure 7.2.

In fluorescence studies the reconstructed parameter is the

absorption coefficient at the excitation wavelength (!axf). The algorithm starts with an initial
guess of uniform distribution (herein, arbitrarily set to 0.003 cm-1), and uses the experimental
data from the hand-held probe along with simulated measurements using the forward model
(diffusion approximation) to get an updated distribution of the parameter of interest (!axf).
Each updated distribution is then used in the algorithm until the convergence criteria is met
and the reconstruction is complete. The AEKF algorithm is carried out recursively, i.e each
set of measurements is used to continuously update the unknown parameter y and the
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parameter error covariance P, without storing the set of measurements from each loop. This
recursive AEKF algorithm is carried out iteratively until the reconstructions converge. The
convergence criteria was met when the root mean square output error RMSE was less than
1%, or the total number of iterations exceeded 50.
The AEKF reconstruction algorithm was developed for frequency-domain based
fluorescence tomography. Modifications were made to the algorithm during the various
tomography studies presented herein to adapt for continuous-wave based measurements,
multiple-scan studies, and in vivo studies. The modification details will be given in the
materials and methods for each tomography study appropriately.

Figure 7.2 Flow diagram of the AEKF based reconstruction algorithm.
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7.6 CONCLUSION
This chapter detailed the reconstruction approach used in the tomography studies performed
herein. The diffusion approximation of the radiative transport equation is used to model
light propagation in biological tissue (forward problem). An approximate extended Kalman
filter (AEKF) based reconstruction algorithm is used to reconstruct the unknown optical
property distribution within tissue given experimental measurements at the tissue surface
(inverse problem). The next chapters detail the experimental studies performed toward the
goals of fast 2D imaging, coregistration, and 3D tomography in tissue phantoms, in vitro, and
in vivo with human subjects.
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CHAPTER 8
Study I: 2D Imaging in Tissue Phantoms and I n V i t r o in Near-Real
Time
8.1 INTRODUCTION
Real-time imaging is a useful tool for on-site cancer diagnosis in the clinical setting. Prior to
performing 3D tomography studies using our hand-held optical imager, studies were
performed to determine the ability of the device to detect a target via 2D imaging in near
real-time.

This chapter describes experimental studies that were performed in tissue

phantoms and in vitro designed to detect the presence and estimate the 2D location of a
fluorescent target using continuous wave based imaging.
8.2 MATERIALS AND METHODS
Fast 2D imaging was facilitated by the use of simultaneous multiple-point illumination and
collection and CW based measurements. Studies were performed using slab tissue phantoms
composed of 10"10"10 cm3 acrylic cubes filled with 650 ml of 1% Liposyn solution
(Liposyn II, 20%, Henry Schein, Melville, NJ) in order to mimic the optical properties of a
typical breast tissue. The fluorescent target was placed at different depths (1.5-2.5 cm) from
the imaging surface and real-time as well as fast (subtracted) images of fluorescence intensity
were acquired. The different experimental cases are summarized in Table 8.1.
Prior to in vivo studies with human subjects, experiments were performed using in
vitro phantoms, which were composed of minced chicken breast combined with 1% Liposyn
solution, in order to introduce a non-uniform scattering background. The in vitro mixture of
minced chicken breast (480 ml) and 1% Liposyn (260 ml) was placed inside a 10"10"10 cm3
acrylic cube. Real-time as well as fast (subtracted) images of fluorescence intensity were
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acquired under different experimental conditions using either a 0.23 cc or 0.45 cc fluorescent
target located at various depths between 1-2 cm (see Table 8.1).

Table 8.1 Summary of experimental cases for slab tissue phantom and in vitro studies.

8.3 RESULTS
8.3.1 Tissue Phantom Studies
Real-time images using the slab phantom with uniform scattering in the background are
shown in Figure 8.1 as 2D surface contour plots of the fluorescence intensity data with a
target placed at different depths (1.5-2.5 cm) from the imaging surface. The non-uniform
intensity distribution in Figure 8.1 is possibly due to the residual excitation leakage around
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the six source fibers (after the implementation of the subtraction technique). Additionally,
the input laser source signal is not evenly distributed amongst the six source fibers, possibly
causing a variation or non-uniformity in the output fluorescence intensity distribution.

Figure 8.1 Near real-time images of fluorescence intensity obtained as 2D surface contour plots,
acquired from slab phantoms (with uniform background scattering). The fluorescent target was
placed at different locations and depths: (A) target location: (x,y,z) = (2.0, 2.7. 1.5), and (B) target
location (x,y,z) = (2.0, 2.7, 2.0) and (C) target location: (x,y,z) = (3.0, 2.2, 2.5). The black hollow
circle in each sub-plot is the true target location.

The images show the feasibility of performing (close to) real-time 2D imaging using
the hand-held device in tissue phantoms.

The actual target location in the images is

indicated in the figures by the black open circle in the x-y plane for different target depths in
the ‘z’ direction. The fast 2D image estimates the 2D target location (instantly) in the x-y
plane. This information can then be further used towards 3D tomography (in the future) in
order to determine the tumor volume, location, and depth [3].
From these plots, it is obvious that the real-time images are capable of differentiating
the target from the background when the 0.45 cc target was 1.5 cm deep. At greater tissue
depths, the target was not distinctly differentiable due to the strong excitation leakage from
the background. Upon applying the subtraction technique (as described in Section 6.4), the
target is clearly differentiable from the background in all the experimental cases (see Figure
8.2). These subtracted images also have potential to obtain 3D target localization via
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tomographic imaging, as long as the probe’s location on the tissue surface is coregistered
with respect to the surface fluorescence images.

Figure 8.2 Fast subtracted images of fluorescence intensity obtained as 2D surface contour plots,
acquired from slab phantoms (with uniform background scattering). The 0.45 cc fluorescent target
was placed at different locations and depths: (A) target location: (x,y,z) = (2.0, 2.7. 1.5), and (B) target
location (x,y,z) = (2.0, 2.7, 2.0) and (C) target location: (x,y,z) = (3.0, 2.2, 2.5). The black hollow
circle in each sub-plot is the true target location.

8.3.2 I n V i t r o Studies
The results for the in vitro phantom experiments are shown in Figures 8.3 (real-time images)
and 8.4 (fast subtracted images) for different target depths (1-2 cm) under T:B contrast ratio
of 1:0. The true target location in the images is given as x,y,z coordinates where ‘x’ is the
lateral position, ‘y’ is the height and ‘z’ is the depth (distance from the imaging surface)
which vary among the images.

Due to heterogeneous scattering of the background

phantom, only the subtracted images were capable of clearly differentiating the target from
the background for targets deeper than 1.0 cm. These studies show the ability of the handheld device to perform fast 2D surface imaging and target localization within a non-uniform
scattering tissue-mimicking background.
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Figure 8.3 Near-real time images of fluorescence intensity obtained as 2D surface contour plots,
acquired from in-vitro slab phantoms (with non-uniform background scattering). The 0.45 cc
fluorescent target was located at a depth of (A) 1.0 cm, and (B) 1.5 cm, from the imaging surface.
The black hollow circle in each sub-plot is the true target location.

Figure 8.4 Fast subtracted images of fluorescence intensity obtained as 2D surface contour plots,
acquired from in-vitro slab phantoms (with non-uniform background scattering). Images were
collected for different target sizes and depths. Images (A)-(C) contain a target size of 0.45 cc at
depths of 1.0, 1.5, and 2.0 cm respectively. Images (D)-(F) contain a target size of 0.23 cc at depths
of 1.0, 1.5, and 2.0 cm respectively. The black hollow circle in each sub-plot is the true target
location.

8.4 DISCUSSION
The fluorescence imaging studies described here demonstrate for the first time the
acquisition of fast 2D surface images (in < 5 sec) of a fluorescent target in uniform tissue
phantoms and in vitro using a hand-held based optical imaging device. The subtracted images
have a potential to clearly differentiate target(s) from the background (under various
experimental conditions), demonstrating the potential to translate the technology towards
on-site breast imaging in a clinical environment. Additional experiments were performed
with the target located at greater depths in the tissue phantoms, but the target was not
detected at a depth of 2.5 cm. At 2.5 cm deep, the detected signal from the target is close to
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the noise floor, and hence not differentiable from the background.

A multi-location

scanning approach is currently developed for differentiating deeply located or small volume
targets from homogenous or heterogeneous background (details in Chapter 9). In short, this
approach will incorporate the use of coregistered images obtained at multiple locations on
the tissue surface, such that the targets can be differentiated from artifacts22 as well as the
background [80]. When comparing Figures 8.2 and 8.4, it can be seen that the images from
the in vitro phantom contain more noise than those from the uniform tissue phantom. This
can possibly be attributed to the heterogeneous distribution of scattering properties or
shifting of the chicken breast as the target is removed (which can cause a change in the signal
distribution when the background image is collected). Experiments were also performed
using the in vitro phantoms with a T:B contrast ratio of 100:1. However, the noise from the
background signal dominated the image and a target was not detected even after subtracting
the excitation background signal. Upon applying our multi-location scanning approach, the
targets were differentiable under imperfect uptake conditions (i.e. T:B = 100:1). In addition
to fast 2D imaging, the hand-held device described here has demonstrated 3D tomography
of fluorescent targets with tissue phantoms using frequency-domain based measurements in
order to estimate the 3D location and volume of the target within the tissue. [3]. Additional
efforts involve the implementation of fast and automated coregistration facilities in order to
enable precise 2D target localization (instantaneously) as well as 3D tomography studies in
vitro as well as in vivo (Chapter 10 and 13, respectively).

22

Any signal that occurs in the image which is not from the target or tumor.
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8.5 SUMMARY AND CONCLUSION
Preclinical testing of a hand-held optical imager was performed to demonstrate the ability of
the device to perform fast 2D imaging toward tumor detection in near real-time.
Experimental studies show the ability of the device to detect and estimate the 2D location of
a 0.45 cm3 fluorescent target up to 2.5 cm deep in a tissue phantom with homogeneous
background and fluorescent targets of 0.23 or 0.45 cm3 volume up to 2.0 cm deep in vitro
with heterogeneous background (more like a true tissue case). The goal of these studies was
to determine if it was possible to detect a signal from the target using only fast 2D imaging.
Target localization can be performed subsequently using 2D or 3D tomography. The results
presented herein demonstrate the potential of the device toward target detection and
estimation of 2D target location even prior to 3D tomographic analysis.
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CHAPTER 9
Study II: Coregistered Imaging towards Improved Target Depth
Detection (using Multiple-scan Coregistered Imaging)
9.1 INTRODUCTION
The feasibility of 2D target detection and 3D tomographic analysis using this hand-held
optical imager has been demonstrated from tissue phantom and in vitro fluorescence imaging
studies. During these studies, a single scan in the region of interest was acquired to detect
and recover the embedded target(s) tomographically (using manually coregistered optical
images). However, it was observed that as the target depth was increased and/or its volume
decreased, the target was not detectable from 2D images, nor was it recovered from 3D
tomography studies. Experimental studies using single fast 2D images showed the ability to
detect a target (0.45 cm3) up to 2.5 cm deep in tissue phantoms and up to 2.0 cm deep in vitro
(details in section 8.3). Herein, an alternate imaging approach of using multiple-scans from
various locations of the tissue surface is developed (using automatically coregistered optical
images) and its feasibility to detect deeper targets is assessed [155].
In the current work, the recently developed multi-scan imaging approach is
extensively assessed to determine the target detection limits of our hand-held optical imager.
Studies were performed using the liquid tissue phantoms in order to determine the extent of
improvement upon the previous studies using single-scan. Studies were also extended to in
vitro tissue models in order to assess the performance of the device in a non-uniform (or
heterogeneous) scattering background, in order to better mimic human tissue.
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9.2 MATERIALS AND METHODS
9.2.1 Phantom and In Vitro Studies
Experimental studies were performed initially using the simple case of the uniform liquid
tissue phantom and were then extended to more realistic in vitro models.

Phantom

experiments were performed using tissue phantoms composed of 1% Liposyn (800 mL) in a
10"10"10 cm3 acrylic cube. Acrylic sphere targets of sizes 0.23 - 0.45 cm3 filled with 1 !M
indocyanine green (ICG) were placed at different depths (2.5-4.0 cm) from the imaging
surface to represent a tumor. Experiments were performed increasing the depth by 0.5 cm
until the target was no longer detected. The experimental set-up is shown in Figure 9.1. The
probe was placed in full contact with the phantom surface and multiple scans (2D
coregistered images) were collected using the method described in section 2.5 below.

Figure 9.1 Experimental set-up for phantom studies. (A) A spherical target filled with 1 !M
indocyanine green is enclosed within the cubical phantom to represent a tumor. (B) The phantom is
composed of a 1% Liposyn solution to mimic the optical properties of human breast tissue.

To represent the heterogeneous nature of human tissue, studies were also performed
in vitro using minced chicken breast (480 mL) combined with 1% Liposyn (260 mL) in a
10"10"10 cm3 acrylic cube in order to introduce a background of non-uniform scattering.
The 0.45 cm3 fluorescent target was placed at different depths between 2.0-4.0 cm, until the
target was no longer detected. The experiments were performed for the perfect uptake case
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with tumor-to-background ratio (T:B) of 1:0 and imperfect uptake case with T:B of ~100:1.
Table 9.1 summarizes the different experimental studies performed in which a target was
detected. For each image collected, a subtraction-based post-processing technique was used
to eliminate excitation light leakage (as described in Section 6.4).
Table 9.1 Summary of experimental studies in which a target was detected in tissue phantoms and in
vitro. The cases where the deepest target was detected for phantom or in vitro, and perfect or
imperfect uptake are highlighted in red.

Experimental Experiment
Case
#

Tissue
Phantom

In Vitro

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Target
Volume
(cm3)
0.45
0.45
0.23
0.23
0.23
0.45
0.45
0.23
0.23
0.23
0.45
0.45
0.45
0.45
0.45

Target
Depth
(cm)
3.0
3.5
2.5
3.0
3.5
2.5
3.0
2.0
2.5
3.0
2.5
3.0
3.5
2.0
2.5

T:B
1:0
1:0
1:0
1:0
1:0
100:1
100:1
100:1
100:1
100:1
1:0
1:0
1:0
100:1
100:1

9.2.2 Validation of Coregistered Imaging in Phantoms
In order to quantitatively determine the accuracy of the tracked position and coregistered
image compared to the true location on the phantom, the probe was placed at five different
reference points of known locations (moving 0.5 cm vertically) and five measured values
were recorded from the tracking software at each position. The average, standard deviation,
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and discrepancy of these measured values for each position are given in Table 9.2. It can be
seen from the standard deviation of the measured values that the tracked probe position
fluctuates between 0.013-0.094 cm. The average total distance off represents the accuracy of
the tracked position compared to the true location. The average total distance off is ~0.19
cm.

The deviation and discrepancy of the measured values can be attributed to

instrumentation error such as fluctuation in the tracked position of the probe. Currently,
efforts are made to overcome these limitations and improve the stability of the tracking
system (Chapter 16).
Table 9.2 Average and standard deviation of x,y,z coordinates as displayed in tracking software and
total distance off between true and measured values. Values are in units of centimeters and each
measured value represents an average of 5 measurements while probe was at each of the 5 positions.

9.2.3 Multiple Scan Technique
The multiple scan technique involves collecting a series of scans at different probe positions
and coregistering each image to its appropriate location. A scan is defined as a 2D surface
contour plot of fluorescence intensity data collected from a CW image (the mean of 5
repeated images at the same location) using the ICCD based detection system. Each image
is immediately coregistered to the discretized phantom mesh. By scanning at multiple
locations, the weak fluorescence signal from the target (which appears at the same location
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on the tissue geometry during each scan) can possibly dominate the strong excitation light
leakage (which tends to appear at different locations on the tissue geometry during each
scan).
Different combinations of image positions were used to determine the optimal
multi-scan method.

Initially 4-5 scans were collected moving the probe 0.5 cm in the

vertical direction between each scan. For the same experimental case, 9 scans were collected
moving the probe in 0.25 cm increments in the vertical direction. Additionally, repeated
scans were collected at each probe location. It was determined that collecting 2-3 repeated
scans (i.e. 2-3 " 5 repeated images or 10-15 repeated images) at each probe location for 4-5
positions 0.5 cm apart resulted in better target detectability with fewer artifacts than
collecting single scans (i.e. 1 " 5 repeated images) at each probe location for 9 positions 0.25
cm apart. This can possibly be attributed to two reasons: (i) the inaccuracy (from instability)
of the positional tracking system (described in section 2.3) has greater impact at smaller
positional increments (e.g. 0.25 cm), leading to increased artifacts; and (ii) the variability in
the instrument’s response is minimized by increasing the number of repeated scans (or
images) at the same location. The number of repeated scans (or images) can be increased
for the case where the probe locations were 0.25 cm apart. However, this further increases
the overall imaging time and hence was not attempted. In the future, for an in vivo case,
multiple images can be collected and summed from arbitrary probe positions and the
number of scans can be optimized to minimize the overall imaging time and number of
artifacts. The position will be known since the image is immediately coregistered at its
location.

92

9.3 RESULTS
Figure 9.2 shows four single images (2D contour plots of fluorescence intensity) for
experimental case # 12 where a 0.45 cm3 fluorescent target was placed 3.0 cm deep in vitro
under perfect uptake condition (T:B=1:0). Multiple scans were collected as described in
section 2.5. In each image, the true target location is indicated by a black open circle. The
images show that the target is not detected in a single scan, and only random distributions of
artifacts (high intensity signals that appear in the image which do not originate from the
target) are visible.

Figure 9.2 Coregistered images from single scans (2D contour plots of fluorescence intensity data)
at four probe positions for experimental case #12 (a 0.45 cm3 fluorescent target placed 3.0 cm deep,
x-dimension in-vitro phantom under T:B=1:0). In each image, the white dotted line represents the
probe position with respect to the phantom and the black open circle represents the true target
location.
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Upon summation of eight scans, the fluorescent signal is detected at the target location
(Figure 9.3). This can be attributed to the random distribution of artifacts that appear in
different locations for each single scan, while the signal from the target remains in the same
location relative to its coregistered position on the phantom. Upon summation of the
coregistered images, the random signals from the artifacts tend to diminish compared to the
consistent signal from the target, which tends to intensify.

Figure 9.3 Summated image of multiple scans shown in Figure 9.2 (experimental case #12). The
summed image represents summation of 8 single scans, where 2 scans were collected at each of the 4
probe positions shown in Figure 9.3, The black open circle represents the true target location.

Figure 9.4 shows the result for summated multi-scan images for experimental cases
5, 10, 13, and 15 (Table 9.1, bold). Case 5 represents a 0.23 cm3 target placed 3.5 cm deep in
the tissue phantom under perfect uptake conditions (T:B=1:0).

The target was detected

close to the true location and no artifacts were present. Case 10 represents a 0.23 cm3 target
placed 3.0 cm deep in the tissue phantom under imperfect uptake condition (T:B=100:1).
The target was detected at the true location with some diffused signal around it. Case 13
represents a 0.45 cm3 target placed 3.5 cm deep in vitro under perfect uptake conditions
(T:B=1:0).

The target was detected at the true location with artifacts also visible far from
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the target location. These artifacts can be attributable to the heterogeneous nature of the in
vitro phantom.

Figure 9.4 Summed images of multiple coregistered scans from the four best experimental cases
listed in Table 1. The black open circle indicates the true target location for each case.

Case 15 represents a 0.45 cm3 target placed 2.5 cm deep in-vitro under imperfect uptake
conditions (T:B=100:1). The target was detected close to the true location along with
minimal artifacts around it.
The initial experiments designed to detect deeper targets consisted of performing a single
scan at 4-5 positions moving the probe 0.5 cm in the vertical (z) direction. For deeper
targets (>3.0 cm), heterogeneous (in vitro) phantoms, and/or imperfect uptake cases, the
target was not detected upon summation of four or five scans. However, it was observed
that when multiple repeated scans were collected at the same location for each probe
position, the targets were detectable. In other words, increasing the number of repeated
scans is as important as increasing the number of scan locations towards deep target
detection under heterogeneous and/or imperfect uptake conditions.
The results presented here demonstrate that deeper and smaller targets can be detected using
the multiple-scan approach than using a single-scan alone. The impact of these results
extend beyond target detection in 2D in that the information can be used as a priori
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information to aid 3D reconstruction using a single frequency-domain image (or scan)
towards deeper target recovery (future work).
9.4 DISCUSSION
The prime hypothesis for the current study is that a single scan (of a large area, 4 x 9 cm2)
can fail in detecting deeper targets during a near real-time optical imaging study. Upon
scanning at multiple locations on the surface of a tissue geometry, the possibility to detect
deeper targets and differentiating them from artifacts tends to improve upon summing all
these multiple scans. The detection limits of our hand-held optical imager, the first of its
kind that can scan large areas in near real-time, has been 2.5 cm for a 0.45 cm3 target under
T:B=1:0 from the past studies (Chapter 8) involving a single scan from the region of interest
on the tissue geometry. In the current study, it was clearly observed that upon summation of
the intensity signals from multiple scans of the tissue surface, targets of smaller volume and
as deep as 3.5 cm were detectable. However, artifacts start appearing when the target depth
is increased, the target volume is decreased, and/or heterogeneity of the background
increased. The reasons for these artifacts are two-fold: (i) The uneven source strength
distribution of the 6 simultaneous sources affects the ability to detect the target depending
on the proximity of the target to the stronger sources. As multiple scans are collected the
strong source may move away from the target resulting in a more diffused signal which
produces a greater number of artifacts upon subtraction of the background.

(ii) The

positional information of the hand-held probe is not accurately coregistered due to the
instability of the motion tracking device, which can lead to misalignment of the target signal
in the multiple images. As a result, some signals which originated from the target can be
mistaken as artifacts due to their improper location in the image. Currently, work is carried
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out to homogenize the source strength distribution by altering the instrumentation set-up at
the source end, and also developing alternate motion tracking approaches that are stable and
more accurate in comparison to the current device.
Researchers in the past have demonstrated detection of targets as deep as 5 cm using
their hand-held optical devices [50]. However, the detection was typically a point location
that was spectroscopically obtained from the tissue surface. In addition, the specificity of
getting a negative result (not detecting any target) in the absence of the target (i.e. in the
surrounding tissues) is not described. In other words, unlike the current hand-held optical
imager that can produce 2D images over large areas in near real-time, the other hand-held
imagers have a limited imaging area (mostly point-based imaging) and typically produce only
spectroscopic measurements from a few sources/detectors.
The advantage of the current hand-held imager’s optical data is that it can be applied
towards 3D tomography studies, since the positional location of the optical data with respect
to the 3D tissue geometry is coregistered during imaging studies.

Hence, the

implementation of the multi-scan imaging approach and using the summated images towards
immediate 2D deep target detection and future 3D tomographic analysis is feasible.
Although the present study is focused on fluorescence-enhanced optical imaging, the multiscan summation and imaging approach is applicable for absorption-based diffuse optical
imaging studies as well.
In the area of fluorescence tomographic imaging, Sevick’s research group was one of
the first groups to demonstrate 3D fluorescence optical tomography in clinically relevant
sized tissue phantoms, using large bulky optical imaging instrumentation [24]. Fluorescent
targets of 1 cm3 volume were recovered at a depth up to 2.8 cm under perfect uptake
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conditions. The first in vivo 3D fluorescence optical tomography of breast cancer in human
subjects was demonstrated by Corlu et. al. where tumors were recovered in vivo up to 2.0 cm
deep in human breast tissue [110]. From our past 3D tomography studies using the handheld imager on large tissue phantoms, 0.45 cm3 targets as deep as 2.5 cm were recovered in
uniform tissue phantoms under perfect uptake conditions [3].
In a recent in vivo study using a simulated fluorescent target, a single scan using our
hand-held optical imager was able to detect a 0.23 cm3 target ~ 2.5 cm deep in human breast
tissue (Chapter 11). These studies demonstrate the potential that upon using multiple scans
and applying the summation approach, deeper and smaller targets can become detectable
from the tissue surface.

In addition, these summated images can also assist in

tomographically recovering deeper targets beyond what is demonstrated to date in the area
of fluorescence optical tomography. However, the developed hand-held optical imager is
limited to reflectance based imaging, which tends to limit the recovery of the target’s true
depth during 3D tomography. Currently, research is carried out to develop alternate imaging
approaches using the hand-held device such that trans-illumination measurements can also
be acquired in an attempt to improve the target depth recovery (during 3D tomography).
9.5 CONCLUSION
Herein we have demonstrated improved detection limits via application of a multiple-scan
technique. The multi-scan imaging approach is facilitated by the use of fast 2D coregistered
imaging in CW mode. Previous results using single-scan imaging showed that the greatest
target depth detected was 2.5 cm and 1.5 cm for a 0.45 cm3 target in a (liquid) tissue
phantom under perfect and imperfect uptake conditions, respectively. By using the multiscan technique, this depth was improved to 3.5 cm for a smaller target (0.23 cm3) under the
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T:B=1:0 condition. Under imperfect uptake conditions (T:B=100:1), the detectable target
depth was increased from 1.5 cm to 3.0 cm. Since these results were promising, studies were
extended to in vitro models, which better represent the non-uniformity of human tissue.
From these in vitro studies the target was detected at depths of 3.5 cm and 2.5 cm for perfect
(1:0) and imperfect uptake (100:1) cases, respectively.

These studies demonstrate that

summation of multiple coregistered images can be used towards deeper target detection than
is capable from single scans alone. In a clinical setting, this technique can be used to acquire
multiple images quickly in order to detect the presence of a tumor, determine its 2D location
within the tissue, and also perform 3D tomography studies (as a follow-up). Thus, the handheld optical imager has potential for fast 2D imaging and 3D tomography in the clinical
setting for breast cancer diagnosis.
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CHAPTER 10
Study III: 3D Tomography Studies in Tissue Phantoms and I n V i t r o
10.1 INTRODUCTION
Parallel to the coregistered imaging studies described in Chapter 9, 3D tomography studies
were carried out in tissue phantoms and in vitro with simple geometries using manual
coregisteration. This chapter describes FDPM tomography studies using a single image and
CW tomography studies using multiple summated images towards recovery of targets at
greater depths.
10.2 MATERIALS AND METHODS
10.2.1 FDPM Based Reconstructions I n V i t r o
Three-dimensional fluorescence tomography studies were performed from FDPM
measurements collected using the hand-held device with in vitro phantoms. The phantoms
were composed of minced chicken breast (480 mL) and 1% Liposyn (260 mL) for a total
volume of 800 mL within a 10x10x10 cm3 acrylic cube. A 0.45 cc acrylic sphere target was
filled with 1 !M ICG and placed at different locations and depths within the phantom. A
FDPM image was collected with the target followed by a background image with the target
removed to use to subtract the excitation signal. In all cases the laser power was set to 217
mA, the frequency synthesizer was set to 2.7 dB, and the exposure time was 200 msec. The
gain setting on the image intensifier was adjusted for each data set and held constant
between images with and without a target. The optical properties of the phantom (!ax, !sx’,
!am, and !sm’) were measured at both the excitation (‘x’) and emission (‘m’) wavelengths (785
and 830 nm, respectively) using a single pixel homodyne FDPM optical property
measurement system. Multiple repetitions (5-10) of the optical property measurements were
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collected and averaged for each in vitro phantom. The phantom was stirred between each
measurement in order to acquire values that are an average representation of the mixture as a
whole.

An example optical property measurement set including mean and standard

deviation of the optical properties at each wavelength is shown in Table 10.1. The table
shows large standard deviations due to the heterogeneous nature of the phantom material,
and hence ten measurements were collected and averaged for each wavelength. The output
intensity of the six source points at the probe face were measured using a digital optical
power meter (PM121 w/ S121 sensor, 500nW-500mW, Thorlabs, NJ) and average values
were used as input parameters in the reconstruction algorithm. The initial guess of the
reconstructed parameter (!axf) was arbitrarily set to a uniform distribution of 0.003 cm-1 and
an initial p-value of 0.01 was used in all cases. Table 10.2 provides a summary of the
experiment parameters for various experimental cases including the average measured source
intensities, the gain setting on the image intensifier, the actual target location in cm, the
actual target volume, the measured optical property values of the phantom at the excitation
and emission wavelengths, the target to background ratio (T:B), the recovered target location
in cm, the recovered !axf values in cm-1, the recovered target volume, the number of
iterations executed before convergence, and the breakpoint (cutoff value selected on the first
breakpoint of a histogram plot of the recovered !axf values). The total distance off between
the true and recovered target locations was calculated using the following equation:

(1)
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Table 10.1 Sample optical property measurements of the in vitro phantom. All optical property
values are in units of cm-1.

The results from two example cases (highlighted in yellow in Table 10.2) are given in Section
10.3.1.
10.2.2 CW Based Reconstructions using Summed Multiple-scan Data
Three-dimensional (3D) reconstructions were performed using the CW based data from all
the multiple-scan experimental cases detailed in Chapter 9 (summarized in Table 9.1). For
the CW based reconstructions, the modulation was set to zero in the reconstruction
algorithm for continuous amplitude. Each experimental set encompassed a series of 8 scans,
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2 repetitions at 4 different probe locations moving vertically in 0.5 cm increments (see
Section 9.2.2 for more details on the multiple-scan acquisition). The 2D images of the
summed multiple-scan data were presented in Section 9.3. Herein, 3D reconstructions were
performed using two methods: (i) individual reconstructions were performed using the data
from each single scan and the recovered !axf values were then summed; (ii) the initial raw
data from the 8 scans was summed together into a single data set which was then used to
perform 3D reconstructions. A separate mesh was generated to input in the reconstruction
algorithm for the different data sets, with different nodes assigned to the source and detector
coordinates according to the coregistered location of the probe with respect to the phantom.
10.3 RESULTS AND DISCUSSION
10.3.1 FDPM Based Reconstructions I n V i t r o
Figure 10.1 shows the result for experimental case #26 (Table 10.2) with a target located 2.0
cm deep from the imaging surface under perfect uptake conditions. The 2D contour plot
represents the subtracted fluorescence intensity data collected in the frequency domain and
the three isosurface contour plots show three different views of the 3D reconstruction of the
target. These plots show a recovered target; however the absorption coefficient values of
the fluorophores (labeled as V1 in Figure 10.1) are low (close to the initial distribution of
0.003). The total distance off between the true and recovered target location was 1.9 cm.
This large value is mostly attributable to the z-coordinate which represents the depth of the
target from the imaging surface.
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Table 10.2 Summary of the experiment parameters for two sample experimental cases including the
average measured source intensities, the gain setting on the image intensifier, the actual target
location in cm, the actual target volume, the measured optical property values of the phantom at the
excitation and emission wavelengths, the target to background ratio (T:B), the recovered target
location in cm, the recovered !axf values in cm-1, the recovered target volume, the number of
iterations executed before convergence, and the breakpoint (cutoff value selected on the first
breakpoint of a histogram plot of the recovered !axf values). A full table of all experimental cases
performed
is ggiven in Appendix
C.
p
pp

The true z-coordinate was 2 cm, while the recovered z-coordinate was only 0.2 cm (Table
10.2). The limited depth recovery is due to the physics of reflectance based measurements
and has been reported by other research groups in the literature.[23,105,114]
Figure 10.2 shows the 3D reconstruction result for experimental case #27 (Table
10.2) with a target located 2.5 cm deep under perfect uptake conditions. The 2D contour
plot shows the presence of more artifacts at this deeper target location; however the
isosurface plots of the 3D reconstructions show that the target was recovered at this depth.
Similar to the previous result, the recovered absorption coefficient values of the
fluorophores (labeled as V1 in Figure 10.2) are low (close to the initial distribution of 0.003),
the reconstructed location was close to the true location in the x-y plane, and the recovered
depth is shallow compared to the true depth. The total distance off between the true and
recovered target location was 2.0 cm, which is mostly attributable to the depth (zcoordinate).

104

Figure 10.1. Reconstruction of 2.0 cm deep target within heterogeneous in vitro phantom under
perfect uptake case. (A) 2D image collected using hand-held device, (B) 3D view of isosurface plot
of reconstructed target, (C) three views of reconstructed target (solid open circle represents true
target location; dotted line encircles recovered target). The term V1 in the legend represents the scale
for the recovered !axf values in cm-1.
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Figure 10.2 Reconstruction of 2.5 cm deep target within heterogeneous in vitro phantom under
perfect uptake case. (A) 2D image collected using hand-held device, (B) 3D view of isosurface plot
of reconstructed target, (C) three views of reconstructed target (solid open circle represents true
target location; dotted line encircles recovered target). The term V1 in the legend represents the scale
for the recovered !axf values in cm-1.

10.3.2 3D CW Based Reconstructions using Summed Multiple-scan Data
Figure 10.3 shows an initial result from the heterogeneous in vitro phantom with the target
located at 2.5 cm depth from the imaging surface under imperfect (100:1) uptake.
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Figure 10.3 3D reconstruction using summed coregistered data. (A) 2D contour plot of summed
images collected using hand-held probe. (B) Coregistered image of summed data with phantom
mesh. (C) Isosurface plot of 3D reconstruction. (D) Contour slices showing intensity data of 3D
reconstruction. The true target location is indicated by a black circle (A-B) or a dark red sphere (CD).

Figure 10.3A shows the 2D contour plot of fluorescence intensity of the summed image
with the true target location indicated by the black open circle. Figure 10.3B shows the
coregistered image of the summed data. Figure 10.3C and 10.3D shows the isosurface and
contour slices of the 3D reconstruction respectively. From the contour slices it can be seen
that a high signal is reconstructed in the region where the target is located and the
reconstructed location is closer to the true depth than previous reconstructions using singlescan FDPM data. There is also noise signal reconstructed close to the imaging surface. This
is a result of reflectance-based measurements and in future the first centimeter can be cut off
during deep target imaging.
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These preliminary results demonstrated the potential for deeper target recovery upon
3D fluorescence reconstructions using summed multiscan coregistered images. In previous
reconstructions using a single image, the target was recovered shallower than the true depth
(~ 1 cm deep). This is due to the use of reflectance based measurements and the same result
was found by other researchers as well.[23,105,114]

Figure 10.3D shows that the

reconstructed signal from the 3.0 cm deep target is located at a depth greater than 2 cm. In
the case of deep target imaging, the first cm of the image can be cut off to minimize this
noise.
Sample results from four of the experimental cases that were reconstructed are
presented herein and the details are summarized in Table 10.3. Figure 10.4 shows the
reconstruction results (shown as contour slices) from experimental case A where the 8 single
scans were reconstructed individually. The true target location is indicated by a grey sphere.
It can be seen that the 3.0 cm deep target was not recovered upon 3D reconstruction using
single scans.

Table 10.3 Summary of selected experimental cases for summated image reconstructions.
Target
Volume

Target
Depth

T:B

Target
(x,y,z)

A

0.45 cm3

3.0 cm

100:1

(4.5, 2.5, 3.0)

B

0.23 cm3

2.0 cm

100:1

(6.0, 2.5, 2.0)

C

0.45 cm3

3.0 cm

1:0

(4.5, 2.5, 3.0)

D

cm3

3.5 cm

1:0

(4.5, 2.5, 3.5)

Experimental Case
Tissue
Phantom
In Vitro

0.45
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Figure 10.4 Individual 3D reconstructions (shown as contour slices) of the 8 single scans from
experimental case A in Table 10.3. The grey sphere represents the true target location.

Figure 10.5 shows results for the first method of CW based summated multiple-scan
reconstructions where the recovered !axf values from the individual reconstructed scans were
summed together. The results show contour slice plots for the four experimental cases
summarized in Table 10.3.

In each case, the plots in the left column represent the

summation of four scans from four probe locations (i.e. scans 1,3,5,7) and the plots in the
right column represent the summation of the repeated set of four scans at the same probe
locations (i.e. scans 2,4,6,8).
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Figure 10.5 Results for the first method of CW based summated multiple-scan reconstruction
(shown as contour slices) where the recovered !axf values from the individual reconstructed scans
were summed together. The true target location in each plot is indicated by a grey sphere.

Plots B1, C1, and C2 in Figure 10.5 show recovered signal close to the true target location
without surrounding artifacts. However, there is no discernible target recovered in the other
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five plots. Hence, it cannot be concluded that a target is recoverable using this method of
summation towards 3D tomography.
The results from the second reconstruction method where the 2D image containing
the summed raw data from the entire set of eight scans was used in the 3D reconstruction
are given in Figure 10.6. Figure 10.6A shows the result for a 0.45 cm3 target with 1 !M ICG
placed 3.0 cm deep in a tissue phantom under imperfect uptake (T:B=100:1). Figure 10.6B
shows the result for a smaller target (0.23 cm3) with 1 !M ICG placed 2.0 cm deep in a tissue
phantom under imperfect uptake (T:B=100:1). Both cases show a region of higher signal
close to the true target location (indicated by the yellow dotted circles). In each case, the
recovered signal is located vertically higher than the true target location, and there are many
surrounding artifacts. Figure 10.6C shows the result for a 0.45 cm3 target with 1 !M ICG
placed 3.0 cm deep in vitro under perfect uptake (T:B=1:0). Figure 10.6D shows the result
for a 0.45 cm3 target with 1 !M ICG placed 3.5 cm deep in vitro under perfect uptake
(T:B=1:0). In both cases, there is no significant signal recovered close to the true target
location.
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Figure 10.6: Results for 3D reconstructions performed using multiple summated coregistered
images. Details of each experimental case are given in Table 10.3. The yellow dotted circles indicate
possible recovered signal from the fluorescent targets. The true target locations are indicated by grey
spheres circled in black for emphasis.

Overall, the results did not show that reconstruction of summated images enables
deeper target recovery. This could be due to several factors. The summed images were
treated as a single image at the initial probe location with six source locations and 165
detector locations. An alternate approach would be to incorporate additional source and
detector positions at the additional probe locations. However, this would misrepresent the
experimental procedure by treating the sequentially collected scans as though they were
collected simultaneously with additional sources and detectors.

A parallel study was

performed where the individual data sets were reconstructed prior to summation and then
the recovered !axf values were summed. However, the results did not show reconstruction
of the deeper targets upon summation. This was likely due to the high amount of noise and
lack of signal at the true target location in each of the individual reconstructed images. In
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the future, some filtration techniques might be applied to reduce the noise in the images
possibly enabling reconstruction of the targets using the summated images.
10.4 SUMMARY AND CONCLUSION
Studies were performed to demonstrate 3D tomography in tissue phantoms and in vitro to
recover a fluorescent target within a heterogeneous scattering background. FDPM based
reconstructions were performed in vitro and fluorescent targets were recovered up to a depth
of 2.5 cm. CW based multiple-scan reconstructions were performed in tissue phantoms and
in vitro toward deeper target recovery using two methods: (i) summation of the recovered !axf
values from the individually reconstructed single scans; (ii) performing 3D reconstruction
using the summed raw data from the entire set of scans.

The results from the CW based

multiple-scan reconstructions did not conclusively show the reconstruction of deeper targets
upon using the summated images. Possible filtration techniques can be applied in the future
to reduce the noise in the summed images.
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CHAPTER 11
Study IV : 2D Imaging I n V i v o with Healthy Human Subjects in NearReal Time towards Target Detection
11.1 INTRODUCTION
Thus far, fast 2D imaging, coregistered imaging, and 3D tomography have been
demonstrated in tissue phantoms and in vitro. Herein, in vivo studies are performed on
healthy human subjects to demonstrate the feasibility of using the hand-held device to image
a fluorescent target with a background of real human breast tissue.[156]
11.2 MATERIALS AND METHODS
All human subject studies were approved by the Florida International University
Institutional Review Board. Healthy female volunteers age 21 and above were recruited for
the studies. A spherical fluorescent target was used to simulate a tumor (the same target
used in phantom and in vitro studies) and was placed underneath the flap of the breast tissue
(i.e. between breast tissue and chest wall, underneath the tissue) as shown in Figure 11.1.
Table 11.1 gives a summary of the in vivo experimental cases performed.

Figure 11.1 Schematic showing the location of an absorbing target placed superficially underneath
the breast tissue and the location of the probe during imaging.
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Table 11.1 Summary of experimental cases performed for in vivo fast 2D imaging studies.

In the first study, a 0.23 cc sphere with 1 !M ICG was placed under the right breast
in the 4 o’clock position. The flat probe face was placed against the breast tissue (centered
at the 6 o’clock location) with gentle compression to achieve full contact with the tissue and
a near-real time CW fluorescent intensity image was acquired (around the target region). The
depth of the target within the tissue was approximately 2.5 cm as measured with a Vernier
caliper. The experiment set-up for in vivo human subject studies is shown in Figure 11.1
(with mannequin for demonstration only).

Figure 11.2 Experimental set-up for in vivo studies with human subject (mannequin shown here for
demonstration only). The hand-held probe is placed in full contact with the breast tissue. The raw
image and the 2D contour plot are displayed on the computer screen.
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A second study was performed using a single target with the probe in the maximum
curved position (i.e. 45° curvature of the two side plates of the 3-plate based probe face).
The images collected with the probe in the curved position possibly include trans-illuminated
measurements in addition to reflectance based measurements. This study was performed to
demonstrate the feasibility of using the probe in its curved position, such that it can contour
along the tissue and also provide fluorescent images that can aid in target detection. Herein,
a 0.45 cc fluorescent target containing 1 !M ICG was placed under the right breast in the 8
o’clock position. A real-time as well as fast (subtracted) image of fluorescence intensity was
acquired.
A third study was performed to demonstrate the feasibility of imaging multiple
targets within real human breast tissue. Two targets were placed under the fold of the left
breast tissue, with a 0.23 cc target at the 6 o’clock position, and a 0.45 cc target was placed at
the eight o’clock position of the same breast. A real-time as well as fast (subtracted) image
of fluorescence intensity was acquired by applying gentle compression on the left breast
tissue.
During the studies, the probe was placed visually over the breast tissue and centered
with respect to the nipple region. For future in vivo studies with human subjects, a more
systematic protocol is currently being developed. The method uses a clear plastic sheet with
holes placed on a grid at premeasured locations. The plastic will be placed over the tissue
and a pen will be used to mark the probe locations on the tissue. The grid is shown in figure
11.2.
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Figure 11.3 Systematic grid developed for future imaging studies. The positions are measured with
reference to the center (nipple) region which is indicated by the red dotted circle.

The positions are measured and numbered from the nipple region and the number of
locations used will be determined by the volume of tissue to be imaged. For the first set of
images, the probe will be centered over the marks in the middle region with the bottom of
the probe aligned with each mark. For the second set the probe will be centered over the
marks in the outer region, and for the third set the probe will be centered over the marks in
the inner region. The positions are labeled with U or L to indicate “upper” and “lower”
region, respectively, and O, M, or I to indicate “outer”, “middle”, or “inner” region,
respectively. The entire set will be repeated on the other breast at the corresponding
locations. For the studies described here, the probe location in all cases roughly corresponds
to the LM4 location in Figure 11.2.
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11.3 RESULTS
Figure 30 shows the fast 2D subtracted images of fluorescence intensity obtained in
vivo (from a normal human subject using a simulated target) with the probe in the flat
position (Figure 30A) and in the curved position (Figure 30B). These subtracted image
results demonstrate the feasibility of fast 2D surface imaging and 2D target localization in a
clinical environment. The real-time (non-subtracted) images of fluorescence intensity were
unable to differentiate the target from the heterogeneous background, and hence only the
fast 2D subtracted images are shown in Figure 11.3.

Figure 11.4 Fast subtracted images of fluorescence intensity obtained as 2D surface contour
plots, acquired in vivo from a human subject using a spherical fluorescent target, for two
experimental cases: (A) the probe was in the flat position and a 0.23 cc target was placed at the 4
o’clock position, and (B) the probe was in the curved position and a 0.45 cc target was placed at
8 o’clock position. The images acquired using the probe in the curved position are illustrated as
projected as a flat 2D image, in order to be consistent with the images presented in case (A) (i.e.
using the probe in flat position).
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Figure 11.5 Fast subtracted image of fluorescence intensity obtained as 2D surface contour plot,
acquired in vivo from a human subject using two spherical fluorescent targets (0.23 and 0.45cc).

The 2D subtracted images of fluorescent intensity from multiple simulated targets in
a human subject are shown in Figure 11.4. The 0.23 cc target is detected in the center of the
image and the 0.45 cc target is detected towards the left side in the image, which are very
close to the true locations of these targets. This study demonstrates the potential to image
and localize multiple fluorescent targets (of different sizes) within human breast tissue.
11.4 DISCUSSION AND CONCLUSION
The fluorescence imaging studies described here demonstrate for the first time the
acquisition of fast 2D surface images (in < 5 sec) of a fluorescent target in vivo using a handheld based optical imaging device.

The subtracted images have a potential to clearly

differentiate target(s) from the background of human breast tissue at a depth of ~2.5 cm
either with the probe in the flat position using gentle compression or with the probe in the
curved position to contour around the tissue curvature.

The results demonstrate the

potential to translate the technology towards on-site breast imaging in a clinical environment.
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CHAPTER 12
Study V: Coregistered Imaging I n V i v o with Healthy Subjects
12.1 INTRODUCTION
In order to perform 3D tomography in complex geometries such as human breast tissues, it
is necessary to accurately coregister the image to the tissue geometry. In the phantom
studies described above, the simple cubical geometries were generated manually using
Gambit software. In the case of human subjects, the geometry shape and volume varies for
each subject and thus must be acquired individually. This chapter describes the process of
acquiring the breast tissue geometry for each human subject, generating the surface mesh of
the tissue geometry, and demonstrating coregistered imaging on normal human subjects.
12.2 MATERIALS AND METHODS
12.2.1 Initial coregistered imaging approach (motorized 3D scanner & sitting
position)
A commercially available hand-held 3D scanner (Polhemus, Inc.) was employed to acquire
the breast tissue geometry. Use of the scanner on human subjects was approved by the FIU
Institutional Review Board.

A motorized system was implemented with scanner to

automatically acquire the scan without requiring an operator to hold the scanner. This
method was designed to enable the scanning procedure to be independent of the operator as
well as to allow more privacy for the subject since the scanner would be operated by
computer from outside a curtained room. The automated scanning system set-up is shown
in Figure 12.1A where the subject was seated in an upright position during the scan
(mannequin is shown for demonstration only). Each scan was composed of a series of four
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sweeps of the scanner which would cover both sides of the breast tissue as well as part of
the chest wall and ribcage area. The acquired geometry was displayed by the

Figure 12.1 Initial set-up for acquiring 3D breast tissue geometry for coregistered imaging.

Polhemus software (Figure 12.1B) and then exported as a .MAT file and discretized using
MATLAB software developed in house to generate the surface mesh geometry to be loaded
into the coregistration software (Figure12.1C). The automated coregistered imaging process
using MATLAB/LabVIEW software developed in house was detailed in Chapter 6.
12.2.2 Validation of coregistered imaging in human subjects
Automated coregistered imaging has been demonstrated in phantoms which have rigid
structure and simple geometry. Translation of this procedure to human tissue is a much
more complex case since human tissue is not rigid and has irregular shapes. Prior to in vivo
studies on human subjects, it is necessary to validate the automated coregistered imaging
process on actual human tissue.
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Coregistered imaging in human breast tissue is validated by the following procedure.
In step one the breast tissue geometry is acquired by using a 3D scanner to scan the breast
tissue (Figure 12.2A). In step two, the 3D geometry is transformed into a discretized surface
mesh (Figure 12.2B). In step three, an initial reference point is automatically inserted into
the mesh at the center region of the tissue which is marked correspondingly at the same
location on the subject (Figure 12.2C). Four additional reference points are generated
automatically and the x-y-z positions are given quantitatively relative to the initial reference
point (Figure 12.2D).

Figure 12.2 Automated input of reference points within any 3D scanned geometry.

In step four, the locations of the additional reference points are measured on the subject and
marked with surgical tape (Figure 12.3A). In step five the probe is positioned such that the
origin is located at the initial reference point on the subject (Figure 12.3B-C) and the
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coregistration software is initialized (Figure 12.3D). In step six, the probe is moved to other
positions marked by the additional reference points and the coordinates of the probe
location given in the tracking software are compared to the known coordinates of the
reference points marked on the subject to validate that the image is coregistered onto the
true location of the tissue.

Figure 12.3
software.

Placement of reference points on the subject and initialization of coregistration

In order to quantitatively determine the accuracy of the tracked position and
coregistered image compared to the true location on the tissue, the probe was placed at the
four different reference points of known coordinates and ten measured values were recorded
from the tracking software at each position.
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The average, standard deviation, and

discrepancy of these measured values for each position are given in Table 12.1. The average
measured value and standard deviation represent the precision of the tracking software.

Table 12.1 Average and standard deviation of x,y,z coordinates as displayed in tracking software and
total distance off between true and measured values. Values are in units of centimeters and each
measured value represents an average of 10 measurements while probe was at each of the 4
positions.

It can be seen from the standard deviation of the measured values that the tracked probe
position fluctuates between 0.1-0.4 cm.

The average total distance off represents the

accuracy of the tracked position compared to the true location. The average total distance
off is 0.99 cm. The deviation and discrepancy of the measured values can be attributed to
several factors: (i) The inherent fluctuation within the tracking instrumentation; (ii) Slight
movements of the operator while holding the hand-held probe in position; (iii) Small errors
in the measuring and placement of the physical reference points marked on the human
subject. In future, efforts will be made to overcome these limitations and improve the
accuracy of the tracking coordinates.
A study was performed with a normal human subject to demonstrate selfcoregistered imaging on actual human tissue. Figure 12.4 shows the front panel for the
coregistration software and the image of the meshed tissue geometry with the reference
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xyz locations of
reference points
points (probe position is not shown here). Once the reference points are added to the mesh,

Distance in cm of each
a text file
is generated
and saved
reference
point
fromwhich contains the x,y,z coordinates of the reference points
initial reference point
and the relative distance of each reference point from the initial reference point which is
used to place the markers at the corresponding location on the subject.

Image of meshed
geometry with
reference points

Figure 12.4 Screen capture of coregistration software showing meshed geometry of breast tissue
with reference points (probe location inactive in this view).

The probe was placed at the initial reference point location and the coregistration
software was initialized. Figure 12.5 shows the tracked probe position at the initial point
(the origin) and at two additional reference points as it was moved to the corresponding
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positions marked on the subject. Images are shown in profile view from the subject’s left
side.

Figure 12.5 Images from coregistration showing probe position tracked in real-time at different
reference locations.

In order to perform coregistered imaging, a 0.45 cc spherical target filled with 2 !M
ICG was placed underneath the flap of the breast tissue (as described in section 11.2) in the
center. The probe was placed in full contact with the tissue without applying pressure and
an image was collected. The target was then removed while keeping the probe in the same
position and a background image was collected. The background image was subtracted from
the target image and the subtracted image was coregistered to the meshed geometry of the
breast tissue at the probe location. The resulting coregistered image is shown in Figure 12.6.
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Figure 12.6 Coregistered image of simulated target behind human breast tissue. White dotted line
represents the probe position.

This initial study demonstrates the ability to track and coregister an image to the
location within the tissue geometry. Some limitations include slight movements of the
subject which are not measured or accounted for in the tracking software and could affect
the accuracy of the coregistered position, and slight conformation of the tissue upon contact
by the hand-held probe face. These limitations were addressed by modifying the imaging
set-up as described in the next section.
12.2.3. Modification of coregistered imaging i n v i v o to improve accuracy (hand-held
3D scanning and imaging in supine position)
The initial set-up for coregistered imaging in vivo with human subjects had several limitations
which resulted in inaccuracy of tracking and coregistration at the true probe location. The
following limitations and proposed solutions were presented:
(1)

Limitation #1:

Movement of subject during imaging process which is not

accounted for in coregistration software.
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Proposed Solution: A chair will be acquired for the human studies, which has the
ability to recline to a 45-90 degree angle to prevent subject from leaning. Once
positioned in the chair in a relaxed posture, the subject will be scanned with the 3D
scanner and then they will remain in same position to be imaged with the hand-held
probe.
(2) Limitation #2: Deformation of the breast tissue upon contact with the hand-held
probe causing the geometry of the tissue to be changed from the 3D scanned
geometry.
Proposed Solution: When the subject is lying at a 45-90 degree reclined positioned,
the breast tissue will naturally flatten against the chest wall. Additionally, surgical
tape will be used to tape the breast tissue in a flattened conformation similar to the
procedure used during ultrasound-guided biopsy. This will enable the probe to be in
contact with the tissue with minimal deformation since the tissue will remain
generally flat.
(3) Limitation #3: Operator error in measurement and placement of markers on the
subject at the reference points.
Proposed Solution: An optically clear plastic covering can be placed over the breast
tissue. The coronal-view coordinates of the reference points can be more accurately
marked on the plastic before it is placed over the tissue surface at the appropriate
position.
The following steps were implemented in the modified experimental study set-up in
order to address the limitations listed above:

128

Solution for Limitation #1: A massage chair capable of reclining 45-90º with arm rests was
acquired for the imaging studies (Figure 12.7). The subjects rested in supine position on the
chair with the back reclined at 45º and arms resting at the sides or on the armrests. This
position was chosen such that it would be reclined enough to minimize movement of the
subject (as opposed to the upright position with no armrests in the initial set-up which
allowed movement of the subject) as well as maintain line-of-sight between the probe and
the tracker which would be inhibited if the chair was reclined to greater angles. In order to
acquire the 3D geometry with the subject in the reclined position, the Fastscan was taken
back as a hand-held scanner and used to scan the tissue by hand (the motorized system will
be used in future applications described in Chapter 16).

Figure 12.7 Modified human subject imaging set-up. Subject lies supine in recliner chair (45º)
during acquisition of tissue geometry with 3D scanner and imaging using handheld imager.

Solution for Limitation #2: The reclined position of the subject also helped to overcome
limitation #2 since the position caused the breast tissue to flatten against the chest wall
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resulting in minimal conformation of the tissue by the probe during imaging. However, the
amount of tissue curvature and deformation depended on the volume and density of the
tissue, thus the amount of deformation varied among subjects. (This issue will be addressed
in future by use of a custom-built garment described in Chapter 16).
Solution for Limitation #3: For the initial studies with normal human subjects, the
subjects were recruited by advertisement and hence the size and shape of the tissues imaged
varied greatly. Hence, it was not feasible at that stage to use a prepared plastic with the
reference points marked. Instead, a more accurate approach of choosing reference points
was implemented in which the center (nipple) was used as the initial reference point and
other reference points were measured and marked at specific distances from the center using
the ‘clock’ notation. This method treats the breast as the face of a clock and locations are
determined by their respective location on the clock (Figure 12.8 left) and the distance from
the nipple is measured in centimeters (Figure 12.8 right). This method is typically used in
the clinical setting during breast ultrasound imaging.

Figure 12.8 ‘Clock’ method for referencing locations on the breast tissue. The relative section of
the tissue is determined by the position on the ‘clock’ (shown on left side) and the distance from the
nipple is measured in centimeters (shown on right side).
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The imaging process using the modified set-up is shown in Figure 12.9, where the
imaging room is closed off from the instrumentation room by a curtain and only the probe is
visible in the room. The probe was placed against the breast tissue while the location was
recorded by the acoustic tracker and the images were automatically coregistered at the probe
location relative to the tissue geometry. The resulting images were immediately displayed on
a monitor in the imaging room that was linked to the computer operated from the
instrumentation room.

Figure 12.9 Modified imaging set-up. The subject lies in supine position in recliner chair while
breast tissue is imaged using hand-held optical imager. Mannequin shown for demonstration only.

12.2.4 Experimental Study I: Automated Coregistered Imaging using Initial Imaging
Set-up

Experiments were performed using the initial coregistered imaging approach where
the subject was seated upright at a 90º angle. A 0.45 cm3 spherical target filled with 1
!M ICG was placed underneath the flap of the breast tissue as illustrated in Figure
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11.1. Images were collected with the target at 3 different locations corresponding to
the 4 o’clock, 6 o’clock, and 8 o’clock positions. In each case, the probe was centered
over the target location and placed in full contact with the breast tissue. CW images
were collected with the target in place and background images were collected (with
the target removed) for subtraction based post-processing.

The post-processed

images were automatically coregistered during live imaging at the probe location with
respect to the tissue.
12.2.4 Experimental Study II Automated Coregistered Imaging using the Modified
Imaging Set-up

Experimental studies were performed with healthy human subjects using the
modified coregistered imaging set-up. The subject lay in the supine position in the
recliner chair at a 45º angle. The chest region including both breast tissues and the
ribcage was scanned by hand using the 3D scanner. Figure 12.10 shows the 3D scanned
geometry of a normal human subject using the modified set-up where the subject was lying
in supine position in a recliner chair at a 45º angle. The reclined position caused the tissue to
flatten against the ribcage in order to minimize deformation of the tissue during imaging. A
default image was used in this study since the purpose of the study was to demonstrate
coregistered imaging using the modified approach and not to detect a target. The probe was
placed in contact with the breast tissue and the default image was coregistered to the tissue
geometry at the probe location.
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Figure 12.10 Geometry acquired using the modified imaging set-up with a healthy subject lying
supine in recliner chair with 45º angle. The white dotted line represents the probe location during
imaging. (A) Frontal view. (B) Side view.

12.2.5 Experimental Study III Manual Coregistered Imaging using the Modified
Imaging Set-up

Absorption based coregistered imaging studies were performed using a target
containing India ink as an absorbing contrast agent. Manual coregistered imaging was
performed since the instability of the acoustic based tracker had increased in time to
the point where it was no longer usable for coregistration purposes. For these studies,
the probe position was measured on the breast tissue and marked using surgical tape. The
image was then manually coregistered at the measured position using post-processing
coregistration software. Two experiments were performed using 0.45 cm3 spherical targets
filled with different concentrations of India ink (0.08% and 0.02%) placed underneath the
flap of the breast tissue at the 6 o’clock location.
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12.3. RESULTS
12.3.1 Experimental Study I: Automated Coregistered Imaging using Initial Imaging
Set-up
Figure 12.11 shows results for coregistered imaging studies with healthy subjects using the
initial set-up. Figure 12.11A shows the position of the probe and the discretized geometry
relative to the subject. Figure 12.11B shows the resulting coregistered image for case #1
where a 0.45 cm3 target was placed at the 6 o’clock position. A zoomed image of the same
result is shown in Figure 12.11C. Figures 12.11D and 12.11E show zoomed images of the
results for cases #2 (0.45 cm3 target at the 8 o’clock position) and #3 (0.23 cm3 target at the
4 o’clock position) respectively. In each case, the probe was placed such that the strongest
source was close to the target location and subtraction based postprocessing was applied to
eliminate excitation leakage (as described in Section 6.4 above). The results show that a
0.23-0.45 cm3 fluorescent target was detected through ~2.5 cm of human breast tissue and
coregistered to the appropriate location on the tissue geometry.
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Figure 12.11 Coregistered images of fluorescence intensity data collected from a normal subject with
an ICG-filled target using the initial set-up (subject seated in upright position). (A) Location of
probe and image relative to the subject. (B) Case #1 image: 0.45 cm3 target at the 6 o’clock position.
(C) Zoomed image of Case #1. (D) Case #2 image: 0.45 cm3 target at the 4 o’clock position. (E)
Case #3 image: 0.23 cm3 target at the 8 o’clock position. All targets contain 1 !M indocyanine green.

12.3.2 Experimental Study II Automated Coregistered Imaging using the Modified
Imaging Set-up
Figure 12.12 shows automated coregistered images from a normal human subject
using the modified imaging set-up with the acoustic tracker. The geometry was rotated to a
45º angle over the y-axis in the coregistration software to correspond to the 45º reclined
position of the subject. The probe location was coregistered to the tissue at two different
locations: the first location was centered over the breast tissue with the bottom of the probe
positioned 2 cm beneath the nipple region (Figure 12.12A-C) and the second location was
above the breast in the chest wall region with the bottom of the probe positioned 3 cm
above the nipple region (Figure 12.12D-F).
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Figure 12.12 Automated coregistered images in a healthy subject (no target) using the modified
imaging set-up. (A) Probe position #1. (B) Frontal view of coregistered image at probe position #1.
(C) Side view of coregistered image at probe position #1. (D) Probe position #2. (E) Frontal view
of coregistered image at probe position #2. (F) Side view of coregistered image at probe position
#2.

12.3.3 Experimental Study III Manual Coregistered Imaging using the Modified
Imaging Set-up
Figure 12.13 shows results from absorption-based studies in a normal subject with a 0.45
cm3 target filled with 0.08% India ink located at the 6 o’ clock position.

Figure 12.13A

shows the location of the probe relative to the subject. Figure 12.13B shows the probe
location placed manually in the post-process coregistration software, and Figure 12.13C
shows the resulting coregistered image. It can be seen that the target is detected as a lower
intensity (blue) signal indicating higher absorption at the location of the target.
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A

background image was also collected (without target) and subtracted to eliminate
background noise.

Figure 12.13 Manually coregistered images from a healthy subject with 0.45 cm3 target with
0.08% India ink placed under the breast tissue at the 6 o’clock position.
Figure 12.14 shows the results for the case of the lower concentration target (0.02% India
ink) placed at the 6 o’ clock position. Figure 12.14A shows the location of the probe relative
to the subject. Figure 12.14B shows the probe location placed manually in the post-process
coregistration software, and Figure 12.14C shows the resulting coregistered image. The
resulting contrast is lower due to the lower concentration of the absorbing agent, but the
lower signal (blue) from the target can be seen at the target location in the 2D image (Figure
12.14B) and the coregistered image (Figure 12.14C).
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Figure 12.14 Manually coregistered images from a healthy subject with 0.45 cm3 target with 0.02%
India ink placed under the breast tissue at the 6 o’clock position.

12.4 DISCUSSION
The modified imaging set-up was designed to overcome the limitations of the initial setup and improve the accuracy of automated coregistered imaging using the acoustic
tracker.

However, during implementation of the modified set-up, there were some

difficulties encountered. The acoustic based tracker operates most effectively when the
transmitter is placed level with the floor and the receiver is parallel to it. When the
subject was reclined at a 45º angle, the tracker lost line of sight on many areas of the
tissue. To overcome this issue, the transmitter was mounted at a 45º angle above the
subject’s head to enable it to be parallel with the receiver on the probe as it was placed on
the breast tissue. However, with this set-up, the tracker would lose line of sight when the
receiver was blocked by the subject’s head.

In addition, the tracker experienced

significant fluctuations and losing/gaining of line-of-sight even when the probe was held
at a constant location. This demonstrates that the accuracy of the tracker is poor even
apart from any error on the part of the operator or movement of the subject or tissue.
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Hence, it was determined that an alternate method of automated tracking must be
pursued. We are currently developing an optical based automated tracking method that
will have much greater accuracy than the acoustic tracker (described in Chapter 16).
Once the alternate tracking method is implemented, quantitative studies will be
performed to determine the improvement in the accuracy of coregistered imaging in
human subjects due to improvements in the imaging set-up and stability of the tracker.
Images can be manually coregistered to the tissue geometry if the probe location
is accurately measured relative to the tissue. The MATLAB software (developed inhouse) that was used to generate the discretized mesh of the scanned geometry was
modified to automatically find the initial reference point (at the nipple region) and lock it
to the origin in the coregsitration software. The imaging locations were measured in
centimeters and marked on the tissue for accurate positioning of the probe with reference
to the origin (nipple). The images were collected with the hand-held imager at the
predetermined locations and manually coregistered using post-process coregistration
software. This method is valid as long as the tissue is relatively flat against the chest wall
making the imaging surface close to planar. For tissues with greater curvature, it would
be more difficult to manually coregister with accuracy due to rotation of the probe with
respect to the origin. For efficient real-time tracking and imaging, a more accurate
tracking system will be implemented.
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12.5 SUMMARY AND CONCLUSION
An automated coregistered imaging approach was implemented and validated in vivo on
human breast tissue. A 3D scanner was used to acquire the breast tissue geometry from
each individual subject and an acoustic based tracking system was used to track the probe
location in real-time. The initial imaging set-up had several limitations which led to
inaccuracy in the coregistered imaging. The set-up was modified to overcome these
limitations; however, the tracking system was unstable. Results demonstrate the ability
to detect an absorbing target through breast tissue of a healthy human subject and images
were manually coregistered at the measured probe locations. These studies demonstrate
that manual coregistered imaging can be performed in human subjects under simple
conditions and automated coregistered imaging is feasible. The coregistered images will
be used to perform 3D tomography in human breast tissue as described in the following
chapter.
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CHAPTER 13
Study VI: 3D Tomography i n v i v o with a Healthy Human Subject
13.1 INTRODUCTION
Previous tomography studies performed using our hand-held optical imager involved
phantoms with simple geometries and structured 3D mesh, and the experimental image data
was manually coregistered at the known probe location with respect to the phantom. The
major challenge in performing 3D tomography in human tissue as opposed to simple
phantoms is to generate the discretized volume geometry (or mesh) for the human breast
tissue. For simple cubicle phantoms, the geometry and mesh were generated within a single
software (Gambit) and the same mesh was used for each phantom reconstruction. In the
case of human subject studies, the various breast tissue geometries must be acquired for each
subject and discretized into tetrahedral volume mesh. This chapter describes the procedure
developed herein for acquiring a tetrahedral volume mesh of the various breast tissues of
different human subjects and extracting the experimental information corresponding to each
coregistered data set, which is needed to input into the reconstruction algorithm to perform
3D reconstructions. 3D fluorescence tomography is performed using a coregistered image
from a healthy human subject with a superficially placed target. The results presented herein
demonstrate for the first time the feasibility of performing 3D tomography in human breast
tissue in vivo using a hand-held optical imager.
13.2 MATERIALS AND METHODS
13.2.1 Procedure for 3D Mesh Acquisition and Reconstruction I n V i v o
A commercially available 3D surface scanner was employed to scan the breast tissue of each
subject. The subject was seated upright in a 90 degree position and the motorized system
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was used to scan both sides of the breast tissue, chestwall, and ribcage. The resulting surface
scan is shown in Figure 13.1 (left). The scanner software was used to cut the surface
geometry to extract only the left breast in order to reduce computation time when
performing the reconstruction.

Figure 13.1 Scanned surface geometry of breast tissue. The imaged section was cut from the full
geometry and used in the reconstruction.

The acquired surface scan was then imported into a software (GiD) and a volume was
generated from the surface scan. Meshing softwares are typically designed such that a
geometry is both generated and meshed within that same software.

However, our

application presented a unique complication in that we required an externally acquired
complex geometry to be imported into the software and used to generate a 3D volume and
mesh. After many trials and much troubleshooting it was determined that the method to
acquire the mesh was to import the scanned surface into GiD and use the software to
generate a volume. The volume generated in the GiD software is shown in Figure 13.2. The
generated volume was then imported into Gambit which was used to generate the
tetrahedral volume mesh.
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Figure 13.2 Volume geometry of scanned breast tissue.

After acquiring the tetrahedral volume mesh from Gambit, there were several steps
required to prepare the mesh for importing into the reconstruction algorithm. The first step
was to determine the coordinates of the optical data image (collected by the hand-held
device) with respect to the volume mesh (since the original coregistered image used only a
surface mesh to reduce the imaging time and the coordinates are different in the volume
mesh generated for reconstruction). A post-processing version of the coregistered imaging
software was used to coregister the image to the new volume mesh using the positional
information stored from the original surface coregistered image acquired during live imaging.
A code was developed in MATLAB to then extract the coordinates and intensity data for use
in the reconstruction algorithm.
Another piece needed for the reconstruction algorithm was the coordinates of the
sources and detectors relative to the volume mesh. In the case of cubical phantoms, the
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coordinates on the simple geometry were manually entered since the 0.5 cm spaced grid of
detectors aligned perfectly with the 0.25 cm spaced grid of the cubical mesh. In the case of
human breast tissue, the mesh is unstructured and the probe location is not perfectly aligned
with the mesh coordinates. Hence, a method was developed to determine the source and
detector coordinates of any random probe position on the various unstructured volume
meshes. A grid was generated corresponding to the source and detector locations of the
hand-held probe image. The source locations in the grid were assigned a high value and the
detector locations were assigned a low value. The grid was then coregistered to the volume
mesh using the same positional information from the original surface coregistered image. A
code was developed in MATLAB to extract the coordinate locations of the sources and
detectors from the volume coregistered image according to the relative intensity values.
Since at this point the coordinates now correspond to the coordinate system in the
coregistration software (which is different from the original coordinate system assigned by
the Gambit software), the volume mesh from the coregistration software was exported to be
used in the reconstruction algorithm. However, a complication existed in the mesh exported
from the coregistration software. The coregistration software assigned nodes and elements
of the mesh using a different method than the Gambit software. In the Gambit software,
the nodes are assigned first and then connected to form the elements, resulting in more
elements than nodes. The coregistration software (using the MATLAB ‘patch’ function)
first generates the elements and then assigns the node numbers individually within each
element (Figure 13.3). Hence, adjacent elements assign multiple numbers to the same node.
This resulted in a very large number of nodes compared to elements which greatly and
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unnecessarily increases the computational time, and the mesh was incompatible with the
reconstruction algorithm.

Figure 13.3 Illustration of the two methods of assigning node numbers. (A) The mesh generated by
MATLAB and exported from the coregistration software assigns the elements first and then gives
each node in the element number assignments independent of the adjacent elements resulting in
multiple numbers assigned to the same node. (B) The preferred method is where the node numbers
are assigned first and then elements are constructed among those nodes such that each node is
shared by multiple elements and only assigned a single number resulting in much fewer nodes than
elements.

To overcome this complication, a code was developed in MATLAB to eliminate the
repeated nodes and reassign the node numbers within the elements correspondingly.
Additionally, a code was generated in MATLAB to reassign the node numbers
corresponding to the source and detector locations and the image intensity data according to
the corrected numbers.

The final mesh and all the extracted information were then

imported into the reconstruction algorithm to perform 3D tomography.
The entire procedure developed herein for acquiring the tetrahedral volume mesh, extracting
the experimental information, and performing 3D tomography in vivo in order to reconstruct
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a target within the breast tissue geometry of a human subject is outlined in the following ten
major steps:
Step 1: Acquire the coregistered image of optical intensity data from the breast tissue
(detailed in Chapter 12 above).
Step 2: Use the 3D surface geometry from the Fastscan to generate a 3D volume.
The 3D surface geometry that was scanned from the breast tissue was imported in IGES
format into the GiD software which was used to generate a 3D volume from the surface.
Figure 13.1 shows the volume geometry generated in the GiD software.
Step 3: Generate a 3D tetrahedral volume mesh and corresponding triangular surface
(or boundary) mesh for the volume breast geometry. The 3D volume from the GiD
software was loaded into Gambit software which was used to generate the unstructured
triangular and tetrahedral mesh.
Step 4: Adjust the coordinates of the Gambit mesh to correspond to the coregistered
image. The coordinate system of the mesh generated in Gambit is independent of the
coordinate system of the coregistered image. The Gambit mesh was imported into the postprocess coregistration software and locked to the location of the geometry during imaging.
The positional information preserved in the coregistered data that was acquired during live
imaging was used to coregister the image at the same location in the Gambit mesh.
Step 5: Determine the nodes and coordinates of the breast mesh that correspond to
the source and detector positions in the coregistered probe location. The positional
information of the coregistered probe location was used to find the closest nodes in the
unstructured breast mesh to each source and detector in the probe, and the coordinates of
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those nodes were assigned as the coordinates of the sources and detectors. The procedure
developed for performing this step ensures that the source and detector positions assigned
to the mesh correspond to the data collected with the probe and coregistered to the tissue
during live imaging.
Step 6: Eliminate duplicate nodes from the breast mesh (as exported from the
coregistration software) and assign the adjusted node numbers appropriately to each
element.
Step 7: Convert text files and source/detector positional information into data files
that will be used in the reconstruction code. This step must be performed for each new
mesh geometry and each different probe position within the same geometry.
Step 8: Acquire the intensity data for each detector position in the 3D breast mesh
from the coregistered image data. A code was written in MATLAB to extract the
intensity data from the coregistered mesh at the detector nodes located in Step 5 and 6 and
generate a data file containing the coordinates of the detector nodes and the corresponding
intensity values from the breast data.
Step 9: Use the intensity data acquired from Step 8 to generate the data files used in
the AEKF algorithm. These data files contain the AC, DC, phase, and modulation depth
information (or DC only for CW data) along with the optical properties of the background
tissue. In this case, average optical property values of human breast tissue acquired from the
literature [134] were used in the reconstruction.
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Step 10: Use the AEKF based algorithm to reconstruct the fluorescent/absorption
intensity values within the 3D discretized geometry of the breast tissue. The AEKF
algorithm is detailed in Chapter 7.
13.2.2 Fluorescence Tomography in a Healthy Human Subject
A 3D reconstruction was performed using data acquired from a healthy human subject with
a 0.45 cm3 spherical target containing 1 !M ICG placed underneath the flap of the breast
tissue at the 6 o’clock position (Case #1 in Section 12.3). The data was acquired by
automated self-coregistered imaging with the acoustic tracker using the initial imaging set-up
where the subject sat in a vertical upright position and the geometry was acquired by the
motorized 3D scanning technique. The geometry consisted of both sides of the breast tissue
and part of the chest wall and ribcage. In order to reduce computational time, the geometry
was cut to include only the breast tissue region in the vicinity where the data was acquired
with the optical imager (as described in Section 13.2.1). The reduced geometry was manually
placed at the appropriate location within the coordinate system using the post-process
coregistration software. The ten steps described in Section 13.2.1 were executed in order to
acquire the 3D meshed geometry and perform 3D tomography in human breast tissue. The
initial p-value in the AEKF reconstruction algorithm was set to 0.01. The input optical
property values were 0.05 cm-1 for !ax and !am, and 8.0 cm-1 for !sx’ and !sm’ (average values
of breast tissue optical properties obtained from the literature [134]. The initial guess for the
optical property distribution (in this case, !axf) was uniformly set to 0.003 cm-1.

The

modulation frequency (�) was set to zero for CW based reconstruction and only the real
part of the equations were used.
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13.3 RESULTS
The experimental data used for the reconstruction is shown in Figure 13.4, where the yellow
dashed line shows the probe location with respect to the disctretized tissue geometry. The
fluorescent signal from the target was detected close to the target location (6 o’clock
position).

Figure 13.4: Automated coregistered image of a fluorescent target placed beneath the breast tissue
in a normal subject which was used to perform the 3D reconstruction.

Figure 13.5 shows the experimental result of the reconstruction plotted in Tecplot. Figure
13.5A shows the 3D tetrahedral unstructured mesh of the breast tissue geometry and Figure
13.5B shows the recovered fluorescence intensity as a series of slices in the x-plane. The
slices are plotted in profile view to show their location within the tissue geometry.
Individual detailed slices are shown in frontal view in Figure 13.6.
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Figure 13.5: (A) Plot of the 3D tetrahedral unstructured mesh used in the reconstruction. (B) Side
view of contour slices in the x-plane.

The coronal slices in Figure 13.6 begin at the tissue surface close to the central (nipple)
region and progress depth-wise toward the chest wall. The initial slices at depths below 1.0
cm (slices 1-3) show signal from the 2D target location although the depth of the signal is
less than the true target depth (~2.5 cm). At a depth of 1.0 cm and greater (slices 4-12),
additional signal appears to the left side of the breast tissue away from the target location.
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Figure 13.6: Contour slices in the x-plane at 0.25 cm intervals. Slice depth is indicated as depth
from the tissue surface at the center (nipple) region.

Figure 13.7 shows slices in y-plane representing the sagittal view. Slice 4 in the
center gives the sagittal slice at the y=0 location which is the central part of the tissue. The
other slices represent the locations in 0.25 cm increments to the left (slices 1-3) and right
(slices 5-7) of the center. The images show that within this central region, there is a
maximum signal intensity at the central location of the tissue which corresponds to the 6
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o’clock position of the fluorescent target, and the signal diminishes in either direction away
from the center.

Figure 13.7 Contour slices in the y-plane at 0.25 cm intervals.
The quantitative results for the in vivo 3D reconstruction are provided in Table 13.1. The
recovered !axf value (9.17) is much larger than expected, which is due to the presence of
signals from artifacts which are all included in the total !axf value. The true target location
was approximated at (x,y,z)=(2.5,0,0) since the target was placed in the center underneath
the flap of the tissue and the approximate tissue depth (x-dimension) was 2.5 cm (as
measured by a Vernier caliper). The recovered target location was (x,y,z)=(3.0,-3.3,-1.8) and
the total distance off was 3.75 cm. The distance off can be due to two factors: (i) inaccuracy
in the estimation of the true target location, and (ii) the artifacts that appear toward the left
side of the reconstruction (as shown in Figure 13.6) which can be mistaken as the true
location due to the high intensity of the signal. Reduction in artifacts and better estimation
of the true target location will likely improve the quantitative results.
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Table 13.1 Quantitative results for the in vivo 3D reconstruction: recovered !axf, true target
volume, recovered target volume, approximate true target location, recovered target location,
total distance off.

13.4 DISCUSSION
Three-dimensional tomography of breast tissue in a human subject using a hand-held based
optical imager was demonstrated for the first time.

The reconstructed result shows

recovered signal at the true target location but at a shallower depth than the true target
location. This depth recovery limitation is a common phenomenon when reflectance based
measurements are used.

More accurate depth recovery may be achieved by using a

combination of transilluminated and reflected measurements or by using multiple
projections in reflectance mode.
Additional signal away from the target location was also present on the left side of
the tissue. This artifact signal might be the result of poor contact with the tissue on one side
of the probe causing detection of excitation light that was reflected off the tissue surface.
The subtraction based post-processing technique was applied to eliminate excitation leakage;
however, the probe might have shifted during removal of the target causing the background
image to have a different noise distribution from the image with the target.
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For this initial preliminary tomography study, a coarse mesh was used in order to
reduce computational time and effort while the reconstruction procedure was developed.
Use of a finer mesh could produce a more accurate reconstruction result. In addition, a
varied mesh might be used which is more refined close to the target location and more
coarse away from the target location which would further reduce the noise away from the
target. This would be applicable in a clinical setting since FDOT is not currently used for
screening and hence the region of tissue suspected of containing a tumor would be known.
This study used data from a normal human subject with a fluorescent target placed
noninvasively beneath the flap of breast tissue, between the breast tissue and the ribcage.
Hence the light passed through two layers of skin and a full layer of breast tissue during both
the incident and returning path which would produce a different result than an actual tumor
embedded within the breast itself under a few centimeters of tissue.
This preliminary study demonstrates the feasibility of performing 3D tomography in
human breast tissue using the ten step procedure developed herein. In the case presented
here, the true target location was roughly estimated and the results analyzed qualitatively.
Future work will involve extensive tomography studies in healthy subjects and breast cancer
patients to improve the accuracy of the quantitative results.
13.5 SUMMARY AND CONCLUSION
A procedure for performing 3D tomography in human tissue using automated selfcoregistered experimental data was developed. A preliminary reconstruction study was
performed using the self-coregistered data from a normal human subject with a fluorescent
target placed underneath the breast tissue. The result shows fluorescent intensity signal
reconstruction close to the true target location along with artifact signal away from the target
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location. This study demonstrates the feasibility of performing 3D tomographic imaging in
human breast tissue using a hand-held based optical imaging system.
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CHAPTER 14
Study VII: I n v i v o Imaging of Breast Cancer Subjects
14.1 INTRODUCTION
The studies described in the previous chapters involved preclinical testing of a hand-held
optical imaging system for breast cancer diagnosis. The final stage of this dissertation
involves testing the performance of the device in actual breast cancer subjects. This chapter
describes preliminary studies designed to demonstrate the feasibility of imaging breast
tumors in human subjects using our hand-held optical imager.
14.2 MATERIALS AND METHODS
Diffuse optical imaging studies were performed with two subjects (age 64 and 51) with
breast cancers masses confirmed by prior image modalities (i.e. x-ray mammography,
ultrasound, MRI). The studies were approved by the FIU Institutional Review Board and
the subjects signed a consent form prior to the study and a HIPAA authorization form (for
release of the medical records). For the diffuse optical studies (non-fluorescent) one neutral
density filter (OD 4) was used to uniformly attenuate the collected laser light. Continuous
wave based images were collected (average of 5 frames) using an exposure time of 200 msec.
The gain on the image intensifier was set while the probe was placed at the initial probe
location and held constant during the entire study performed at various probe locations.
The studies were performed using the modified imaging set-up described in Chapter
12, where the subject lay in the supine position in a recliner chair at a 45º angle. The probe
was placed at different locations on the ipsilateral (tumor-containing) and contralateral (nontumor-containing) breast and images of continuous-wave absorption-based measurements
were collected. The probe positions were determined visually to cover the entire breast
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tissue. Initially the probe was centered over the 12 o’clock position covering the upper
region of the breast tissue and part of the chest wall (probe location #1 in Figure 14.1), then
moved vertically down toward the 6 o’clock position (probe location #4 in Figure 14.1).
The four imaging locations relative to the subject are shown in Figure 14.1 (not to scale).

Figure 14.1: Schematic showing the probe locations during the imaging studies. The probe was
placed at four different locations on the left breast tissue followed by the same four locations on the
right breast tissue. All probe positions were estimated with reference to the nipple location and are
not drawn to scale in the schematic.

Currently, a more structured and accurate approach is developed for measuring and marking
the probe locations using the same method in all subjects (described in detail in Section 11.2
and Figure 11.2). For the studies describe herein, the positions were estimated at the
following locations corresponding to Figure 11.2: UM4 (location 1), UM2 (location 2), LM2
(location 3), and LM4 (location 4). In each case, both the left and right breast tissues were
imaged at the same symmetrical probe locations and the images from the contralateral breast
were normalized and used in subtraction based post-processing.
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In every case, the

normalized intensity data from the ipsilateral breast was subtracted from the normalized
intensity data from the contralateral breast so that the signal due to higher absorption shows
as a higher (more red) signal in the 2D contour plot.
For subject #1 a second set of images were collected from the outer side of the
breast tissue under the arm because the medical records indicated lymphatic spread to the
axillary lymph nodes.

The subject was asked to lie on the right side while resting the left

arm above the head and the probe was placed under the arm for location #1. The probe
was then moved down toward the ribcage and images were collected at four different
locations as shown in Figure 14.2. The axillary lymph nodes are located in the outer chest
wall region under the arm as indicated in Figure 14.2. The entire set of images was repeated.

Figure 14.2 Probe locations for second set of images in subject #2. The subject was asked to lie on
the right side and rest the left arm above the head while the probe was placed at four different
locations on the outer side of the left breast starting under the arm and moving down toward the
ribcage. The procedure was repeated on the right breast at symmetric locations. All probe positions
were estimated with reference to the nipple location and are not drawn to scale in the schematic.
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14.3 RESULTS
The optical images from both subjects were compared to the medical records provided. For
subject #1, a palpable mass in the left breast produced a negative result in x-ray
mammography. However, MRI images showed a region of abnormal tissue behind the
nipple in the left breast which was determined by needle biopsy to be invasive ductal
carcinoma with lymphatic spread. Figure 14.3 shows slices from an MRI scan. The yellow
arrows indicate the abnormal tissue located in the periariolar region (i.e. near the nipple
area).

Figure 14.3: Three slices of an MRI scan from 64 year-old breast cancer patient. The yellow arrows
indicate the location of abnormal tissue behind the nipple region.

Figure 14.4 shows the first set of continuous-wave absorption-based images collected from
subject #1 using the hand-held optical imager (repetition #1). For each of the four probe
locations (indicated in Figure 14.1), an image was collected from the left breast (on left) and
right breast (center) and the data were subtracted to yield the post-processed images (on
right). The optical signal due to absorption is indicated by the dashed yellow line. The
location of the signal corresponds to the location of abnormal tissue indicated in the MRI
images (Figure 14.3). The probe locations began at the top part of the breast and moved
down toward the bottom of the breast tissue (as described in the previous section). Since
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the region of abnormal tissue was located in the central part of the breast tissue behind the
nipple, the optical signal from that region of tissue would be visible in the lower part of the
image for probe position #1, in the center of image for probe positions #2 and #3, and
toward the top of the image for probe position #4. These areas are indicated in the images
by a yellow dotted circle. Additional signal appears in the lower right corner of each postprocessed image which is likely due to incomplete contact of the outer edge of probe with
the tissue. Figure 14.5 shows the results from the second repetition of images collected at
the same locations and post-processed. The images show similar result to Figure 14.4 which
demonstrates repeatability of the data collected.

Figure 14.4: Continuous-wave absorption-based optical images collected from subject #1 at four
probe locations (first repetition of images). The images on the left were collected from the left breast
tissue and the images in the center were collected from the right breast tissue. The post-processed
images on the right represent the normalized intensity data from the ipsilateral (left) breast subtracted
from the normalized intensity data from the contralateral (right) breast showing the optical signal due
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to absorption as a higher (red) signal in the images. The yellow dotted circle was hand-drawn to
represent the region of interest in each image.

Figure 14.5 Continuous-wave absorption-based optical images collected from subject #1 at four
probe locations (second repetition of images). The images on the left were collected from the left
breast tissue and the images in the center were collected from the right breast tissue. The postprocessed images on the right represent the normalized intensity data from the ipsilateral (left) breast
subtracted from the normalized intensity data from the contralateral (right) breast showing the
optical signal due to absorption as a higher (red) signal in the images. The yellow dotted circle was
hand-drawn to represent the region of interest in each image.

Figure 14.6 shows ultrasound images from subject #1 of suspicious enlarged lymph nodes in
the axillary region (indicated in Figure 14.2). Needle biopsy confirmed that at least three
lymph nodes in the axillary region contained lymphatic spread of carcinoma.
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Figure 14.6 Ultrasound images from subject #1 of suspicious enlarged axillary lymph nodes. (The
axillary region is indicated in Figure 14.2.)

The second set of four optical images collected from the outer part of the tissue under the
arm in the axillary region and the side of the breast tissue (probe locations indicated in
Figure 14.2) are shown in Figure 14.7. The first image from probe location #1 shows a
strong absorption signal (indicated by the dashed yellow circle) which might be from an
enlarged axillary lymph node. Additional (weaker) absorption signals in images from probe
locations #2 and #3 might also indicate regions of affected lymph nodes. The fourth image
from probe location #4 no longer covered the axillary region and was located over the
breast tissue. The diffused signal in the fourth image is likely from the abnormal tissue
located behind the nipple (similar to the signal in Figure 14.4). Figure 14.8 shows the results
from the second repetition of images collected at the same locations and post-processed.
The images show similar result to Figure 14.7, however there is also the presence of artifacts
because the probe was not in full contact with the tissue.
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Figure 14.7 Continuous-wave absorption-based optical images collected from subject #1 at the
second set of four probe locations (repetition #1). The images on the left were collected from the
left breast tissue and the images in the center were collected from the right breast tissue. The postprocessed (subtracted) images on the right show the optical signal due to absorption. The yellow
dotted circle was hand-drawn to represent the region of interest in each image.
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Figure 14.8 Continuous-wave absorption-based optical images collected from subject #1 at the
second set of four probe locations (repetition #2). The images on the left were collected from the
left breast tissue and the images in the center were collected from the right breast tissue. The postprocessed (subtracted) images on the right show the optical signal due to absorption. The yellow
dotted circle was hand-drawn to represent the region of interest in each image.

Figure 14.9 shows x-ray mammography images from the left breast of a 51 year-old
breast cancer patient (subject #2). Figure 14.9A is the axial view where the top of the image
is toward the left side of the breast and the bottom of the image is toward the right side of
the breast. Figure 14.9B is the oblique view where the top of the image is toward the
patient’s head and left side and the bottom of the image is toward the patient’s feet and right
side. The images show the presence of 3 masses in the outer quadrant of the tissue
(indicated by the yellow arrows). The medical reports indicated that two of the masses were
cancerous with regions of abnormal tissue between the three masses.
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Figure 14.9 X-ray mammography images of the left breast from a 51 year-old breast cancer patient.
(A) The top of the image is the left side and the bottom of the image is the right side of the breast
tissue. (B) Oblique image where the top of the image is toward the patient’s head and left side and
the bottom of the image is toward the patient’s feet and right side. The yellow arrows indicate 3
lesions (labeled as L1, L2, and L3) located in the 1 o’clock to 2 o’clock region of the breast.

Figure 14.10 shows ultrasound images from the left breast of the same subject. The image in
Figure 14.10A was collected from the 1 to 2 o’clock position at 2-3 cm from the nipple and
the image in Figure 14.10B was collected from the 1 to 2 o’clock position at 6 cm from the
nipple. The three tumor masses in the outer quadrant of the tissue are indicated by the
yellow arrows.
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Figure 14.10 Ultrasound images of the left breast from a 51 year-old breast cancer patient. Both
images were collected in the 1 to 2 o’clock location where image (A) was 2-3 cm from the nipple and
image (B) was 6 cm from the nipple. The yellow arrows indicate 3 lesions (labeled as L1, L2, ans L3
corresponding to Figure 14.7) located in the 1 o’clock to 2 o’clock region of the breast.

Figure 14.11 shows the continuous-wave absorption-based images collected using
the hand-held optical imager. The images on the left were collected from the ipsilateral
breast and the images in the center were collected from the contralateral breast. The images
on the left were subtracted from the images in the center to yield the resulting postprocessed
images on the right. In the post-processed images, the area of higher absorption shows as a
higher (or more red) signal. The post-processed images from locations 1-3 show high
intensity signal (greater absorption) in the outer quadrant of the left breast tissue which
corresponds to the location of the 3 tumor masses indicated in the x-ray mammogram and
ultrasound images. The image from location 4 which is from the lowest part of the tissue
does not show higher absorption.
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Figure 14.11 Optical images collected from the breast tissue of a 51 year-old breast cancer patient.
The images in Set #1 were collected from the ipsilateral breast and the images in Set #2 were
collected from the contralateral breast. The images from Set #1 were subtracted from Set #2 so that
the area of higher absorption shows as a higher (or more red) signal in the post-processed images.
The yellow dotted circle was hand-drawn to indicate the region of interest.

The subject returned for a second study 42 days following the initial study. The
same set of images was collected at the same locations on the breast tissue and the postprocessed images from the two studies are compared in Figure 14.12. The images from
study #2 show intensity signal (absorption) located in the outer quadrant of the left breast
tissue; however, the signal is reduced and diffused compared to the images from study #1.
The subject had been undergoing treatment therapy during the time that the images were
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collected and the results in Figure 14.12 might be indicative of reduction of the tumor
masses due to the treatment.

Figure 14.12 Comparison of the results from two different image sets collected on different dates
from subject #2. Study #2 was performed 42 days after Study #1 in the same breast cancer subject.
Four images were collected at the same probe locations (see Figure 14.1). For each study, images
were collected from both the right and left breast tissues and used to subtract the excitation leakage.
All images are the final post-processed images. The probe locations were estimated with respect to
the nipple location.

14.4 DISCUSSION
This chapter presented preliminary data from the first studies performed using our handheld optical imager with actual breast cancer subjects. Subject #1 had invasive ductal
carcinoma with lymphatic spread which was not detected by x-ray mammography. The first
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set of optical images show absorption signal corresponding to the region of abnormal breast
tissue indicated in the MRI images. The second set of optical images show absorption signal
corresponding to the location of axillary lymph nodes in the region where needle biopsy
confirmed lymphatic spread of carcinoma. This study shows the potential of the hand-held
device to image cancerous tissues that are undetectable by MRI as well as affected lymph
nodes in the axillary region.
The images from subject #2 show absorption signal corresponding to the location of
tumors in a subject undergoing chemotherapy treatment for invasive ductal carcinoma. In a
subsequent study with the same subject 42 days following the first study, the signal in the
same region was weaker and more diffused. This possibly indicates shrinkage of the tumor
masses due to the chemotherapy treatment. These results show the potential of the device
in monitoring of response to treatment.
All of the images show artifacts located outside the region of interest. These artifacts
might be due to improper contact of the probe with the tissue or the uneven source intensity
distribution among the six sources.

Additionally, the subtraction post-processing to

eliminate excitation leakage was performed using images from two different breast tissues.
Hence, differences in the signal distribution due the different composition of the tissue
would produce artifacts after subtraction. Filtration methods will be applied in the future to
reduce the number of artifacts (Chapter 16).
The hand-held optical imager described herein has potential as a complementary
imaging modality for breast cancer imaging in the clinical setting. Currently most breast
masses are found by x-ray mammography and/or breast ultrasound and then diagnosed as
malignant or benign by surgical biopsy. Since 80% of biopsies turn out to be negative [2]
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there is a clear need for a method of noninvasively imaging breast tumors to gain more
information. Optical imaging provides functional information without any additional harm
or discomfort to the patient.
In addition to breast cancer diagnosis, another potential application for optical
imaging is for monitoring the progression of tumor response to treatment therapy. Since
optical imaging does not use harmful radiation like x-ray and nuclear techniques, the patient
can be imaged more frequently. This will reduce the distress of the patients who currently
have to wait several months between imaging scans to determine if the treatment therapy is
effective. The results shown in the previous section show potential of our hand-held optical
imager for use in this application.
14.5 SUMMARY AND CONCLUSION
The performance of our hand-held based optical imager was tested in the clinical setting for
the first time on actual breast cancer patients. These preliminary results indicate the ability
of the device to detect tumors via continuous-wave absorption-based imaging. In addition,
multiple studies during treatment therapy demonstrate the potential application of the device
to be used to monitor tumor progression at different stages of therapy. Extensive studies
will be performed in the future to demonstrate coregistered imaging and 3D tomography in
cancer subjects as well as determine the sensitivity and specificity of the device.
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CHAPTER 15
Summary and Conclusion: Overall Discussion and Significance of the
Work

A hand-held probe based optical imaging device has been developed in our Optical Imaging
Laboratory towards breast cancer imaging. It is distinctive from other hand-held optical
devices in its ability to perform 3D tomography in complex human breast tissues via unique
self-coregistration capabilities. In the past, our device has demonstrated 3D tomography
using manual coregistration in simple cubicle phantoms. The overall goal of this dissertation
was towards translation of our device to the clinical setting for 3D tomographic imaging in
human breast tissues with complex geometries. A systematic experimental approach was
designed and executed to evaluate the performance of the device at each stage of clinical
translation. The major objectives of the studies were to demonstrate fast 2D imaging,
coregistered imaging, and 3D tomography in tissue phantoms, in vitro, and in vivo with human
subjects.
The first major goal was to perform fast 2D imaging in order to determine if the
device could detect and estimate the 2D location of a target even prior to 3D tomographic
analysis. In the clinical setting, fast 2D imaging is useful to quickly gain a visual picture of
the entire breast tissue and determine the specific “areas of interest” to which more in-depth
analysis will be applied. For the phantom, in vitro, and in vivo studies performed herein, the
term “fast imaging” is used to describe the acquisition and initial post-processing to visualize
the target or tumor in a 2D contour plot. Each image was acquired in near-real time (~5
seconds).

171

Fast 2D imaging was initially demonstrated in the simple case of homogeneous tissue
phantoms composed of 1% Liposyn solution. A 0.45 cm3 spherical target filled with 1 !M
Indocyanine green (ICG) fluorescent contrast agent was detectable up to a depth of 2.5 cm
under perfect uptake conditions (Section 8.3.1).

The next step was to introduce a

heterogeneous background which better mimicked the properties of actual human tissue.
Studies were performed in vitro using minced chicken breast combined with 1% Liposyn.
Spherical targets of 0.45 and 0.23 cm3 volume filled with 1 !M ICG were detectable up to
2.0 cm deep under perfect uptake conditions (Section 8.3.2). The final step was to see if a
target could be detected through actual human breast tissue. Healthy female subjects above
age 21 were recruited for the IRB-approved study. Spherical targets of 0.45 and 0.23 cm3
filled with 1 !M ICG were noninvasively placed underneath the flap of the breast tissue and
were detected through ~ 2.5 cm of human breast tissue (Section 11.3).
The fast 2D imaging studies demonstrated that small targets (0.23-0.45 cm3) could be
detected in near-real time using our hand-held optical imager in tissue phantoms, in vitro, and
in vivo. It is interesting to note that the deepest target detected for in vitro studies was at a
depth of 2.0 cm, whereas in the more complex human subject case, the target was detected
through ~2.5 cm of tissue. Chicken breast tissue is composed primarily of muscle whereas
human breast tissue has various components such as mammary glands, milk ducts, and fatty
tissue.

Hence, while phantom and in vitro experiments are useful for preliminary

investigations of the capabilities of a device and optimization, they do not accurately predict
what result will occur in a true human subject case. The scattering coefficient of the in vitro
phantom ranged between 6 and 12 cm-1 which is close to the average value of human breast
tissue (~ 8 cm-1).[134] Extensive clinical studies are required to fully define the performance
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of the device in order to account for the wide variability between subjects. The research
performed for this dissertation has effectively translated the device from the laboratory
testing stage to the clinical studies phase and the imaging set-up and protocol have been
methodically structured to be conducive now for a continuous flow of human subject
studies.
Fast 2D imaging in near-real time is useful to gain an initial estimation of the area of
interest to be interrogated in more detail. In order to proceed with further analysis, it is
necessary to determine the location of the probe image with reference to the geometry of the
tissue (i.e. coregister the images). The second major goal was to demonstrate automated
coregistered imaging which is necessary to perform 3D tomography.

The optical

tomography studies performed by other research groups typically used bulky
instrumentation with the breast placed within a fixed geometry (between two compression
plates or in a ring).[22,110] The fixed location and geometry enables the image location
relative to the breast geometry to be known, allowing for tomography. Only one research
group has demonstrated 3D tomography using a dual optical/ultrasound hand-held
device.[66]

The additional data from the ultrasound was used as structural a priori

information for tomography.

Our device is unique in that is has self-coregistration

capabilities enabling 3D tomography to be performed using a hand-held optical-only device,
without requiring a second imaging modality.
An acoustic based tracking system was implemented with the hand-held device and
automated coregistration software (developed in-house using MATLAB/LabVIEW) was
used to perform self-coregistered imaging.

Automated coregistered imaging was

quantitatively validated in tissue phantoms and the average distance off between the
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measured location and true location of the probe with respect to the phantom was ~0.19
cm. The discrepancy was attributed to instability of the tracking system. Coregistered
imaging was performed in tissue phantoms and in vitro where multiple coregistered images
were summed in order to increase the signal from the target while relatively reducing the
random artifacts enabling deeper target detection.

The depth of detection for tissue

phantoms was improved from 2.5 to 3.5 cm in tissue phantoms under perfect uptake and 3.0
cm under imperfect (T:B=100:1) uptake. The depth of detection in vitro was improved from
2.0 cm to 3.5 cm under perfect uptake and 2.5 cm under imperfect (T:B=100:1) uptake for
target volumes of 0.23 – 0.45 cm3 (Section 9.3).
Coregistered imaging was performed in vivo in healthy human subjects. Tracking of
the probe was quantitatively validated by automatically inserting reference points into the 3D
meshed geometry via code developed in MATLAB. The average total distance off between
the measured location and true location was ~1 cm.

The much larger discrepancy

(compared to the discrepancy in phantoms) was attributed to movement of the subject,
deformation of the breast tissue, and probe-operator error.

The imaging set-up was

modified to minimize human error during in vivo imaging (by scanning and imaging the
subject in supine position at a 45º degree angle, Section 12.2.3). Currently efforts are made
by others in our lab to develop an optical tracking system to reduce the error due instability.
Future work will involve testing the total reduction in error using the new tracking method
(as described in Chapter 16). Automated coregistered imaging was performed on a healthy
human subject with a spherical target (0.45 cm3) filled with 1 !M ICG placed noninvasively
underneath the flap of the breast tissue. Due to increased instability of the acoustic tracking
system, a manual coregistration approach was temporarily implemented and performed in a
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healthy human subject with a 0.45 cm3 spherical target filled with 0.08% and 0.04% India ink
placed underneath the flap of the breast tissue. The results demonstrated the ability to
detect both fluorescent and absorption based targets through human breast tissue and
coregister the image at the appropriate tissue location using both automated and manual
coregistered imaging (Section 12.3).
Coregistered images provide the appropriate positional information to enable 3D
tomographic analysis. The third major goal was to perform 3D tomography in tissue
phantoms, in vitro, and in vivo using our hand-held optical imager. Initially, 3D tomography
was performed using manual coregistration of the fast 2D images of fluorescent targets in
vitro with the simple cubicle geometries. The targets were recovered close to the true
location; however, the recovered optical property (!axf) values were very low which could be
due to the highly diffused signal from depths of 2-2.5 cm in a heterogeneous background
(Section 10.3.1). Subsequent tomography studies were performed using the summated
coregistered data. The reconstruction results showed many artifacts and it could not be
conclusively determined that the target was recovered (Section 10.3.2). Future work will be
performed to apply some filtration techniques and to use frequency-domain data for the
reconstructions which provides additional phase information that is not present in CW
imaging employed in the current research studies (as described in Chapter 16).
The major challenge in performing 3D tomography in human tissue as opposed to
simple phantoms is to generate the discretized volume geometry (or mesh) for the human
breast tissue. For simple cubicle phantoms, the geometry and mesh were generated within a
single software (Gambit) and the same mesh was used for each phantom reconstruction. In
the case of human subject studies, the various breast tissue geometries must be acquired for
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each subject and discretized into tetrahedral volume mesh. Complications occurred in the
process of trying to import an acquired surface scan into appropriate software to generate
the 3D volume and mesh. Meshing softwares are typically designed such that a geometry is
both generated and meshed within that same software. However, our application presented
a unique complication in that we required an externally acquired complex geometry to be
imported into the software and used to generate a 3D volume and mesh. A ten-step
procedure was developed to acquire the tetrahedral volume mesh of the breast tissue and
extract the experimental information corresponding to the individual volume breast mesh
needed to input into the reconstruction algorithm (Section 13.2.1).
Three-dimensional (3D) tomography was performed using the data from a healthy
human subject with a fluorescent target placed underneath the flap of the breast tissue. The
signal from the target was recovered close to the true location along with artifacts (Section
13.3). The artifacts could be caused by improper contact of the probe with the tissue
surface, uneven intensity distribution among the six sources in the probe face, or noise in the
experimental data. Efforts will be made to reduce the artifacts as part of the future work
(Chapter 16). The result demonstrates for the first time the feasibility of performing 3D
tomography in breast tissue of a human subject using a hand-held optical imager.
The final stage of the dissertation involved preliminary studies using the hand-held
optical imager on actual breast cancer subjects.

Diffuse optical imaging studies were

performed in two female patients with invasive ductal carcinoma. The images showed
higher absorption signals in the regions of the tumor locations along with artifacts (Section
14.3). The results demonstrate the potential of the device to detect the presence of cancer
within a known region of interest which has clinical application towards prognostic imaging
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since the location of the tumor versus surrounding artifacts will be known. In order for the
device to be used for diagnostic purposes, the artifacts that have occurred in the images must
be minimized. Future work will involve efforts to improve the instrumentation as well as
the imaging procedure in order to reduce the artifacts.
There are several unique advantages of our hand-held optical imager. The probe
contains six illumination points and 165 detection points (distributed over a 4x9 cm) area
which illuminate and collect the signal simultaneously to enable rapid data acquisition in
large volumes of tissue. The probe is designed with a flexible face to contour to the
curvature of the breast tissue allowing maximum patient comfort.

Self-coregistration

facilities are implemented with the probe to accurately position the image on the complex
3D breast tissue geometry. The hand-held optical imager is the only one of its kind that is
capable of performing 3D tomography in human breast tissue.
There are also several limitations of the hand-held device. The probe uses a subsurface based imaging configuration which limits the collected signal to reflectance
measurements only. The physics of reflectance based imaging leads to recovery of targets
closer to the imaging surface limiting the ability to accurately recover the true target depth.
The acoustic tracking system proved unstable causing error in image coregistration. The
bulky design of the bench-top hand-held imaging device is not portable and operatorfriendly for efficient bedside imaging.

The next chapter will describe the efforts to

overcome these limitations as part of our ongoing and future work.
The significance of the work presented in this dissertation is towards the clinical
translation of a hand-held optical imager for bedside imaging and 3D tomography of human
breast tissue. The process of clinical translation of our hand-held optical imager involved
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modification of the experimental set-up and method from bench-top phantom studies to
bedside human subject imaging.

The performance of the device was evaluated using

progressively more complex subjects, beginning with the simple case of homogeneous tissue
phantoms, then using more complex heterogeneous in vitro phantoms, and finally testing in
actual human breast tissue. While phantom and in vitro studies are useful for gaining some
insight into how the device will perform, extensive human subject studies are integral to
gaining a true assessment of the device performance in the clinical setting. The hand-held
optical imager has potential impact for women with breast cancer by providing a safe and
patient comfortable method for functional imaging of breast tissue towards cancer diagnosis
and prognosis.
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CHAPTER 16
Ongoing and Future Work

The work performed for this dissertation has brought the development of our handheld optical imager from the stage of bench-top testing in simple cubical phantoms to the
stage of performing extensive bedside human subject studies. Through collaboration with a
breast surgeon and a cancer center, we are continuously recruiting breast cancer patients to
participate in our research studies. Parallely, we will continue to perform studies in healthy
subjects as a control group, and in the future we will recruit subjects with various types of
non-cancerous breast lesions (e.g. cysts, fibroadenoma, etc.) Our imager must be tested on
many subjects over a wide range of demographics in order to determine the sensitivity,
specificity, positive predictive value, and negative predictive value of the device.
The three major aspects that the ongoing and future work will focus on to improve
the imaging results are (i) instrumentation, (ii) data acquisition, and (iii) post-processing. The
current limitations in the instrumentation are the bulky bench-top design of the optical
imaging system, the heavy and awkward hand-held probe, and the unstable tracking system.
In order to address the limitations in the bulky bench-top system and probe design, a second
generation of the hand-held optical imager is being developed which has a more sleek and
portable design. The instrumentation is more compact and fits on a portable cart for ease of
bedside imaging. The hand-held-probe has a two-piece design which is smaller and lighter
for comfort and better control of operation as well as the addition of transillumination based
measurements to improve target depth recovery. Another limitation of the first generation
device is the uneven source intensity distribution which causes artifacts in the images. The
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second generation device will contain six independent laser diodes to enable a uniform
source intensity distribution. This second generation device will be tested extensively in
healthy human subjects and breast cancer patients.
Another limitation in the instrumentation is the instability of the tracking system,. An
alternate optical-based tracking system is being developed to enable more accurate image
coregistration. Once the optical-based tracking system is developed, coregistered imaging in
human subjects will be reevaluated quantitatively to determine how much the discrepancy
between true and measured probe locations was reduced by the combined efforts of (i)
improving the stability of the tracking system and (ii) modifying the imaging set-up to reduce
human error.
Efforts will be made to improve the methods of data acquisition in order to
systemize the imaging approach across multiple human subjects. To this end, a structured
imaging approach will be implemented which uses a template of predefined locations of the
probe which are marked on each breast tissue to ensure continuity of imaging among
repetitions with each subject and across multiple subjects. In order to reduce the movement
and conformation of the breast tissue, an optically clear custom-built garment will be used
with the Generation II system to confine the breast tissue. The hand-held 3D scanner will
be used as the motorized system with the subject seated in an upright position.
Post-processing techniques will also be applied as part of the future work in order to
minimize the presence of artifacts. Filtration will be applied to the data to try to remove
noisy data points that contribute to artifacts. Since each image represents an average of 510 repetitions, there may be noisy data in one of the repetitions which can be identified by
the magnitude of the standard deviation and removed.[157]
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Several challenges were encountered and lessons were learned throughout the
dissertation process. One lesson is the importance of maintaining a systematic experimental
approach at every stage in the research. If a new method or idea is applied that produces an
improved result it can be tempting to immediately try it to the most extreme case to see the
improvement.

However, any new method must be systematically applied at each

incremental stage in order to see the effect on the experimental results. During preparation
for human subject studies, experience was gained while assisting in writing the IRB proposal.
It can be a strenuous process and it is important to think ahead and cover every possible
aspect of the experimental procedure. The procedure will naturally be altered as limitations
are discovered and more effective methods are implemented and every detail must be
documented in the IRB protocol. There is also the challenge of collaborating with other
institutions requiring an additional IRB approval from the other institutions which can be a
lengthy process.
Several major lessons were learned during this process occurred during the transition
from phantom and in vitro studies to human subject studies. During the experience acquired
throughout the dissertation research, many things have been discovered that must be taken
into consideration when performing human subject studies as opposed to phantom studies.
In phantom studies there is much more control over the experiment in that the phantom is
made the same way each time, and once it is set in place it remains fixed for the extent that is
required during data collection and troubleshooting. With a human subject, there is much
more variability and many more unknowns. The tissues of human subjects differ widely in
size and density. The imaging procedure must be generalized enough to account for the
differences. Although the subject is asked to remain still during the imaging procedure, there
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inevitably will be some movement which can impact the results. Human subject studies
must be performed in a limited amount of time, so if problems occur, troubleshooting must
be done quickly on the spot or the data cannot be collected at that time. Another lesson is
that the behavioral conduct of the researchers performing the experiment must be much
more formal than during phantom studies. Problems inevitably occur and it is important not
to cause tension or panic in subject who does not understand the operation of the
instrumentation and might worry that the problem would affect them. It is also important
to maintain awareness of the demographics in the area where the subjects will be recruited.
The studies described here were performed in an area that has a high Hispanic population
and some of the subjects spoke very limited English. It was necessary to have the consent
forms prepared in both English and Spanish so the subject could be informed in their
preferred language.

Another aspect that is required for human subject studies is the

confidentiality of sensitive information. The identity of the subject is never associated with
the data collected, and the medical records must be kept locked to protect the privacy of the
subject.
The lessons learned during the dissertation process will be incorporated in the
ongoing and future work with the hand-held optical imager. Clinical studies with patient
trials are integral to the translation of any device. Extensive clinical trials will provide a
broader scope of the device capabilities and expected performance in a true clinical setting.
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Modality

Meas.
Techniq
ue

Source Type

Source
Wavelengt
h

Tromb
erg,
1997
[26]

NIR
Spectrosc
opy

FDPM
(300 kHz
- 1 GHz)

amplitude
modulated
diode lasers
(10-30 mW)

674, 811,
849, 956
nm

APD

1.0 cm

Lannin
g,
1999
[27]

NIR
Spectrosc
opy

FDPM
(5 MHz 1 GHz)

amplitude
modulated
diode lasers

674, 803,
849, 956
nm

APD

1.26
cm

Tromb
erg,
2000
[28]

NIR
Spectrosc
opy

FDPM

amplitude
modulated
diode lasers
(10-30 mW)

674, 811,
849, 956
nm

APD

0.74
cm

Holbok
e,
2000
[29]

NIR
Spectrosc
opy (w/
ultrasoun
d
constraint
s)

FDPM
(400
MHz)

diode lasers
(10-30 mW)

674, 782,
803, 849
nm

Ceruss
i, 2001
[30]

NIR
Spectrosc
opy

FDPM
(1 GHz)

amplitude
modulated
diode lasers
(5-25 mW)

672, 800,
806, 852,
896, 913,
978 nm

APD

1.0 cm

Shah,
2001
[31]

NIR
Spectrosc
opy

FDPM
(50-1000
MHz)

amplitude
modulated
diode lasers
(10-20 mW)

674, 803,
849, 894,
947,
956/980 nm

APD

N/A

Shah,
2004
[32]

NIR
Spectrosc
opy

FDPM
(50-700
MHz)

amplitude
modulated
diode lasers
(5-25 mW)

674, 780,
803, 849,
894, 915,
980 nm

APD

N/A

Device # 1a

Refere
nce

(300 kHz
- 1 GHz)

Detector
Type

Target
Depth

0.74
cm

APD
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Subject
Studied
2
abnormal
human
subjects
(breast
tissue)
4
abnormal
human
subjects
(breast
tissue)
4 normal
&3
abnormal
human
subjects
(breast
tissue)
1
abnormal
human
subject
(breast
tissue)
28 normal
human
subjects
(breast
tissue)
14 normal
human
subjects
(breast
tissue)
31 normal
human
subjects
(breast
tissue)

#
Sources,
Detector
s

1,1

1,2

1,1

1,1

1,1

1,1

1,1

Picture / Schematic

Bevilac
qua,
2000
[33]

Device # 1b

Ceruss
i, 2002
[34]

Jakubo
wski,
2004
[35]

NIR
Spectrosc
opy

NIR
Spectrosc
opy

NIR
Spectrosc
opy

CW &
FDPM
(100-700
MHz)
CW &
FDPM
(300 kHz
- 1 GHz)
[2
separate
probes]

CW &
FDPM
(50-1000
MHz)

Shah,
2005
[36]

NIR
Spectrosc
opy

CW &
FDPM
(50-600
MHz)

Hsiang
, 2005
[37]

NIR
Spectrosc
opy
(w/ MRI
coregistra
tion)

CW &
FDPM
(50-600
MHz)

Ceruss
i, 2006
[38]

NIR
Spectrosc
opy

CW &
FDPM
(50-500
MHz)

FD - amplitude
modulated
diode lasers
(<20 mW)
CW - 150 W
halogen lamp

672, 800,
806, 852,
896, 913,
978 nm

FD - 7 diode
lasers
(525 mW)
CW - 150 W
halogen lamp

672, 800,
806, 852,
896, 913,
978 nm

FD - amplitude
modulated
diode lasers
CW - highintensity
tungsten
halogen

660, 685,
786, 809,
822, 852,
898, 911,
946, 973
nm

FD - amplitude
modulated
diode lasers
CW - highintensity
tungsten
halogen
FD - amplitude
modulated
diode lasers
(10-20 mW)
CW - highintensity
tungsten
halogen
FD - amplitude
modulated
diode lasers
(<20 mW)
CW - 150 W
halogen lamp

658, 682,
785, 810,
830, 850
nm

FD - APD
CW - fibercoupled
spectrogra
ph w/
linear
CCD
detector
FD - APD
CW - fibercoupled
spectrogra
ph w/
linear
CCD
detector
FD - APD
CW - fibercoupled
spectrogra
ph w/
linear
CCD
detector
FD - APD
CW - fibercoupled
spectrogra
ph w/
linear
CCD
detector

658, 682,
785, 810,
830, 850
nm

FD - APD
CW - fibercoupled
spectrogra
ph w/
linear
CCD
detector

661, 686,
786, 808,
822, 852
nm

FD - APD
CW - fibercoupled
spectrogra
ph w/
linear
CCD
detector

N/A

1.0 cm
(averag
e)

N/A

0.5 cm
(averag
e)

phantom
&2
normal
human
subjects
(breast
tissue)
30 normal
&1
abnormal
human
subjects
(breast
tissue)
1
abnormal
human
subject
(breast
tissue)
1
abnormal
human
subject
(breast
tissue)

4.2 cm

6
abnormal
human
subjects
(breast
tissue)

N/A

57
abnormal
human
subjects
(breast
tissue)
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2,2
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al
illuminatio
n)

1,1

2,2

(sequenti
al
illuminatio
n)

2,2

(sequenti
al
illuminatio
n)

2,2

(sequenti
al
illuminatio
n)

2,2

(sequenti
al
illuminatio
n)

Device # 2
Device # 3

Ceruss
i, 2007
[39]

NIR
Spectrosc
opy

CW &
FDPM
(50-1000
MHz)

FD - amplitude
modulated diode
lasers (20 mW)
CW - fibercoupled
broadband
white-light
source

660, 690,
780, 808,
830, 850
nm

FD - APD
CW - fibercoupled
spectrogra
ph w/
linear
CCD
detector

N/A

11
abnormal
human
subjects
(breast
tissue)

No,
2005
[40]

NIR
Spectrosc
opy

FDPM
(10 MHz
- 1 GHz)

8 laser diodes
(50 mW)

783 nm

photodete
ctor

N/A

Phantom

No,
2006
[41]

NIR
Spectrosc
opy

FDPM
(50-300
MHz)

4 laser drivers
(20 mW)

681, 783,
806, 823
nm

N/A

breast
phantom
& muscle
phantom

No,
2007
[42]

NIR
Spectrosc
opy

FDPM
(50-300
MHz)

4 laser diodes
(20 mW)

681, 783,
823, 850
nm

APD

Chanc
e,
2005
[43]

NIR
Spectrosc
opy

CW

light emitting
diodes
(10-15 mA)

760, 805,
850 nm

8 silicon
diode
detectors

Nioka,
2005
[44]

NIR
Spectrosc
opy

CW

light emitting
diodes
(10-15 mA)

735, 805,
850 nm

8 silicon
diode
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4.0 cm

Sao,
2003
[45]

NIR
Spectrosc
opy

CW

2 light emitting
diodes

730, 850
nm

8
photodete
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N/A

APD

2,2
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n)

1,1
4,1
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al
illuminatio
n)

4,1

N/A

4.0 cm
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N/A
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(breast
tissue)
116
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human
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Phantom

(sequenti
al
illuminatio
n)

1,8

1,8

2,8

Device # 4

NIR
Spectrosc
opy

FDPM
(3 kHz)

2 light emitting
diodes
(20 mA)

Device # 5

Liu,
2004
[47]

NIR
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Spectrosc
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FDPM
(3 kHz)

4 light emitting
diodes

(infrared)

PMT

Xu,
2005
[48]

NIR
Spectrosc
opy

CW
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photodiod
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Xu,
2005
[49]

NIR
Spectrosc
opy (w/
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d)

laser diode

690, 830
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photo
diode

Device # 7

Device # 6b

Device # 6a

Chanc
e,
2006
[46]

Xu,
2007
[50]

Choe,
2005
[51]

NIR
Spectros
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NIR
Spectrosc
opy

CW

CW

CW

laser diodes
(0.15 W/cm2)

long coherence
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to 1x4 optical
switch

800 nm

silicon
diode
detector

Phantom
& Human

2,1
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illuminatio
n)

N/A

Phantom

4,1
(simultan
eous
illuminatio
n)

1.5 cm

Simulatio
n

8,8

N/A

abnormal
human
subjects
(breast
tissue)

8,8

N/A

phantom
&2
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human
subjects
(calf
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breast
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16,8

N/A

5
abnormal
&2
normal
human
subjects
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4,4

5.0 cm

690, 830
nm

siliconbased
photodiod
es

785 nm
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photoncounting
avalanche
photodiod
es
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CW

NIR
Spectrosc
opy

Sunar,
2006
[54]

Diffuse
Correlatio
n
Spectrosc
opy*
(DCS) &
Diffuse
Reflectanc
e
Spectrosc
opy**
(DRS)

DCS CW
DRS FDPM
(70 MHz)

Zhu,
1999
[55]

NIR &
Ultrasoun
d

Guo,
2000
[56]

Device # 10b

Liebert
, 2005
[53]

Device # 9a,b

NIR
Spectrosc
opy

Device # 10a

Device # 8

Durdur
an,
2005
[52]

long coherence
laser coupled
to 1x4 optical
switch

785 nm

4 fast
photoncounting
avalanche
photodiod
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1.0 cm

Human

4,4

N/A

2 normal
&2
abnormal
human
subjects
(brain
tissue)

2,4

CW - 2,4
FDPM 2,4

803, 807
nm

PMTs

DCS - long
coherence
laser
DRS - laser
diodes

CW - 785
nm FDPM 690, 785,
830 nm

CW - 4
fast
photoncounting
avalanche
photodiod
es
FDPM - 2
avalanche
photodete
ctors

1.5 cm

8
abnormal
human
subjects
(head &
neck
tissue)

FDPM
(200
MHz)

12 light
sources from
single diode
laser

776, 834
nm

4 APDs

2.6 cm

Breast
Phantom

12,4

NIR &
Ultrasoun
d

FDPM
(140
MHz)

12 dual
wavelength
laser diodes

780, 830
nm

8 PMTs

N/A

Breast
Phantom

12,8

Zhu,
2000
[57]

NIR &
Ultrasoun
d

FDPM
(140
MHz)

12 dual
wavelength
laser diodes

780, 830
nm

8 PMTs

2.5 cm

Breast
Phantom

12,8

Chen,
2001
[58]

NIR &
Ultrasoun
d

FDPM
(140
MHz)

12 pairs of dual
wavelength
laser diodes

760, 830
nm

8 PMTs

2.5 cm

Breast
Phantom

12,8

TDPM

2 picosecond
diode lasers
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Device # 11
Device # 12

Zhu,
2003
[59]

NIR &
Ultrasoun
d

FDPM
(140
MHz)

12 pairs of dual
wavelength
laser diodes

780, 830
nm

8 PMTs

N/A

Zhu,
2003
[60]

NIR &
Ultrasoun
d

FDPM
(140
MHz)

12 pairs of dual
wavelength
laser diodes

780, 830
nm

8 PMTs

N/A

Chen,
2004
[61]

NIR &
Ultrasoun
d

FDPM
(140
MHz)

laser diodes
(~10 mW)

660, 780,
830 nm

silicon
avalanche
photodiod
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3.7 cm

Zhu,
2005
[62]

NIR &
Ultrasoun
d

FDPM
(140
MHz)

12 pairs of dual
wavelength
laser diodes

780, 830
nm

8 PMTs

N/A

Zhu,
2005
[63]

NIR &
Ultrasoun
d

FDPM
(140
MHz)

12 pairs of dual
wavelength
laser diodes

780, 830
nm

8 PMTs

N/A

Xu,
2007
[64]

NIR &
Ultrasoun
d

FDPM

9 pairs of triple
wavelength
sources

690, 780,
830 nm

8 PMTs

1.5 cm

Jayach
andran,
2007
[21]

NIR
fluoresce
nce
tomograp
hy

FDPM

laser diode

785 nm

ICCD
Camera
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N/A

abnormal
human
subjects
(breast
tissue)
abnormal
human
subjects
(breast
tissue)
abnormal
human
subjects
(breast
tissue)
64
abnormal
human
subjects
(breast
tissue)
6
abnormal
human
subjects
(breast
tissue)
Simulatio
n&
Breast
Phantom

Simulatio
n&
Breast
Phantom

12,8

12,8

9,10

12,8

12,8

9,8

6,165
(simultan
eous
illuminatio
n)

APPENDIX B Fluorescence-enhanced Diffuse Optical Tomography; Experimental Studies
(Adapted from Ge, 2008 [154])

Refer
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(Wu et
al.,
1995)
(Wu et
al.,
1997)

Backgrou
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R = 3.2
cm glass
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Contrast
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e
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Sphere
R = 1.5
mm
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yanine

1:0

TDPM

Glass
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Iodide dye

1:0
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(geometr
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y)
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camera
laser
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Ti:
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Sapphire
camera
laser
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2D
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3D

Forward
Method

Inverse
Method

3D

None

Localizatio
n

2D

Analytical

Laplace
transform

(Chan
g et
al.,
1997)

Cylinder
R = 4 cm
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Balloon
V=
0.5mL

Rhodamin
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500:1

CW

Argon ion
laser
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CCD camera
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2D
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(Hull
et al.,
1998)

Slab
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Spheric
al glass
bulb
R = 3.0
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Nile blue
A

1:0

CW

Dye laser
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CCD camera
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2D

Monte carlo

Localizatio
n

Delrin
phantom
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size
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e
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CW

Argon
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CCD camera
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2D/
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1:0 &
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(seq.
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PMT
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3D

MFD
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(Chern
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ik et
al.,
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ysz et
al.,
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in et
al.,

Slab
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Cube
1 cm3
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2002)
(Ntzia
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s and
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2001)
(Ntzia
christo
s et
al.,
2002)
(Lee
and
Sevick
Murac
a,
2001;
2002)

Cylinder
R = 1.25
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H = 15 cm

Cylinde
r
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1.75mm
H=
1,:3.5
cm

In vivo
(rat)

Tumor
NS for
size

Slab
V=
8!8!8
cm3
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cm3

Cube
V=
1cm3
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Cy5.5
based
activatabl
e
fluorescen
t probe

1:0

ICG

100:1
,
1:0

(Grave
s et
al.,
2003)

In vivo
(rat)

Tumor
R = 1.5
mm

(Goda
varty
et al.,
2003;
Godav
arty et
al.,
2004b;
Godav
arty et
al.,

Breast
phantom
V = 1087
cm3
& Semiinfinite
phantom

Target
V=
1cm3

ICG in
backgroun
d and
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contrast
tumor
Enzyme
activatabl
e
fluorochro
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1:0

1:0

100:1

CW
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diode
(seq.point)

CCD camera
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3D

FD
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CW
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CCD camera
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3D

FD
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(seq.
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CW
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CCD camera
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FD

SVD

FDPM

Modulate
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diode
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CCD camera
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3D

FEM
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2004a)

(Wu et
al.,
2005b;
Wu et
al.,
2005a)

Slab
S = 42
cm2
H = 1.3
cm

Tube
R=
0.1cm
H=4
cm

Cylinder
R = 25mm
H=
100mm

Tube
R=7
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(Roy,
2005)

Cube
V=83cm3

Cube
V=1cm3

(Klose
et al.,
2005)

(Goda
varty
et al.,
2005)

(Chen
et al.,
2005)
(Patwa
rdhan
et al.,
2005)
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rakis
et al.,
2005)

Breast
phantom
V=
1087cm3
Slab
phantom
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cm3
In vivo

V=1
cm3

Cube
V=
1cm3
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1:0

CW

Metal
nanoshell;
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virus-dye
nanopartic
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Laser
diode
(seq.
point/
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1:0

CW
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diode
(seq.point)

PMT
(seq. point)

2D

FEM

FDPM
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diode
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CCD camera
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3D

Experimenta
l method

FDPM

Laser
diode
(area)

CCD camera
(area)

3D

FEM

AEKF

FDPM

Laser
diode
(sim.
Point)

PMT
(seq. point)

2D

Analytical

Backprojection

CCD camera
(area)

3D
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CCD camera
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3D

FD

ART
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ICG;
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70:1
100:1
Lifeti
me
1:1
2.1:1

1:0

In vivo
(mice)
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up to 5
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N/A

CW

In vivo
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glass
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y tube
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n
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1:0

CW
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diode
(seq.
point0
Laser
diode
(seq.
point/
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optimizatio
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Newton’s
iterative
method
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FDPM
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(seq.
point)

CCD camera
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AEKF

1:0
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CCD
camera
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3D

FEM

AEKF
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100:1
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CCD camera
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3D

FEM
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NTN
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diode
(seq.point
&
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3D

FEM

Normalized
Born
approach
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3D
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Born
Approximati
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Total least
square
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gradient
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(Fedel
e et
al.,
2005)

Breast
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ICG

100:1
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et al,
2006)

Cube
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(Roy
et al,
2006)
(Schul
z et al,
2006)
(Yuan
and
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2006)
(Moha
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et al,
2007)
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et al,
2007)
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3D

FEM
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(Delio
lanis
et al,
2007)

(Herve
et al,
2007)

(Keps
hire et
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et et
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in vivo
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(sim.
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CCD camera
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APPENDIX C

Summary of the experiment parameters for various experimental cases including the average
measured source intensities, the gain setting on the image intensifier, the actual target
location in cm, the actual target volume, the measured optical property values of the
phantom at the excitation and emission wavelengths, the target to background
ratio (T:B),
the recovered target location in cm, the recovered !axf values in cm-1, the recovered target
volume, the number of iterations executed before convergence, and the breakpoint (cutoff
value selected on the first breakpoint of a histogram plot of the recovered !axf values).
Results from experimental cases 26 and 27 (highlighted in yellow) are presented in Section
10.3.
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